{ "instance": { "iva-20201231x20f.htm": { "axisCustom": 5, "axisStandard": 34, "contextCount": 666, "dts": { "calculationLink": { "local": [ "iva-20201231_cal.xml" ] }, "definitionLink": { "local": [ "iva-20201231_def.xml" ] }, "inline": { "local": [ "iva-20201231x20f.htm" ] }, "labelLink": { "local": [ "iva-20201231_lab.xml" ] }, "presentationLink": { "local": [ "iva-20201231_pre.xml" ] }, "schema": { "local": [ "iva-20201231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 865, "entityCount": 1, "hidden": { "http://www.inventivapharma.com/20201231": 4, "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 14, "http://xbrl.sec.gov/dei/2021q4": 7, "total": 25 }, "keyCustom": 222, "keyStandard": 371, "memberCustom": 134, "memberStandard": 42, "nsprefix": "iva", "nsuri": "http://www.inventivapharma.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentRegistrationStatement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentRegistrationStatement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Accounting Principles", "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples", "shortName": "Accounting Principles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LoansReceived", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Debt - Debt and borrowings (Details)", "role": "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails", "shortName": "Debt - Debt and borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_MEEGMYDJTEKMyk14v0SXeA", "decimals": "-5", "lang": null, "name": "iva:IncreaseDecreaseInBorrowings", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LoansReceived", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Debt - Breakdown between long term and short term debt (Details)", "role": "http://www.inventivapharma.com/role/DisclosureDebtBreakdownBetweenLongTermAndShortTermDebtDetails", "shortName": "Debt - Breakdown between long term and short term debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_mrZ4u6Fz9EqJwmJIuROcIQ", "decimals": "-3", "lang": null, "name": "ifrs-full:LoansReceived", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2020__eIUru2YIUmpUIbHEmSmWg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Borrowings", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41103 - Disclosure - Debt - Repayments of borrowings and accrual of interests (Details)", "role": "http://www.inventivapharma.com/role/DisclosureDebtRepaymentsOfBorrowingsAndAccrualOfInterestsDetails", "shortName": "Debt - Repayments of borrowings and accrual of interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInBorrowingsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2020__eIUru2YIUmpUIbHEmSmWg", "decimals": "-3", "lang": null, "name": "iva:SubscriptionOfBankBorrowings", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2020__eIUru2YIUmpUIbHEmSmWg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:OtherLongtermProvisions", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Provisions (Details)", "role": "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "shortName": "Provisions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_MEEGMYDJTEKMyk14v0SXeA", "decimals": "-3", "lang": null, "name": "iva:AdditionalProvisionsOtherLongTermProvisions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:ActuarialAssumptionOfRetirementAge2019", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Provisions for Retirement Benefit Obligations - Principal actuarial assumptions (Details)", "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails", "shortName": "Provisions for Retirement Benefit Obligations - Principal actuarial assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:ActuarialAssumptionOfRetirementAge2019", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - Provisions for Retirement Benefit Obligations- Net provision (Details)", "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsNetProvisionDetails", "shortName": "Provisions for Retirement Benefit Obligations- Net provision (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R106": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2020__eIUru2YIUmpUIbHEmSmWg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41303 - Disclosure - Provisions for Retirement Benefit Obligations - Change in net provision (Details)", "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangeInNetProvisionDetails", "shortName": "Provisions for Retirement Benefit Obligations - Change in net provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "lang": null, "name": "ifrs-full:IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41304 - Disclosure - Provisions for Retirement Benefit Obligations - Breakdown of expense recognized for the period (Details)", "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForPeriodDetails", "shortName": "Provisions for Retirement Benefit Obligations - Breakdown of expense recognized for the period (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41305 - Disclosure - Provisions for Retirement Benefit Obligations - Breakdown of actuarial gains and losses recognized in comprehensive income (Details)", "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails", "shortName": "Provisions for Retirement Benefit Obligations - Breakdown of actuarial gains and losses recognized in comprehensive income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_ActuarialAssumptionsAxis_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_52jlOxb_9EezcQtTsIeBvw", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_nQcrkvp6uEG3sOwzjWo2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41306 - Disclosure - Provisions for Retirement Benefit Obligations - Sensitivity analysis (Details)", "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails", "shortName": "Provisions for Retirement Benefit Obligations - Sensitivity analysis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_ActuarialAssumptionsAxis_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_52jlOxb_9EezcQtTsIeBvw", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_nQcrkvp6uEG3sOwzjWo2iQ", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Intangible Assets", "role": "http://www.inventivapharma.com/role/DisclosureIntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Trade Payables and Other Current Liabilities (Details)", "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesDetails", "shortName": "Trade Payables and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "lang": null, "name": "iva:TradePayablesAndOtherCurrentLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41402 - Disclosure - Trade Payables and Other Current Liabilities - Summary of Trade Payables Break Down By Payment Date (Details)", "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfTradePayablesBreakDownByPaymentDateDetails", "shortName": "Trade Payables and Other Current Liabilities - Summary of Trade Payables Break Down By Payment Date (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "iva:EmployeeRelatedPayables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41403 - Disclosure - Trade Payables and Other Current Liabilities - Summary of Other Current Liabilities (Details)", "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails", "shortName": "Trade Payables and Other Current Liabilities - Summary of Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "iva:EmployeeRelatedPayables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "p", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-5", "first": true, "lang": null, "name": "iva:IncreasedTradePayables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41404 - Disclosure - Trade Payables and Other Current Liabilities - Additional information (Details)", "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetails", "shortName": "Trade Payables and Other Current Liabilities - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-5", "first": true, "lang": null, "name": "iva:IncreasedTradePayables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Financial Assets and Liabilities (Details)", "role": "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "shortName": "Financial Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "lang": null, "name": "ifrs-full:FinancialLiabilitiesAtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R115": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:RevenueAndOtherIncomeTableTextBlock", "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Revenues and Other Income (Details)", "role": "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "shortName": "Revenues and Other Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:RevenueAndOtherIncomeTableTextBlock", "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_7YbvvvqRFkKBY1ARsG2bbg", "decimals": "-5", "first": true, "lang": null, "name": "iva:CollaborativeArrangementMilestonePaymentsReceivedFollowingEnrollmentOfFirstPatient", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41602 - Disclosure - Revenues and Other Income - Additional information (Details)", "role": "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "shortName": "Revenues and Other Income - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_7YbvvvqRFkKBY1ARsG2bbg", "decimals": "-5", "first": true, "lang": null, "name": "iva:CollaborativeArrangementMilestonePaymentsReceivedFollowingEnrollmentOfFirstPatient", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R117": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "iva:Disposables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41701 - Disclosure - Research and Development, Marketing - Business Development and General and Administrative Expenses (Details)", "role": "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails", "shortName": "Research and Development, Marketing - Business Development and General and Administrative Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "iva:Disposables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfEmployees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_employee_tgOlBs_VBUSU965g40zMww", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41702 - Disclosure - Research and Development, Marketing - Business Development and General and Administrative Expenses - Personnel costs and headcount (Details)", "role": "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails", "shortName": "Research and Development, Marketing - Business Development and General and Administrative Expenses - Personnel costs and headcount (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfEmployees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_employee_tgOlBs_VBUSU965g40zMww", "xsiNil": "false" } }, "R119": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_MEEGMYDJTEKMyk14v0SXeA", "decimals": "-3", "first": true, "lang": null, "name": "iva:CorrectiveClaimsFrenchResearchTaxCreditRevenue", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41801 - Disclosure - Other Operating Income (expenses) - (Details)", "role": "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails", "shortName": "Other Operating Income (expenses) - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "lang": null, "name": "iva:ProceedsFromDisposalsOfFixedAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Property, Plant and Equipment", "role": "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R120": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:OtherLongtermProvisions", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41802 - Disclosure - Other Operating Income (expenses) - Additional Information (Details)", "role": "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "shortName": "Other Operating Income (expenses) - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-5", "lang": null, "name": "iva:InitialPublicOfferingInsuranceCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R121": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41901 - Disclosure - Financial Income and Expenses (Details)", "role": "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "shortName": "Financial Income and Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R122": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AccountingProfit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42001 - Disclosure - Income Tax (Details)", "role": "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "shortName": "Income Tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AccountingProfit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R123": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42101 - Disclosure - Commitments (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "shortName": "Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_4_1_2021_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithSpauldingMember_RMn9-iePNEKoSHn2_6rn2A", "decimals": "-5", "lang": null, "name": "iva:CommitmentsAmountPayableForServicesReceivedUnderContract", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_2ztUNSLNGki8lDD0UU_MNw", "xsiNil": "false" } }, "R124": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42102 - Disclosure - Commitments - Commitments Received (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails", "shortName": "Commitments - Commitments Received (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_11_1_2017_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_PremisesAndFacilitiesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_AgreementWithNovolyzeMember_Kg4S8BSBCUuvC2eZETHKhg", "decimals": "-3", "lang": null, "name": "iva:AmountOfIncreaseInMonthlyRent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R125": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2020__eIUru2YIUmpUIbHEmSmWg", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:NotionalAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_2ztUNSLNGki8lDD0UU_MNw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42103 - Disclosure - Commitments - Commitments related to financing activities (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsRelatedToFinancingActivitiesDetails", "shortName": "Commitments - Commitments related to financing activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_ClassesOfFinancialInstrumentsAxis_iva_IfrsForeignExchangeForwardMember_YPWzZqpGCUaLUoyTmIFNbw", "decimals": "-5", "lang": null, "name": "iva:ChangeInFairValueOfDerivatives", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R126": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember__40k3Kn4d0imGFXM4uv-1A", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42201 - Disclosure - Related-Party Transactions - Summary of transactions with key management personnel (Details)", "role": "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails", "shortName": "Related-Party Transactions - Summary of transactions with key management personnel (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember__40k3Kn4d0imGFXM4uv-1A", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R127": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_IslsConsultingMember_tp2OcEUkgEK1LPzlyZsGnQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ServicesReceivedRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42202 - Disclosure - Related-Party Transactions (Details)", "role": "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "shortName": "Related-Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_IslsConsultingMember_tp2OcEUkgEK1LPzlyZsGnQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ServicesReceivedRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R128": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42301 - Disclosure - Basic and Diluted Loss Per Share (Details)", "role": "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "shortName": "Basic and Diluted Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R129": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_7_15_2020_To_7_15_2020_WlcgW-mGqU-r-ZXupdQG3A", "decimals": "-5", "first": true, "lang": null, "name": "iva:GrossProceedsFromIssuingShares", "reportCount": 1, "unitRef": "Unit_Standard_USD_2ztUNSLNGki8lDD0UU_MNw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42401 - Disclosure - Financial Risk management - Exposure to foreign exchange risk (Details)", "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "shortName": "Financial Risk management - Exposure to foreign exchange risk (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Other Non-Current Assets", "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssets", "shortName": "Other Non-Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R130": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsAtFairValue", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42402 - Disclosure - Financial Risk management - Exposure to foreign exchange risk - Sensitivity Analysis (Details)", "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "shortName": "Financial Risk management - Exposure to foreign exchange risk - Sensitivity Analysis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_GifWxCeRTk20dJRgVa6cWg", "decimals": "2", "lang": null, "name": "iva:PercentageOfReasonablyPossibleIncreaseDecreaseInRiskAssumption", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_nQcrkvp6uEG3sOwzjWo2iQ", "xsiNil": "false" } }, "R131": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfGoingConcernExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-5", "first": true, "lang": null, "name": "iva:CollaborativeArrangementMilestonePaymentsReceived", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42501 - Disclosure - Events After the Reporting Date (Details)", "role": "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "shortName": "Events After the Reporting Date (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_1_31_2022_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_ReceiptOfMilestonePaymentsMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ResearchCollaborationWithAbbvieMember_Xgj3IsCeIkaPdbXZN2J92w", "decimals": "-5", "lang": null, "name": "iva:CollaborativeArrangementMilestonePaymentsReceived", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Inventories", "role": "http://www.inventivapharma.com/role/DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Trade Receivables and Other Current Assets and Receivables", "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivables", "shortName": "Trade Receivables and Other Current Assets and Receivables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Cash and Cash Equivalents", "role": "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalents", "shortName": "Cash and Cash Equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Shareholders' Equity", "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Debt", "role": "http://www.inventivapharma.com/role/DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Provisions", "role": "http://www.inventivapharma.com/role/DisclosureProvisions", "shortName": "Provisions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - STATEMENTS OF FINANCIAL POSITION", "role": "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition", "shortName": "STATEMENTS OF FINANCIAL POSITION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "lang": null, "name": "ifrs-full:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Provisions for Retirement Benefit Obligations", "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligations", "shortName": "Provisions for Retirement Benefit Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Trade Payables and Other Current Liabilities", "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilities", "shortName": "Trade Payables and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Financial Assets and Liabilities", "role": "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilities", "shortName": "Financial Assets and Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Revenues and Other Income", "role": "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncome", "shortName": "Revenues and Other Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:ResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11701 - Disclosure - Research and Development, Marketing - Business Development and General and Administrative Expenses", "role": "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpenses", "shortName": "Research and Development, Marketing - Business Development and General and Administrative Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:ResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11801 - Disclosure - Other Operating Income (expenses)", "role": "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpenses", "shortName": "Other Operating Income (expenses)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11901 - Disclosure - Financial Income and Expenses", "role": "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpenses", "shortName": "Financial Income and Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12001 - Disclosure - Income Tax", "role": "http://www.inventivapharma.com/role/DisclosureIncomeTax", "shortName": "Income Tax", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12101 - Disclosure - Commitments", "role": "http://www.inventivapharma.com/role/DisclosureCommitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12201 - Disclosure - Related-Party Transactions", "role": "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - STATEMENTS OF INCOME (LOSS)", "role": "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss", "shortName": "STATEMENTS OF INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12301 - Disclosure - Basic and Diluted Loss Per Share", "role": "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShare", "shortName": "Basic and Diluted Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12401 - Disclosure - Financial Risk Management", "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagement", "shortName": "Financial Risk Management", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12501 - Disclosure - Events After the Reporting Date", "role": "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDate", "shortName": "Events After the Reporting Date", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20302 - Disclosure - Accounting Principles (Policies)", "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies", "shortName": "Accounting Principles (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - General principles and statement of compliance (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceTables", "shortName": "General principles and statement of compliance (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Accounting Principles (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables", "shortName": "Accounting Principles (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Intangible Assets (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Property, Plant and Equipment (Tables)", "role": "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Other Non-Current Assets (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsTables", "shortName": "Other Non-Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:IfrsScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Inventories (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureInventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:IfrsScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "role": "http://www.inventivapharma.com/role/StatementStatementsOfComprehensiveIncomeLoss", "shortName": "STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "lang": null, "name": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfTradeReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Trade Receivables and Other Current Assets and Receivables (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTables", "shortName": "Trade Receivables and Other Current Assets and Receivables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfTradeReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Cash and Cash Equivalents (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsTables", "shortName": "Cash and Cash Equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Debt (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureDebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Provisions (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureProvisionsTables", "shortName": "Provisions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - Provisions for Retirement Benefit Obligations (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables", "shortName": "Provisions for Retirement Benefit Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Trade Payables and Other Current Liabilities (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesTables", "shortName": "Trade Payables and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31503 - Disclosure - Financial Assets and Liabilities (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesTables", "shortName": "Financial Assets and Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31603 - Disclosure - Revenues and Other Income (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeTables", "shortName": "Revenues and Other Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "iva:ResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesTextBlock", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:ResearchAndDevelopmentMarketingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31703 - Disclosure - Research and Development, Marketing - Business Development and General and Administrative Expenses (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesTables", "shortName": "Research and Development, Marketing - Business Development and General and Administrative Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "iva:ResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesTextBlock", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:ResearchAndDevelopmentMarketingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - STATEMENTS OF CASH FLOWS", "role": "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows", "shortName": "STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "lang": null, "name": "iva:AdjustmentsForDepreciationAmortisationAndProvisions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31803 - Disclosure - Other Operating Income (expenses) - (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesTables", "shortName": "Other Operating Income (expenses) - (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:FinancialIncomeAndExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31903 - Disclosure - Financial Income and Expenses (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesTables", "shortName": "Financial Income and Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:FinancialIncomeAndExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32003 - Disclosure - Income Tax (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureIncomeTaxTables", "shortName": "Income Tax (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32203 - Disclosure - Related-Party Transactions (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsTables", "shortName": "Related-Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32303 - Disclosure - Basic and Diluted Loss Per Share (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareTables", "shortName": "Basic and Diluted Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32403 - Disclosure - Financial Risk Management (Tables)", "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementTables", "shortName": "Financial Risk Management (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_6_9_2021_To_6_9_2021_tcjaAXzMQECsOSvgziDWWA", "decimals": "-5", "first": true, "lang": null, "name": "iva:AmountOfOffsettingVatCreditReceivables", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Company Information - Tax audit on payroll tax (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "shortName": "Company Information - Tax audit on payroll tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_ClassesOfProvisionsAxis_iva_ProvisionForTaxAuditForYearsEnded20132014And2015Member_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_GuaranteeGivenToTaxAuthoritiesMember_1-RSGhwa_kSvQAXYky4x6A", "decimals": "-5", "lang": null, "name": "ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-5", "first": true, "lang": null, "name": "iva:AmountOfSubcontractingTaxRebateGrantedByTaxAuthorities", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40102 - Disclosure - Company Information - Tax audit on research tax credit (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "shortName": "Company Information - Tax audit on research tax credit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_6_30_2018_ifrs-full_ClassesOfProvisionsAxis_iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYears2013To2015Member_RZc9lFR6QUaZ1235-4A88A", "decimals": "-5", "lang": null, "name": "iva:AmountOfAdditionalClaim", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_2ztUNSLNGki8lDD0UU_MNw", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_4_16_2021_To_4_16_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_5td8xzBu5ECeeuQHb3GodQ", "decimals": "INF", "first": true, "lang": null, "name": "iva:ClassOfWarrantOrRightGranted", "reportCount": 1, "unitRef": "Unit_Standard_shares_qjDrgh6Tl0-VIiAV30E1vQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40103 - Disclosure - Company Information - Capital increase (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseDetails", "shortName": "Company Information - Capital increase (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardsMember_Tm2NyB4Kh0GA7mdu4oEasQ", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "Unit_Standard_pure_nQcrkvp6uEG3sOwzjWo2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40104 - Disclosure - Company Information - Vesting of bonus shares (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationVestingOfBonusSharesDetails", "shortName": "Company Information - Vesting of bonus shares (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "iva:AdjustmentsForSubscriptionsToShareWarrants", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00405 - Statement - STATEMENTS OF CASH FLOWS (Parenthetical)", "role": "http://www.inventivapharma.com/role/StatementStatementsOfCashFlowsParenthetical", "shortName": "STATEMENTS OF CASH FLOWS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "link:footnote", "p", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "iva:AdjustmentsForSubscriptionsToShareWarrants", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_6_30_2021_To_6_30_2021_Z-nW-Des6EKJTO4XIJx4EA", "decimals": "-5", "first": true, "lang": null, "name": "iva:PaymentsReceivedFromResearchTaxCredit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40105 - Disclosure - Company Information - Payments received from the Research Tax Credit (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationPaymentsReceivedFromResearchTaxCreditDetails", "shortName": "Company Information - Payments received from the Research Tax Credit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_6_30_2021_To_6_30_2021_Z-nW-Des6EKJTO4XIJx4EA", "decimals": "-5", "first": true, "lang": null, "name": "iva:PaymentsReceivedFromResearchTaxCredit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2020__eIUru2YIUmpUIbHEmSmWg", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:NotionalAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_2ztUNSLNGki8lDD0UU_MNw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40106 - Disclosure - Company Information - Unwinding of the three forward contracts (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationUnwindingOfThreeForwardContractsDetails", "shortName": "Company Information - Unwinding of the three forward contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_ifrs-full_ClassesOfFinancialInstrumentsAxis_iva_IfrsForeignExchangeForwardMember_ztwg8dKZyUiZEI4UgC1FbQ", "decimals": "INF", "lang": null, "name": "iva:NumberOfForwardContractsExpired", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_contract_X6vmbOOEuE-okO22eMiUgg", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IssueOfEquity", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40107 - Disclosure - Company Information - Equity financing (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "shortName": "Company Information - Equity financing (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_8_2_2021_To_8_2_2021_ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis_iva_IfrsAdrMember_XWt6f1mzqUuWzXNRxP1bWA", "decimals": "-6", "lang": null, "name": "iva:MaximumAggregateSalesProceedsFromIssuanceOfShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_2ztUNSLNGki8lDD0UU_MNw", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_3_31_2021_To_3_31_2021_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_VzUuA49zuk-S--029BoRBw", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary", "reportCount": 1, "unitRef": "Unit_Standard_pure_nQcrkvp6uEG3sOwzjWo2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40108 - Disclosure - Company Information - Creation of Inventiva U.S. subsidiary (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationCreationOfInventivaUsSubsidiaryDetails", "shortName": "Company Information - Creation of Inventiva U.S. subsidiary (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_EUR_shares_uU7QOFDg1EW-7-3SvA2hhQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40109 - Disclosure - Company Information - Capital increase of 14.7 million (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails", "shortName": "Company Information - Capital increase of 14.7 million (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_2_7_2020_To_2_7_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_BvfPartnersL.p.NovoSNewEnterpriseAssociates17L.p.AndSofinnovaPartnersMember_w4ihjyKwZ0C_72Q8rMC4xg", "decimals": "INF", "lang": null, "name": "ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_qjDrgh6Tl0-VIiAV30E1vQ", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_7_15_2020_To_7_15_2020_WlcgW-mGqU-r-ZXupdQG3A", "decimals": "-5", "first": true, "lang": null, "name": "iva:GrossProceedsFromIssuingShares", "reportCount": 1, "unitRef": "Unit_Standard_USD_2ztUNSLNGki8lDD0UU_MNw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40110 - Disclosure - Company Information - USD 107.7 million initial public offering (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "shortName": "Company Information - USD 107.7 million initial public offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_7_15_2020_dDhxwMhpX0O-CpNhqG44Lw", "decimals": "-5", "lang": null, "name": "iva:InsuranceCoveragePremium", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_2ztUNSLNGki8lDD0UU_MNw", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40111 - Disclosure - Company Information - Bonus share award plans (\"AGA\") (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "shortName": "Company Information - Bonus share award plans (\"AGA\") (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_6_28_2021_To_6_28_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20191Member_VWtCEJfheUy7NH6B1IKdlg", "decimals": "-3", "lang": null, "name": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_WFZIDfPG8U2JufZ6gWxr5Q", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "reportCount": 1, "unitRef": "Unit_Standard_item_hkKLZPruOkSvvdkkyulN2w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40112 - Disclosure - Company information - New share warrant plans (\"BSA\") (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "shortName": "Company information - New share warrant plans (\"BSA\") (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R68": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_ifrs-full_ClassesOfProvisionsAxis_iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2018Member_EEZKWq2q8U2s9q8DMSv6ng", "decimals": "-5", "first": true, "lang": null, "name": "iva:ProceedsFromFrenchResearchTaxCredit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40113 - Disclosure - Company Information - Research tax credit (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationResearchTaxCreditDetails", "shortName": "Company Information - Research tax credit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_ifrs-full_ClassesOfProvisionsAxis_iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2018Member_EEZKWq2q8U2s9q8DMSv6ng", "decimals": "-5", "first": true, "lang": null, "name": "iva:ProceedsFromFrenchResearchTaxCredit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_MEEGMYDJTEKMyk14v0SXeA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40114 - Disclosure - Company Information - Non-dilutive financing (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationNonDilutiveFinancingDetails", "shortName": "Company Information - Non-dilutive financing (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_5_1_2020_To_5_31_2020_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_XQ1TQb5yIEufCcrW5du3zQ", "decimals": "INF", "lang": null, "name": "iva:NumberOfLoansObtainedGuaranteedByFrenchState", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_loan_ZzBqOHhYyEmnMYxdTaRn7w", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_CLypZ5XXaEONBW7yU0p5CA", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00500 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "role": "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity", "shortName": "STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_d0aDQNXRW0W5vwFli-GSOg", "decimals": "-3", "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_12_31_2020_To_12_31_2020_ifrs-full_ClassesOfFinancialInstrumentsAxis_iva_IfrsForeignExchangeForwardMember_qd0f4d-YGUWTPir0VdvBGg", "decimals": "0", "first": true, "lang": null, "name": "iva:NumberOfDerivativeContractsCompleted", "reportCount": 1, "unitRef": "Unit_Standard_contract_X6vmbOOEuE-okO22eMiUgg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40115 - Disclosure - Company Information - Completion of a future currency contract (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompletionOfFutureCurrencyContractDetails", "shortName": "Company Information - Completion of a future currency contract (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_10_1_2020_To_10_31_2020_ifrs-full_ClassesOfFinancialInstrumentsAxis_iva_IfrsForeignExchangeForwardMember_ipwWwxF4P0CqZa17YPR89g", "decimals": "-6", "lang": null, "name": "iva:NotionalAmountOfForwardContractsCompleted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_2ztUNSLNGki8lDD0UU_MNw", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_9_1_2020_To_10_31_2020_1aEtSNXzN0askK2iFh4uKA", "decimals": "-6", "first": true, "lang": null, "name": "iva:ReinvestmentOfShortTermDeposits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_2ztUNSLNGki8lDD0UU_MNw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40116 - Disclosure - Company Information - Reinvestment of short-term USD deposits (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationReinvestmentOfShortTermUsdDepositsDetails", "shortName": "Company Information - Reinvestment of short-term USD deposits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_9_1_2020_To_10_31_2020_1aEtSNXzN0askK2iFh4uKA", "decimals": "-6", "first": true, "lang": null, "name": "iva:ReinvestmentOfShortTermDeposits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_2ztUNSLNGki8lDD0UU_MNw", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_3_31_2021_To_3_31_2021_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_VzUuA49zuk-S--029BoRBw", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary", "reportCount": 1, "unitRef": "Unit_Standard_pure_nQcrkvp6uEG3sOwzjWo2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - General principles and statement of compliance - Significant Investments In Subsidiaries (Details)", "role": "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "shortName": "General principles and statement of compliance - Significant Investments In Subsidiaries (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R73": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - General principles and statement of compliance - Consolidated financial statements (Details)", "role": "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "shortName": "General principles and statement of compliance - Consolidated financial statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutConsolidatedStructuredEntitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "lang": null, "name": "ifrs-full:Assets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_2ztUNSLNGki8lDD0UU_MNw", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:AverageForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_EUR_GNDns89KoU-ccphUYMQcCA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40203 - Disclosure - General principles and statement of compliance - Foreign Exchange Rates (Details)", "role": "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceForeignExchangeRatesDetails", "shortName": "General principles and statement of compliance - Foreign Exchange Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:AverageForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_EUR_GNDns89KoU-ccphUYMQcCA", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-full_ComputerSoftwareMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_85rP8lKMO0OMuQ9FBvITTw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Accounting Principles - Intangible assets (Details)", "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesIntangibleAssetsDetails", "shortName": "Accounting Principles - Intangible assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ifrs-full_ComputerSoftwareMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_85rP8lKMO0OMuQ9FBvITTw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_zVr9lIj_o0SCmQ4rqTcqOQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Accounting Principles - Property, plant and equipment (Details)", "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "shortName": "Accounting Principles - Property, plant and equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_zVr9lIj_o0SCmQ4rqTcqOQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_InitiallyAppliedIFRSsAxis_iva_Ifrs16Member_a2ne8-MS-UWNtkUrL-eEag", "decimals": "0", "first": true, "lang": null, "name": "iva:IFRS16RestatementThreshold", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - Accounting Principles - Leases contracts (Details)", "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesLeasesContractsDetails", "shortName": "Accounting Principles - Leases contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_InitiallyAppliedIFRSsAxis_iva_Ifrs16Member_a2ne8-MS-UWNtkUrL-eEag", "decimals": "0", "first": true, "lang": null, "name": "iva:IFRS16RestatementThreshold", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40304 - Disclosure - Accounting Principles - Fair value measurement (Details)", "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "shortName": "Accounting Principles - Fair value measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2019_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_0Cj7-0MASEqQbAaGackt4A", "decimals": "0", "lang": null, "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-5", "first": true, "lang": null, "name": "iva:AmountOfPurchasesInForeignCurrencyTranslatedToReportingCurrency", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40305 - Disclosure - Accounting Principles - Foreign currency transactions and Segment information (Details)", "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesForeignCurrencyTransactionsAndSegmentInformationDetails", "shortName": "Accounting Principles - Foreign currency transactions and Segment information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-5", "first": true, "lang": null, "name": "iva:AmountOfPurchasesInForeignCurrencyTranslatedToReportingCurrency", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:CompanyInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Company Information", "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformation", "shortName": "Company Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:CompanyInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "0", "first": true, "lang": null, "name": "iva:IfrsNumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_nQcrkvp6uEG3sOwzjWo2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40306 - Disclosure - Accounting Principles - Segment information (Details)", "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesSegmentInformationDetails", "shortName": "Accounting Principles - Segment information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "0", "first": true, "lang": null, "name": "iva:IfrsNumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_nQcrkvp6uEG3sOwzjWo2iQ", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40307 - Disclosure - Accounting Principles - Going Concern (Details)", "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "shortName": "Accounting Principles - Going Concern (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfGoingConcernExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-5", "lang": null, "name": "ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2020__eIUru2YIUmpUIbHEmSmWg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Intangible Assets (Details)", "role": "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2018_-tQYh-2oiUutn7BqujwjuQ", "decimals": "-3", "lang": null, "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2020__eIUru2YIUmpUIbHEmSmWg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Property, Plant and Equipment (Details)", "role": "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails", "shortName": "Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2018_-tQYh-2oiUutn7BqujwjuQ", "decimals": "-3", "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2019_dV4NCvwvD0Gakn6b74Gvaw", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentAccruedIncomeIncludingNoncurrentContractAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Other Non-Current Assets (Details)", "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails", "shortName": "Other Non-Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2019_dV4NCvwvD0Gakn6b74Gvaw", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncurrentAccruedIncomeIncludingNoncurrentContractAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-6", "first": true, "lang": null, "name": "iva:IndemnificationAmountReceivableUnderGuaranteeMaximum", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Other Non-Current Assets - Long-term deposit accounts (Details)", "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails", "shortName": "Other Non-Current Assets - Long-term deposit accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "lang": "en-US", "name": "iva:PeriodForTaxCreditRecoverable", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Inventories", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Inventories (Details)", "role": "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:IfrsScheduleOfInventoryCurrentTableTextBlock", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_NfUzNdRRFUyhEjWlWOHKYA", "decimals": "-3", "lang": null, "name": "ifrs-full:Inventories", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentTradeReceivables", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Trade Receivables and Other Current Assets and Receivables - Trade Receivables (Details)", "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "shortName": "Trade Receivables and Other Current Assets and Receivables - Trade Receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "lang": "en-US", "name": "iva:CurrentTradeReceivablesAveragePaymentPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "iva:CurrentTaxCreditResearch", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Trade Receivables and Other Current Assets and Receivables - Other Current Assets and Receivables (Details)", "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "shortName": "Trade Receivables and Other Current Assets and Receivables - Other Current Assets and Receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "iva:CurrentTaxCreditResearch", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfGoingConcernExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-5", "first": true, "lang": null, "name": "iva:TaxCreditsReceivableResearchCreditsFromCurrentTaxYearCurrent", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Trade Receivables and Other Current Assets and Receivables - Additional Information (Details)", "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "shortName": "Trade Receivables and Other Current Assets and Receivables - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": "-5", "lang": null, "name": "iva:TaxCreditsReceivableResearchCreditsFromPriorTaxYearsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:StatementOfIFRSCompliance", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - General principles and statement of compliance", "role": "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfCompliance", "shortName": "General principles and statement of compliance", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_HokPjaQgVk6SsrrFN2hFAA", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:StatementOfIFRSCompliance", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Cash and Cash Equivalents (Details)", "role": "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails", "shortName": "Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IssuedCapital", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Shareholders' Equity (Details)", "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityDetails", "shortName": "Shareholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R92": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_TY285_lNM0qHqGtp23S1rQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Shareholders' Equity - Changes in share capital (Details)", "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "shortName": "Shareholders' Equity - Changes in share capital (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_4_18_2020_To_4_18_2020_ttoI0oVqeU-qbuiWRcl0Dw", "decimals": "-5", "lang": null, "name": "iva:ReclassificationOfAccumulatedDeficitRetainedEarningsToPremiumToShareCapital", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_EUR_XOSkqjTOuUqApmT4_Y6ncg", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_19_2018_To_1_19_2018_27hAm-KfGUWJcCnqT1J1JA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:LiquidityAgreementTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Shareholders' Equity - Liquidity agreement (Details)", "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityLiquidityAgreementDetails", "shortName": "Shareholders' Equity - Liquidity agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_19_2018_To_1_19_2018_27hAm-KfGUWJcCnqT1J1JA", "decimals": null, "first": true, "lang": "en-US", "name": "iva:LiquidityAgreementTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2017_To_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DirectorsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_wHq-VF_L_EmfoCAa2AvoCQ", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_EUR_shares_uU7QOFDg1EW-7-3SvA2hhQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41004 - Disclosure - Shareholders' Equity - Share warrants plans (Details)", "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "shortName": "Shareholders' Equity - Share warrants plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2017_To_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DirectorsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_wHq-VF_L_EmfoCAa2AvoCQ", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_EUR_shares_uU7QOFDg1EW-7-3SvA2hhQ", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_DUbz_NuCkkqN56KcZwQuuw", "decimals": "INF", "first": true, "lang": null, "name": "iva:IfrsClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_qjDrgh6Tl0-VIiAV30E1vQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41005 - Disclosure - Shareholders' Equity - Characteristics of BSPCE share warrants plans (Details)", "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "shortName": "Shareholders' Equity - Characteristics of BSPCE share warrants plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_U6nKJwiEGUCADZ9jh8CUzA", "decimals": "INF", "lang": null, "name": "iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_qjDrgh6Tl0-VIiAV30E1vQ", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_vnCvFHIT8kar3aPQk_smQw", "decimals": "3", "first": true, "lang": null, "name": "iva:SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_EUR_shares_uU7QOFDg1EW-7-3SvA2hhQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41006 - Disclosure - Shareholders' Equity - Characteristics of BSA share warrant plans (Details)", "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "shortName": "Shareholders' Equity - Characteristics of BSA share warrant plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_vnCvFHIT8kar3aPQk_smQw", "decimals": "3", "first": true, "lang": null, "name": "iva:SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_EUR_shares_uU7QOFDg1EW-7-3SvA2hhQ", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_gTpgN4IvkkedJJDFa0dfLA", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "reportCount": 1, "unitRef": "Unit_Divide_EUR_shares_uU7QOFDg1EW-7-3SvA2hhQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41007 - Disclosure - Shareholders' Equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)", "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "shortName": "Shareholders' Equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_gTpgN4IvkkedJJDFa0dfLA", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_nQcrkvp6uEG3sOwzjWo2iQ", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_cTdIFteB-UmRbndSrQMmbg", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "reportCount": 1, "unitRef": "Unit_Standard_pure_nQcrkvp6uEG3sOwzjWo2iQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41008 - Disclosure - Shareholders' Equity - Bonus share award plans (Details)", "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "shortName": "Shareholders' Equity - Bonus share award plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20191Member_y07n02OYLkqxZbWAN__nTA", "decimals": null, "lang": "en-US", "name": "iva:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_7YbvvvqRFkKBY1ARsG2bbg", "decimals": "INF", "first": true, "lang": null, "name": "iva:NumberOfNewSharesIssuedUponVestingOfAwardsInShareBasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_qjDrgh6Tl0-VIiAV30E1vQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41009 - Disclosure - Shareholders' Equity - Bonus share movements (in number of shares issuable upon exercise) (Details)", "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "shortName": "Shareholders' Equity - Bonus share movements (in number of shares issuable upon exercise) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "iva-20201231x20f.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_7YbvvvqRFkKBY1ARsG2bbg", "decimals": "INF", "first": true, "lang": null, "name": "iva:NumberOfNewSharesIssuedUponVestingOfAwardsInShareBasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_qjDrgh6Tl0-VIiAV30E1vQ", "xsiNil": "false" } } }, "segmentCount": 180, "tag": { "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "USD" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r283", "r284", "r285" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ifrs-full_AccountingProfit": { "auth_ref": [ "r58", "r59" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Accounting profit", "terseLabel": "Loss before tax" } } }, "localname": "AccountingProfit", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccrualsClassifiedAsCurrent": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } }, "en-us": { "role": { "label": "Accruals classified as current", "terseLabel": "Accrued expenses" } } }, "localname": "AccrualsClassifiedAsCurrent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "auth_ref": [ "r67", "r74", "r122", "r132", "r135" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Amortization and impairment" } } }, "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AccumulatedImpairmentMember": { "auth_ref": [ "r67", "r122", "r132", "r135", "r204", "r215", "r220", "r272", "r277" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]" } }, "en-us": { "role": { "label": "Inventories write-down" } } }, "localname": "AccumulatedImpairmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "auth_ref": [ "r81" ], "lang": { "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]" } }, "en-us": { "role": { "label": "Actuarial assumption of discount rates", "terseLabel": "Discount rate" } } }, "localname": "ActuarialAssumptionOfDiscountRates", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": { "auth_ref": [ "r83" ], "lang": { "en": { "role": { "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [member]]" } }, "en-us": { "role": { "label": "Discount rate" } } }, "localname": "ActuarialAssumptionOfDiscountRatesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": { "auth_ref": [ "r81" ], "lang": { "en": { "role": { "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]" } }, "en-us": { "role": { "label": "Actuarial assumption of expected rates of salary increases", "terseLabel": "Salary growth rate" } } }, "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ActuarialAssumptionOfRetirementAge2019": { "auth_ref": [ "r81" ], "lang": { "en": { "role": { "documentation": "The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]" } }, "en-us": { "role": { "label": "Actuarial assumption of retirement age", "terseLabel": "Retirement age" } } }, "localname": "ActuarialAssumptionOfRetirementAge2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_ActuarialAssumptionsAxis": { "auth_ref": [ "r83" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Actuarial assumptions [axis]" } } }, "localname": "ActuarialAssumptionsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ActuarialAssumptionsMember": { "auth_ref": [ "r83" ], "lang": { "en": { "role": { "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used." } }, "en-us": { "role": { "label": "Actuarial assumptions [member]" } } }, "localname": "ActuarialAssumptionsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans": { "auth_ref": [ "r76" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions]" } }, "en-us": { "role": { "label": "Actuarial gains (losses) arising from changes in demographic assumptions, net of tax, defined benefit plans", "terseLabel": "Demographic changes" } } }, "localname": "ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans": { "auth_ref": [ "r76" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions]" } }, "en-us": { "role": { "label": "Actuarial gains (losses) arising from changes in financial assumptions, net of tax, defined benefit plans", "terseLabel": "Changes in actuarial assumptions" } } }, "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionalProvisionsOtherProvisions": { "auth_ref": [ "r118" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of additional other provisions made. [Refer: Other provisions]" } }, "en-us": { "role": { "label": "Additional provisions, other provisions", "terseLabel": "Additions", "verboseLabel": "Additional provisions" } } }, "localname": "AdditionalProvisionsOtherProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Additions other than through business combinations, property, plant and equipment", "terseLabel": "Acquisitions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustedWeightedAverageShares": { "auth_ref": [ "r112" ], "lang": { "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Adjusted weighted average number of ordinary shares outstanding", "terseLabel": "Weighted average number of outstanding shares used for computing diluted loss per share" } } }, "localname": "AdjustedWeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "sharesItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "auth_ref": [ "r146" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "terseLabel": "Decrease / (Increase) in inventories" } } }, "localname": "AdjustmentsForDecreaseIncreaseInInventories", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in prepaid expenses", "terseLabel": "Decrease / (increase) of prepaid expenses" } } }, "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "auth_ref": [ "r148" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Decrease / (Increase) in operating and other receivables" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "auth_ref": [ "r147" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for fair value losses (gains)", "terseLabel": "Fair value variation in the result" } } }, "localname": "AdjustmentsForFairValueGainsLosses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "auth_ref": [ "r148" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for finance income (cost)", "negatedLabel": "Cost of net debt" } } }, "localname": "AdjustmentsForFinanceIncomeCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "auth_ref": [ "r153" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Deferred and current taxes" } } }, "localname": "AdjustmentsForIncomeTaxExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "auth_ref": [ "r148" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "negatedLabel": "Increase / (Decrease) in operating and other payables" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Elimination of other non-cash, non-operating income and expenses" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r147" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "auth_ref": [ "r147", "r158" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for unrealised foreign exchange losses (gains)", "terseLabel": "Exchange gains / losses" } } }, "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedMeasurementMember": { "auth_ref": [ "r130", "r134", "r180" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated measurement [member]" } } }, "localname": "AggregatedMeasurementMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r27", "r84", "r189", "r194", "r195", "r208", "r233", "r237", "r256", "r257", "r259", "r265" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtBreakdownBetweenLongTermAndShortTermDebtDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfTradePayablesBreakDownByPaymentDateDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "auth_ref": [ "r80", "r181" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } }, "en-us": { "role": { "label": "All levels of fair value hierarchy [member]" } } }, "localname": "AllLevelsOfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r124" ], "lang": { "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Amortisation, intangible assets other than goodwill", "terseLabel": "Depreciation expenses" } } }, "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AmountsArisingFromInsuranceContractsAxis": { "auth_ref": [ "r270" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Amounts arising from insurance contracts [axis]" } } }, "localname": "AmountsArisingFromInsuranceContractsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r59" ], "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Applicable tax rate", "verboseLabel": "Theoretical tax rate" } } }, "localname": "ApplicableTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r24", "r180", "r181", "r182", "r246", "r249" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "terseLabel": "Total assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_AtFairValueMember": { "auth_ref": [ "r130", "r134", "r180" ], "lang": { "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } }, "en-us": { "role": { "label": "At fair value" } } }, "localname": "AtFairValueMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "auth_ref": [ "r3", "r11" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } } }, "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AverageEffectiveTaxRate": { "auth_ref": [ "r59" ], "lang": { "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Average effective tax rate", "terseLabel": "Effective tax rate" } } }, "localname": "AverageEffectiveTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_AverageForeignExchangeRate": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } }, "en-us": { "role": { "label": "Average foreign exchange rate", "terseLabel": "Average exchange rate for the period" } } }, "localname": "AverageForeignExchangeRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceForeignExchangeRatesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_BalancesWithBanks": { "auth_ref": [ "r155" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash balances held at banks." } }, "en-us": { "role": { "label": "Balances with banks", "verboseLabel": "Bank accounts" } } }, "localname": "BalancesWithBanks", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r110", "r111" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic loss per share" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "perShareItemType" }, "ifrs-full_Borrowings": { "auth_ref": [ "r24" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } }, "en-us": { "role": { "label": "Borrowings", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total debt", "verboseLabel": "Total longterm debt" } } }, "localname": "Borrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtBreakdownBetweenLongTermAndShortTermDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails", "http://www.inventivapharma.com/role/DisclosureDebtRepaymentsOfBorrowingsAndAccrualOfInterestsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BorrowingsByNameAxis": { "auth_ref": [ "r227" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Borrowings by name [axis]" } } }, "localname": "BorrowingsByNameAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNonDilutiveFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BorrowingsByNameMember": { "auth_ref": [ "r227" ], "lang": { "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings by name [member]" } } }, "localname": "BorrowingsByNameMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNonDilutiveFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r184", "r185", "r186", "r198", "r227", "r259" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom of range [Member]", "terseLabel": "Minimum" } } }, "localname": "BottomOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BuildingsMember": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Buildings" } } }, "localname": "BuildingsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CapitalCommitmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments" } } }, "localname": "CapitalCommitmentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "auth_ref": [ "r67", "r71", "r122", "r125", "r131", "r132", "r133", "r134", "r135", "r204", "r215", "r216", "r272", "r278" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountMember": { "auth_ref": [ "r71", "r125", "r131", "r133", "r134", "r204", "r215", "r216", "r272", "r276" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Carrying amount [member]" } } }, "localname": "CarryingAmountMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r155" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash", "terseLabel": "Cash at bank and at hand" } } }, "localname": "Cash", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r19", "r155", "r175" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalent", "periodEndLabel": "Net cash and cash equivalents at end of period", "periodStartLabel": "Net cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "auth_ref": [ "r139" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } }, "en-us": { "role": { "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments", "terseLabel": "Decrease / (Increase) in short-term deposit accounts" } } }, "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r136", "r157" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash flows provided by financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows provided by (used in) financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r136", "r157" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash flows used in investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows provided by (used in) investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r136", "r157" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash flows used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows provided by (used in) operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "auth_ref": [ "r148", "r158" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } }, "en-us": { "role": { "label": "Cash flows used in operations before tax, interest and changes in working capital" } } }, "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of financial assets [axis]" } } }, "localname": "CategoriesOfFinancialAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of financial liabilities [axis]" } } }, "localname": "CategoriesOfFinancialLiabilitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r101" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsAxis": { "auth_ref": [ "r114", "r116", "r183", "r193" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of assets [axis]" } } }, "localname": "ClassesOfAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsMember": { "auth_ref": [ "r114", "r183", "r193" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } }, "en-us": { "role": { "label": "Assets [member]" } } }, "localname": "ClassesOfAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "auth_ref": [ "r225", "r226", "r255", "r266", "r267", "r268" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial assets [axis]" } } }, "localname": "ClassesOfFinancialAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "auth_ref": [ "r215", "r217", "r219", "r221" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial instruments [axis]" } } }, "localname": "ClassesOfFinancialInstrumentsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsRelatedToFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompletionOfFutureCurrencyContractDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUnwindingOfThreeForwardContractsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "auth_ref": [ "r215", "r217", "r219", "r221" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial instruments, class [member]" } } }, "localname": "ClassesOfFinancialInstrumentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsRelatedToFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompletionOfFutureCurrencyContractDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUnwindingOfThreeForwardContractsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "auth_ref": [ "r225", "r226", "r255", "r267" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } } }, "localname": "ClassesOfFinancialLiabilitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "auth_ref": [ "r126" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfInventoriesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories" } } }, "localname": "ClassesOfInventoriesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r72" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfProvisionsAxis": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of other provisions [axis]" } } }, "localname": "ClassesOfProvisionsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r39" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r39" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "ifrs-full_ClosingForeignExchangeRate": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } }, "en-us": { "role": { "label": "Closing foreign exchange rate", "terseLabel": "Exchange rate at period end" } } }, "localname": "ClosingForeignExchangeRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceForeignExchangeRatesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_CommunicationAndNetworkEquipmentMember": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing communications and network equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Technical facilities, equipment and tooling" } } }, "localname": "CommunicationAndNetworkEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r4", "r43", "r162", "r164", "r167", "r172" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComputerEquipmentMember": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "IT equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ComputerSoftwareMember": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Software licenses" } } }, "localname": "ComputerSoftwareMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ConsolidatedStructuredEntitiesAxis": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Consolidated structured entities [axis]" } } }, "localname": "ConsolidatedStructuredEntitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceConsolidatedFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ConstructionInProgressMember": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property, plant and equipment in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CounterpartiesAxis": { "auth_ref": [ "r238" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Counterparties [axis]" } } }, "localname": "CounterpartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CounterpartiesMember": { "auth_ref": [ "r238" ], "lang": { "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } }, "en-us": { "role": { "label": "Counterparties [member]" } } }, "localname": "CounterpartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrencyRiskMember": { "auth_ref": [ "r241", "r260", "r261", "r262", "r263" ], "lang": { "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Exposure to foreign exchange risk" } } }, "localname": "CurrencyRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets": { "auth_ref": [ "r24", "r36" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "order": 3.0, "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]" } }, "en-us": { "role": { "label": "Current accrued income including current contract assets", "terseLabel": "Current accrued income" } } }, "localname": "CurrentAccruedIncomeIncludingCurrentContractAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r28", "r167", "r168" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "auth_ref": [ "r24" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Current borrowings and current portion of non-current borrowings", "terseLabel": "Short-term debt" } } }, "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r30", "r167", "r170" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPrepaidExpenses": { "auth_ref": [ "r11" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } }, "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Prepaid expenses" } } }, "localname": "CurrentPrepaidExpenses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentProvisions": { "auth_ref": [ "r21" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Current provisions", "terseLabel": "Short-term provisions" } } }, "localname": "CurrentProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]" } }, "en-us": { "role": { "label": "Current receivables from taxes other than income tax", "terseLabel": "Tax receivables" } } }, "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentServiceCostDefinedBenefitPlans": { "auth_ref": [ "r76" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForPeriodDetails": { "order": 1.0, "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of employee service in the current period arising from defined benefit plans. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase in net defined benefit liability (asset) resulting from current service cost]" } }, "en-us": { "role": { "label": "Current service cost, defined benefit plans", "negatedLabel": "Service cost for the period" } } }, "localname": "CurrentServiceCostDefinedBenefitPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForPeriodDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxAssetsNoncurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails": { "order": 2.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The non-current amount of current tax assets. [Refer: Current tax assets]" } }, "en-us": { "role": { "label": "Current tax assets, non-current", "terseLabel": "Tax loss carry back" } } }, "localname": "CurrentTaxAssetsNoncurrent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxExpenseIncome": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } }, "en-us": { "role": { "label": "Current tax expense (income)", "terseLabel": "Current taxes" } } }, "localname": "CurrentTaxExpenseIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTradeReceivables": { "auth_ref": [ "r29", "r33" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Current trade receivables", "terseLabel": "Trade receivables" } } }, "localname": "CurrentTradeReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentValueAddedTaxPayables": { "auth_ref": [ "r36" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]" } }, "en-us": { "role": { "label": "Current value added tax payables", "terseLabel": "Sales tax payables" } } }, "localname": "CurrentValueAddedTaxPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxAssets": { "auth_ref": [ "r23", "r25", "r60" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Deferred tax assets", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DefinedBenefitObligationAtPresentValue": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]" } }, "en-us": { "role": { "label": "Defined benefit obligation, at present value", "terseLabel": "Benefit obligation at December 31" } } }, "localname": "DefinedBenefitObligationAtPresentValue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "auth_ref": [ "r70", "r73" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation, property, plant and equipment", "terseLabel": "Depreciation charges" } } }, "localname": "DepreciationPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Description of accounting policy for borrowings [text block]", "terseLabel": "Loans and borrowings" } } }, "localname": "DescriptionOfAccountingPolicyForBorrowingsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for derivative financial instruments. [Refer: Financial instruments, class [member]; Derivatives [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for derivative financial instruments [text block]", "terseLabel": "Derivatives" } } }, "localname": "DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Provisions for retirement benefit obligations" } } }, "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for fair value measurement [text block]", "terseLabel": "Fair value measurement" } } }, "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for finance income and costs. [Refer: Finance income (cost)]" } }, "en-us": { "role": { "label": "Description of accounting policy for finance income and costs [text block]", "terseLabel": "Net financial income" } } }, "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for foreign currency translation." } }, "en-us": { "role": { "label": "Description of accounting policy for foreign currency translation [text block]", "terseLabel": "Foreign currency transactions" } } }, "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Description of accounting policy for impairment of non-financial assets [text block]", "terseLabel": "Impairment of non-financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for income tax." } }, "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Current and deferred tax" } } }, "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Description of accounting policy for intangible assets other than goodwill [text block]", "terseLabel": "Intangible assets" } } }, "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for issued capital. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Description of accounting policy for issued capital [text block]", "terseLabel": "Share capital" } } }, "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } }, "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Lease contracts" } } }, "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "auth_ref": [ "r89" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Description of accounting policy for measuring inventories [text block]", "terseLabel": "Inventories" } } }, "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "terseLabel": "Property, plant and equipment" } } }, "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for provisions. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Description of accounting policy for provisions [text block]", "terseLabel": "Other provisions" } } }, "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Description of accounting policy for recognition of revenue [text block]", "terseLabel": "Revenue" } } }, "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for segment reporting." } }, "en-us": { "role": { "label": "Description of accounting policy for segment reporting [text block]", "terseLabel": "Segment information" } } }, "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Share-based payments" } } }, "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Description of accounting policy for trade and other payables [text block]", "terseLabel": "Trade payables and other current liabilities" } } }, "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for trade and other receivables. [Refer: Trade and other receivables]" } }, "en-us": { "role": { "label": "Description of accounting policy for trade and other receivables [text block]", "terseLabel": "Trade receivables" } } }, "localname": "DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for trading income and expense. [Refer: Trading income (expense)]" } }, "en-us": { "role": { "label": "Description of accounting policy for trading income and expense [text block]", "terseLabel": "Other operating income and expenses" } } }, "localname": "DescriptionOfAccountingPolicyForTradingIncomeAndExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "auth_ref": [ "r156" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "The option life of share options granted." } }, "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Average life (years)" } } }, "localname": "DescriptionOfOptionLifeShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk free rate" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r110", "r111" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted loss per share" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "perShareItemType" }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Use of estimates and judgment" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [line items]" } } }, "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "auth_ref": [ "r3", "r11" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to attribution of expenses by nature to analysis of expenses by function in the statement of profit or loss." } }, "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [table]" } } }, "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Disclosure of borrowings [text block]", "terseLabel": "Debt" } } }, "localname": "DisclosureOfBorrowingsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders' Equity" } } }, "localname": "DisclosureOfClassesOfShareCapitalAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "auth_ref": [ "r39" ], "lang": { "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of changes in share capital" } } }, "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]" } } }, "localname": "DisclosureOfClassesOfShareCapitalLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "auth_ref": [ "r39" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } } }, "localname": "DisclosureOfClassesOfShareCapitalTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments." } }, "en-us": { "role": { "label": "Disclosure of commitments [text block]", "terseLabel": "Commitments" } } }, "localname": "DisclosureOfCommitmentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Provisions for Retirement Benefit Obligations" } } }, "localname": "DisclosureOfDefinedBenefitPlansAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "auth_ref": [ "r227" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [text block]", "terseLabel": "Schedule of debt" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNonDilutiveFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtBreakdownBetweenLongTermAndShortTermDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "auth_ref": [ "r227" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNonDilutiveFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtBreakdownBetweenLongTermAndShortTermDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "auth_ref": [ "r211", "r217", "r227" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities" } } }, "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "auth_ref": [ "r126" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Schedule of intangible Assets" } } }, "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r72" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Schedule of property, Plant and Equipment" } } }, "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r113" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "Basic and Diluted Loss Per Share" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShare" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "auth_ref": [ "r94" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } }, "en-us": { "role": { "label": "Disclosure of effect of changes in foreign exchange rates [text block]", "terseLabel": "Schedule of exchange differences are recognized in other comprehensive income" } } }, "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "auth_ref": [ "r88" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for employee benefits." } }, "en-us": { "role": { "label": "Disclosure of employee benefits [text block]", "terseLabel": "Provisions for Retirement Benefit Obligations" } } }, "localname": "DisclosureOfEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligations" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r54" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "Events After the Reporting Date" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDate" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } }, "en-us": { "role": { "label": "Disclosure of fair value of financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities measured at fair value" } } }, "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]" } }, "en-us": { "role": { "label": "Disclosure of finance income (cost) [text block]", "terseLabel": "Financial Income and Expenses" } } }, "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of financial assets [line items]" } } }, "localname": "DisclosureOfFinancialAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "auth_ref": [ "r227" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } }, "en-us": { "role": { "label": "Disclosure of financial assets [table]" } } }, "localname": "DisclosureOfFinancialAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Assets and Liabilities" } } }, "localname": "DisclosureOfFinancialInstrumentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r242" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for financial instruments." } }, "en-us": { "role": { "label": "Disclosure of financial instruments [text block]", "terseLabel": "Financial Assets and Liabilities" } } }, "localname": "DisclosureOfFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilities" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]", "terseLabel": "Accounting Principles" } } }, "localname": "DisclosureOfFinancialInstrumentsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsRelatedToFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompletionOfFutureCurrencyContractDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUnwindingOfThreeForwardContractsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "auth_ref": [ "r211", "r217", "r227" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } } }, "localname": "DisclosureOfFinancialInstrumentsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsRelatedToFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompletionOfFutureCurrencyContractDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUnwindingOfThreeForwardContractsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } }, "en-us": { "role": { "label": "Disclosure of financial risk management [text block]", "terseLabel": "Financial Risk Management" } } }, "localname": "DisclosureOfFinancialRiskManagementExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagement" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGoingConcernExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the entity's ability to continue as a going concern." } }, "en-us": { "role": { "label": "Disclosure of going concern [text block]", "terseLabel": "Going concern" } } }, "localname": "DisclosureOfGoingConcernExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "Income Tax" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTax" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInformationAboutConsolidatedStructuredEntitiesExplanatory": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about consolidated structured entities. [Refer: Consolidated structured entities [member]]" } }, "en-us": { "role": { "label": "Disclosure of information about consolidated structured entities [text block]", "terseLabel": "Schedule of consolidated financial statements" } } }, "localname": "DisclosureOfInformationAboutConsolidatedStructuredEntitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of initial application of standards or interpretations [line items]" } } }, "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesLeasesContractsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable": { "auth_ref": [ "r160" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the initial application of standards or interpretations." } }, "en-us": { "role": { "label": "Disclosure of initial application of standards or interpretations [table]" } } }, "localname": "DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesLeasesContractsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets" } } }, "localname": "DisclosureOfIntangibleAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "auth_ref": [ "r129" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for intangible assets." } }, "en-us": { "role": { "label": "Disclosure of intangible assets [text block]", "terseLabel": "Intangible Assets" } } }, "localname": "DisclosureOfIntangibleAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "terseLabel": "Accounting Principles" } } }, "localname": "DisclosureOfIntangibleAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "auth_ref": [ "r126" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } } }, "localname": "DisclosureOfIntangibleAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": { "auth_ref": [ "r166" ], "lang": { "en": { "role": { "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Disclosure of interests in subsidiaries [text block]", "terseLabel": "Schedule of subsidiaries" } } }, "localname": "DisclosureOfInterestsInSubsidiariesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "auth_ref": [ "r91" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for inventories." } }, "en-us": { "role": { "label": "Disclosure of inventories [text block]", "terseLabel": "Inventories" } } }, "localname": "DisclosureOfInventoriesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Risk Management" } } }, "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]" } } }, "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": { "auth_ref": [ "r212", "r213" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments." } }, "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [table]" } } }, "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Events After the Reporting Date" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]", "verboseLabel": "Events after the reporting date" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "auth_ref": [ "r53" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } }, "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "terseLabel": "Schedule of movements in BSPCE and BSA share warrants and Bonus shares" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of other current assets. [Refer: Other current assets]" } }, "en-us": { "role": { "label": "Disclosure of other current assets [text block]", "terseLabel": "Schedule of other current assets and receivables" } } }, "localname": "DisclosureOfOtherCurrentAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of other current liabilities. [Refer: Other current liabilities]" } }, "en-us": { "role": { "label": "Disclosure of other current liabilities [text block]", "terseLabel": "Schedule of other current liabilities" } } }, "localname": "DisclosureOfOtherCurrentLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]" } }, "en-us": { "role": { "label": "Disclosure of other non-current assets [text block]", "terseLabel": "Other Non-Current Assets" } } }, "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of other operating income or expense. [Refer: Other operating income (expense)]" } }, "en-us": { "role": { "label": "Disclosure of other operating income (expense) [text block]", "terseLabel": "Other Operating Income (expenses)" } } }, "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherProvisionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Provisions" } } }, "localname": "DisclosureOfOtherProvisionsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOtherProvisionsExplanatory": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "The disclosure of other provisions. [Refer: Other provisions]" } }, "en-us": { "role": { "label": "Disclosure of other provisions [text block]", "terseLabel": "Schedule of provisions" } } }, "localname": "DisclosureOfOtherProvisionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherProvisionsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of other provisions [line items]" } } }, "localname": "DisclosureOfOtherProvisionsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCreationOfInventivaUsSubsidiaryDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationVestingOfBonusSharesDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOtherProvisionsTable": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to other provisions." } }, "en-us": { "role": { "label": "Disclosure of other provisions [table]" } } }, "localname": "DisclosureOfOtherProvisionsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCreationOfInventivaUsSubsidiaryDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationVestingOfBonusSharesDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r75" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure of property, plant and equipment [text block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "terseLabel": "Accounting Principles" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r72" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfProvisionsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of provisions. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Disclosure of provisions [text block]", "terseLabel": "Provisions" } } }, "localname": "DisclosureOfProvisionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r103" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfRevenueExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for revenue." } }, "en-us": { "role": { "label": "Disclosure of revenue [text block]", "terseLabel": "Revenues and Other Income" } } }, "localname": "DisclosureOfRevenueExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncome" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory": { "auth_ref": [ "r83" ], "lang": { "en": { "role": { "documentation": "The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]" } }, "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [text block]", "terseLabel": "Schedule of sensitivity analysis" } } }, "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [line items]" } } }, "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable": { "auth_ref": [ "r83" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the sensitivity analysis for actuarial assumptions." } }, "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [table]" } } }, "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r40" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of subsidiaries [line items]" } } }, "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "auth_ref": [ "r106", "r108", "r178" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } }, "en-us": { "role": { "label": "Disclosure of subsidiaries [table]" } } }, "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r13" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "Accounting Principles" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Schedule of trade payables break down by payment" } } }, "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } }, "en-us": { "role": { "label": "Disclosure of trade and other receivables [text block]", "terseLabel": "Trade Receivables and Other Current Assets and Receivables" } } }, "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related-Party Transactions" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r99" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block]", "terseLabel": "Schedule of transactions with key management personnel" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r101" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Disposals, intangible assets other than goodwill", "negatedLabel": "Decreases" } } }, "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted Loss Per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareExplanatory": { "auth_ref": [ "r110" ], "lang": { "en": { "role": { "documentation": "The disclosure of earnings per share." } }, "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of basic earnings (loss) per share" } } }, "localname": "EarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r150", "r151" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange gains / losses" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EmployeeBenefitsExpense": { "auth_ref": [ "r1", "r3", "r51" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails": { "order": 3.0, "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0 }, "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee benefits expense", "negatedTerseLabel": "Personnel costs", "negatedTotalLabel": "Total personnel costs" } } }, "localname": "EmployeeBenefitsExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember": { "auth_ref": [ "r179" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Consolidated structured entities' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for consolidated structured entities [member]" } } }, "localname": "EntitysTotalForConsolidatedStructuredEntitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceConsolidatedFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r101" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "auth_ref": [ "r106", "r108", "r178" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for subsidiaries [member]" } } }, "localname": "EntitysTotalForSubsidiariesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCreationOfInventivaUsSubsidiaryDetails", "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r24", "r35", "r161", "r163", "r180", "r181", "r182" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Total Shareholders' equity", "verboseLabel": "Shareholders' equity" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Shareholders' equity" } } }, "localname": "EquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r24" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "EquityAndLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "EquityAndLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } }, "en-us": { "role": { "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets", "terseLabel": "Share based payment expense" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "auth_ref": [ "r11" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails": { "order": 1.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "negatedLabel": "Share-based compensation expense" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseOfRestructuringActivities": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations." } }, "en-us": { "role": { "label": "Expense of restructuring activities", "negatedLabel": "Restructuring expenses" } } }, "localname": "ExpenseOfRestructuringActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r45" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance costs", "negatedTerseLabel": "Financial expenses", "negatedTotalLabel": "Total financial expenses" } } }, "localname": "FinanceCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r48" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income", "terseLabel": "Financial income", "totalLabel": "Total financial income" } } }, "localname": "FinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncomeCost": { "auth_ref": [ "r48" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income (cost)", "totalLabel": "Financial income (loss)" } } }, "localname": "FinanceIncomeCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssets": { "auth_ref": [ "r210", "r215", "r216", "r219", "r220" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial assets", "terseLabel": "Financial assets" } } }, "localname": "FinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "auth_ref": [ "r229" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } }, "en-us": { "role": { "label": "Financial assets carried at amortized cost" } } }, "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsAtFairValue": { "auth_ref": [ "r210" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, at fair value", "terseLabel": "Financial assets, at fair value", "verboseLabel": "Fair value of financial assets" } } }, "localname": "FinancialAssetsAtFairValue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "auth_ref": [ "r228" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } }, "en-us": { "role": { "label": "Financial assets carried at fair value through profit or loss" } } }, "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsCategoryMember": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, category [member]" } } }, "localname": "FinancialAssetsCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsMember": { "auth_ref": [ "r225", "r226", "r255", "r266", "r267", "r268" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, class [member]" } } }, "localname": "FinancialAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities": { "auth_ref": [ "r206" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Contingent liabilities [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial assets pledged as collateral for liabilities or contingent liabilities", "terseLabel": "Bank guarantee and pledge of gradual rate deposit account", "verboseLabel": "Amount of guarantee" } } }, "localname": "FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilities": { "auth_ref": [ "r210" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } }, "en-us": { "role": { "label": "Financial liabilities", "terseLabel": "Financial liabilities" } } }, "localname": "FinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "auth_ref": [ "r230", "r274" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } }, "en-us": { "role": { "label": "Liabilities carried at amortized cost" } } }, "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "auth_ref": [ "r210" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial liabilities, at fair value", "verboseLabel": "Financial liabilities, at fair value" } } }, "localname": "FinancialLiabilitiesAtFairValue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesCategoryMember": { "auth_ref": [ "r231" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial liabilities, category [member]" } } }, "localname": "FinancialLiabilitiesCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesMember": { "auth_ref": [ "r225", "r226", "r255", "r267" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Financial liabilities, class [member]" } } }, "localname": "FinancialLiabilitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FixturesAndFittingsMember": { "auth_ref": [ "r63" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Fixtures and fittings" } } }, "localname": "FixturesAndFittingsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ForeignExchangeGain": { "auth_ref": [ "r15", "r92" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 3.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Foreign exchange gain", "terseLabel": "Foreign exchange gains" } } }, "localname": "ForeignExchangeGain", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ForeignExchangeLoss": { "auth_ref": [ "r15", "r92" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Foreign exchange loss", "negatedLabel": "Foreign exchange losses" } } }, "localname": "ForeignExchangeLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ForeignExchangeRatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exchange rate (USD per EUR)" } } }, "localname": "ForeignExchangeRatesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income", "terseLabel": "Actuarial gains or losses recognized in other comprehensive income" } } }, "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangeInNetProvisionDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r11" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": 4.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GrossAmountArisingFromInsuranceContractsMember": { "auth_ref": [ "r270" ], "lang": { "en": { "role": { "documentation": "This member stands for the gross amount arising from insurance contracts. [Refer: Types of insurance contracts [member]]" } }, "en-us": { "role": { "label": "Gross amount arising from insurance contracts [member]" } } }, "localname": "GrossAmountArisingFromInsuranceContractsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GrossCarryingAmountMember": { "auth_ref": [ "r67", "r122", "r132", "r135", "r204", "r216", "r219", "r220", "r272", "r278" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Gross" } } }, "localname": "GrossCarryingAmountMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_HedgingGainsLossesForHedgeOfGroupOfItemsWithOffsettingRiskPositions": { "auth_ref": [ "r209", "r254" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The hedging gains (losses) for hedge of group of items with offsetting risk positions." } }, "en-us": { "role": { "label": "Hedging gains (losses) for hedge of group of items with offsetting risk positions", "terseLabel": "Gain from favorable position" } } }, "localname": "HedgingGainsLossesForHedgeOfGroupOfItemsWithOffsettingRiskPositions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF INCOME (LOSS)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r46", "r55", "r58", "r59", "r104", "r177", "r245" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": 3.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax", "netLabel": "Tax rate differences" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "auth_ref": [ "r137", "r153" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } }, "en-us": { "role": { "label": "Income taxes paid (refund), classified as operating activities", "negatedLabel": "Tax credit received" } } }, "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r155" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from expense (income) included in profit or loss. [Refer: Net defined benefit liability (asset); Profit (loss)] [Contrast: Post-employment benefit expense in profit or loss, defined benefit plans]" } }, "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss", "negatedLabel": "Expense for the period" } } }, "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangeInNetProvisionDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "auth_ref": [ "r38" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } }, "en-us": { "role": { "label": "Increase (decrease) in number of shares outstanding", "terseLabel": "Increase in liquidity agreement", "verboseLabel": "Issue of ADSs" } } }, "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "auth_ref": [ "r148" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in working capital." } }, "en-us": { "role": { "label": "Increase (decrease) in working capital", "negatedTotalLabel": "Tax, interest and changes in operating working capital" } } }, "localname": "IncreaseDecreaseInWorkingCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Increase (decrease) through appropriation of retained earnings, equity", "terseLabel": "Appropriation of net loss" } } }, "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from other changes", "terseLabel": "Other changes" } } }, "localname": "IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangeInNetProvisionDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment": { "auth_ref": [ "r69" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Increase (decrease) through other changes, property, plant and equipment", "terseLabel": "Others" } } }, "localname": "IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r7" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based compensation expense", "verboseLabel": "Capital increase arising from the vesting of bonus share awards" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through other changes, equity", "terseLabel": "Other changes" } } }, "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Increase (decrease) through transfers, property, plant and equipment", "terseLabel": "Reclassifications" } } }, "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } }, "en-us": { "role": { "label": "Increase (decrease) through treasury share transactions, equity", "terseLabel": "Treasury shares" } } }, "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InitiallyAppliedIFRSsAxis": { "auth_ref": [ "r160" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Initially applied IFRSs [axis]" } } }, "localname": "InitiallyAppliedIFRSsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesLeasesContractsDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_InitiallyAppliedIFRSsMember": { "auth_ref": [ "r160" ], "lang": { "en": { "role": { "documentation": "This member stands for IFRSs that have been initially applied by the entity. It also represents the standard value for the 'Initially applied IFRSs' axis if no other member is used. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Initially applied IFRSs [member]" } } }, "localname": "InitiallyAppliedIFRSsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesLeasesContractsDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InsuranceExpense": { "auth_ref": [ "r11" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from purchased insurance." } }, "en-us": { "role": { "label": "Insurance expense", "terseLabel": "Additional expense including offering expense" } } }, "localname": "InsuranceExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r17", "r125" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "auth_ref": [ "r115", "r126", "r193" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill [member]" } } }, "localname": "IntangibleAssetsOtherThanGoodwillMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestCostsCapitalised": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset." } }, "en-us": { "role": { "label": "Interest costs capitalised", "terseLabel": "Capitalized interests" } } }, "localname": "InterestCostsCapitalised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtRepaymentsOfBorrowingsAndAccrualOfInterestsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpense": { "auth_ref": [ "r176", "r244", "r250" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from interest." } }, "en-us": { "role": { "label": "Interest expense", "negatedLabel": "Interest cost" } } }, "localname": "InterestExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseDefinedBenefitPlans": { "auth_ref": [ "r76" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForPeriodDetails": { "order": 2.0, "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense arising from defined benefit plans. [Refer: Interest expense; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]" } }, "en-us": { "role": { "label": "Interest expense, defined benefit plans", "negatedLabel": "Interest cost for the period" } } }, "localname": "InterestExpenseDefinedBenefitPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForPeriodDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnBorrowings": { "auth_ref": [ "r11" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]" } }, "en-us": { "role": { "label": "Interest expense on borrowings", "negatedLabel": "Accrued interests" } } }, "localname": "InterestExpenseOnBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtRepaymentsOfBorrowingsAndAccrualOfInterestsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestIncomeOnCashAndCashEquivalents": { "auth_ref": [ "r11" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Interest income on cash and cash equivalents", "terseLabel": "Income from cash and cash equivalents" } } }, "localname": "InterestIncomeOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "auth_ref": [ "r152" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } }, "en-us": { "role": { "label": "Interest paid, classified as financing activities", "negatedLabel": "Accrued interests" } } }, "localname": "InterestPaidClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtRepaymentsOfBorrowingsAndAccrualOfInterestsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Inventories": { "auth_ref": [ "r18", "r29", "r90" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventories" } } }, "localname": "Inventories", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfEquity": { "auth_ref": [ "r7" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } }, "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issue of ordinary shares" } } }, "localname": "IssueOfEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r35" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Share capital" } } }, "localname": "IssuedCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r98" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation", "totalLabel": "Net total" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "auth_ref": [ "r96" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails": { "order": 2.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, post-employment benefits", "terseLabel": "Pension plan expenses", "verboseLabel": "Post-employment benefits" } } }, "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r97" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails": { "order": 3.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Share-based compensation expense", "verboseLabel": "Share-based payment" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "auth_ref": [ "r95" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails": { "order": 1.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, short-term employee benefits", "terseLabel": "Short-term benefits" } } }, "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "auth_ref": [ "r100" ], "lang": { "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } }, "en-us": { "role": { "label": "Executive and corporate officers" } } }, "localname": "KeyManagementPersonnelOfEntityOrParentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LandMember": { "auth_ref": [ "r62" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Land" } } }, "localname": "LandMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember": { "auth_ref": [ "r11", "r220", "r239", "r273" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one month and not later than two months." } }, "en-us": { "role": { "label": "Due in 30 60 days" } } }, "localname": "LaterThanOneMonthAndNotLaterThanTwoMonthsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfTradePayablesBreakDownByPaymentDateDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": { "auth_ref": [ "r233", "r235", "r240" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than three years." } }, "en-us": { "role": { "label": "Between 1 and 3 years" } } }, "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtBreakdownBetweenLongTermAndShortTermDebtDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": { "auth_ref": [ "r233", "r236", "r240" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than five years." } }, "en-us": { "role": { "label": "Between 3 and 5 years" } } }, "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtBreakdownBetweenLongTermAndShortTermDebtDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r192" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails": { "order": 1.0, "parentTag": "ifrs-full_Borrowings", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease liabilities", "terseLabel": "Lease liabilities", "verboseLabel": "First application of IFRS 16 Leases" } } }, "localname": "LeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtBreakdownBetweenLongTermAndShortTermDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails", "http://www.inventivapharma.com/role/DisclosureDebtRepaymentsOfBorrowingsAndAccrualOfInterestsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Level1OfFairValueHierarchyMember": { "auth_ref": [ "r80", "r181" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } }, "en-us": { "role": { "label": "Level 1" } } }, "localname": "Level1OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level2OfFairValueHierarchyMember": { "auth_ref": [ "r181" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } }, "en-us": { "role": { "label": "Level 2" } } }, "localname": "Level2OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "auth_ref": [ "r80", "r181" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } } }, "localname": "LevelsOfFairValueHierarchyAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "auth_ref": [ "r77" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]" } }, "en-us": { "role": { "label": "Net defined benefit liability (asset)", "negatedPeriodEndLabel": "At end of period", "negatedPeriodStartLabel": "At beginning of period", "terseLabel": "Retirement benefit obligation", "verboseLabel": "Provisions for retirement benefit obligations" } } }, "localname": "LiabilityAssetOfDefinedBenefitPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangeInNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsNetProvisionDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LineItemsByFunctionMember": { "auth_ref": [ "r3", "r11" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used." } }, "en-us": { "role": { "label": "Line items by function [member]" } } }, "localname": "LineItemsByFunctionMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LoansReceived": { "auth_ref": [ "r11" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails": { "order": 2.0, "parentTag": "ifrs-full_Borrowings", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of loans received." } }, "en-us": { "role": { "label": "Loans received", "terseLabel": "Bank borrowings" } } }, "localname": "LoansReceived", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtBreakdownBetweenLongTermAndShortTermDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LongtermBorrowings": { "auth_ref": [ "r24" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Non-current portion of non-current borrowings", "terseLabel": "Long-term debt" } } }, "localname": "LongtermBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LongtermBorrowingsMember": { "auth_ref": [ "r154", "r159" ], "lang": { "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Long-term debt" } } }, "localname": "LongtermBorrowingsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax" } } }, "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "auth_ref": [ "r222" ], "lang": { "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } }, "en-us": { "role": { "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]", "terseLabel": "Schedule of maturity of long-term debt and of short-term borrowings" } } }, "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r27", "r84", "r189", "r194", "r195", "r208", "r224", "r233", "r256", "r257", "r259", "r265" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtBreakdownBetweenLongTermAndShortTermDebtDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfTradePayablesBreakDownByPaymentDateDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MeasurementAxis": { "auth_ref": [ "r130", "r134", "r180" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Measurement [axis]" } } }, "localname": "MeasurementAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MiscellaneousNoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Non-Current Assets" } } }, "localname": "MiscellaneousNoncurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_MiscellaneousOtherOperatingExpense": { "auth_ref": [ "r11" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]" } }, "en-us": { "role": { "label": "Miscellaneous other operating expense", "totalLabel": "Total other operating expenses" } } }, "localname": "MiscellaneousOtherOperatingExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "auth_ref": [ "r11" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]" } }, "en-us": { "role": { "label": "Miscellaneous other operating income", "totalLabel": "Total other operating income" } } }, "localname": "MiscellaneousOtherOperatingIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetAmountArisingFromInsuranceContractsMember": { "auth_ref": [ "r270" ], "lang": { "en": { "role": { "documentation": "This member stands for the net amount arising from insurance contracts. It also represents the standard value for the 'Amounts arising from insurance contracts' axis if no other member is used. [Refer: Types of insurance contracts [member]]" } }, "en-us": { "role": { "label": "Net amount arising from insurance contracts [member]" } } }, "localname": "NetAmountArisingFromInsuranceContractsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NetworkInfrastructureMember": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing network infrastructure. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Technical facilities" } } }, "localname": "NetworkInfrastructureMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r53" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsMember": { "auth_ref": [ "r53" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]" } } }, "localname": "NonadjustingEventsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAccruedIncomeIncludingNoncurrentContractAssets": { "auth_ref": [ "r24", "r36" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails": { "order": 4.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current accrued income including non-current contract assets. [Refer: Accrued income including contract assets]" } }, "en-us": { "role": { "label": "Non-current accrued income including non-current contract assets", "terseLabel": "Accrued income" } } }, "localname": "NoncurrentAccruedIncomeIncludingNoncurrentContractAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r28", "r167", "r169" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r30", "r167", "r171" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NotLaterThanOneMonthMember": { "auth_ref": [ "r232", "r234", "r240" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one month." } }, "en-us": { "role": { "label": "Due in 30 days" } } }, "localname": "NotLaterThanOneMonthMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfTradePayablesBreakDownByPaymentDateDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NotLaterThanOneYearMember": { "auth_ref": [ "r26", "r194", "r195", "r233", "r240", "r265" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } }, "en-us": { "role": { "label": "Less than 1 year" } } }, "localname": "NotLaterThanOneYearMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtBreakdownBetweenLongTermAndShortTermDebtDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NotLaterThanThreeMonthsMember": { "auth_ref": [ "r11", "r271", "r275" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than three months." } }, "en-us": { "role": { "label": "3 months or less" } } }, "localname": "NotLaterThanThreeMonthsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NotionalAmount": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } }, "en-us": { "role": { "label": "Notional amount", "verboseLabel": "Amount of foreign currency forward contract" } } }, "localname": "NotionalAmount", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsRelatedToFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUnwindingOfThreeForwardContractsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NumberOfEmployees": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } }, "en-us": { "role": { "label": "Number of employees", "verboseLabel": "Number of employees" } } }, "localname": "NumberOfEmployees", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r196", "r203" ], "lang": { "en": { "role": { "documentation": "The number of instruments granted in share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of instruments granted in share-based payment arrangement", "terseLabel": "Number of bonus shares granted", "verboseLabel": "Number of share warrants granted" } } }, "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "auth_ref": [ "r199", "r201" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Issued", "verboseLabel": "Number of bonus shares granted" } } }, "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Number of shares exercisable" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments exercised or vested in share-based payment arrangement", "negatedLabel": "Exercised/Vesting", "terseLabel": "Number of bonus shares fully vested", "verboseLabel": "Number of bonus shares vested" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationVestingOfBonusSharesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "negatedLabel": "Forfeited", "terseLabel": "Number of bonus shares forfeited" } } }, "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding, Ending balance", "periodStartLabel": "Outstanding, Beginning balance" } } }, "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued", "terseLabel": "Number of shares issued" } } }, "localname": "NumberOfSharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesOutstanding": { "auth_ref": [ "r38" ], "lang": { "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)", "terseLabel": "Number of shares outstanding", "verboseLabel": "Number of fully authorized, subscribed and paid up shares" } } }, "localname": "NumberOfSharesOutstanding", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityDetails", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesRepresentedByOneDepositaryReceipt": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The number of shares represented by one depositary receipt." } }, "en-us": { "role": { "label": "Number of shares represented by one depositary receipt" } } }, "localname": "NumberOfSharesRepresentedByOneDepositaryReceipt", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "xbrltype": "pureItemType" }, "ifrs-full_OfficeEquipmentMember": { "auth_ref": [ "r64" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r39", "r110" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Ordinary shares" } } }, "localname": "OrdinarySharesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "auth_ref": [ "r147" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Other adjustments for non-cash items", "terseLabel": "Other" } } }, "localname": "OtherAdjustmentsForNoncashItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherBorrowings": { "auth_ref": [ "r11" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails": { "order": 3.0, "parentTag": "ifrs-full_Borrowings", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Other borrowings", "terseLabel": "Other loans and similar borrowings" } } }, "localname": "OtherBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtBreakdownBetweenLongTermAndShortTermDebtDetails", "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncome": { "auth_ref": [ "r6", "r42", "r49", "r174" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations": { "auth_ref": [ "r49" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to exchange differences on translation of the financial statements of a parent company or a stand-alone entity to a different presentation currency. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation, other than translation of foreign operations", "terseLabel": "Currency translation differences" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "auth_ref": [ "r31", "r49", "r76" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inventivapharma.com/role/StatementStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans", "terseLabel": "Remeasurement of defined benefit plans", "totalLabel": "Total" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails", "http://www.inventivapharma.com/role/StatementStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "auth_ref": [ "r47", "r52" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax", "totalLabel": "Items that will not be reclassified subsequently to profit or loss" } } }, "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentAssets": { "auth_ref": [ "r24" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "order": 2.0, "parentTag": "iva_OtherCurrentAssetsAndReceivables", "weight": 1.0 }, "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets", "totalLabel": "Other current assets" } } }, "localname": "OtherCurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentLiabilities": { "auth_ref": [ "r24" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0 }, "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Other current liabilities", "totalLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentPayables": { "auth_ref": [ "r24" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other current payables", "terseLabel": "Other miscellaneous payables" } } }, "localname": "OtherCurrentPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentReceivables": { "auth_ref": [ "r33" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "order": 7.0, "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } }, "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other receivables" } } }, "localname": "OtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherFinanceCost": { "auth_ref": [ "r11" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 3.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]" } }, "en-us": { "role": { "label": "Other finance cost", "negatedLabel": "Other financial expenses" } } }, "localname": "OtherFinanceCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities": { "auth_ref": [ "r149" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as investing activities", "verboseLabel": "Decrease / (Increase) in other noncurrent financial assets" } } }, "localname": "OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": { "auth_ref": [ "r138" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as operating activities", "verboseLabel": "Other" } } }, "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherLongtermProvisions": { "auth_ref": [ "r34" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]" } }, "en-us": { "role": { "label": "Other non-current provisions", "periodEndLabel": "Closing balance", "periodStartLabel": "Beginning balance", "positiveLabel": "Reversal of provisions", "terseLabel": "Long-term provisions" } } }, "localname": "OtherLongtermProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentAssets": { "auth_ref": [ "r24" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } }, "en-us": { "role": { "label": "Other non-current asset", "terseLabel": "Other non-current assets", "totalLabel": "Other noncurrent assets" } } }, "localname": "OtherNoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherPropertyPlantAndEquipmentMember": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Other property, plant and equipment" } } }, "localname": "OtherPropertyPlantAndEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherProvisions": { "auth_ref": [ "r34", "r117" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Other provisions", "periodEndLabel": "Other provisions at end of period", "periodStartLabel": "Other provisions at beginning of period" } } }, "localname": "OtherProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherProvisionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Provisions" } } }, "localname": "OtherProvisionsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_OtherProvisionsMember": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Other provisions [member]" } } }, "localname": "OtherProvisionsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherShorttermProvisions": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Other current provisions", "periodEndLabel": "Closing balance", "periodStartLabel": "Beginning balance" } } }, "localname": "OtherShorttermProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "auth_ref": [ "r58" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "order": 4.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)", "negatedLabel": "Other differences" } } }, "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par value per share", "terseLabel": "Par value per share", "verboseLabel": "Nominal value per share" } } }, "localname": "ParValuePerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans": { "auth_ref": [ "r76" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForPeriodDetails": { "order": 4.0, "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense (income) resulting from past service cost and losses (gains) arising from settlements. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans; Past service cost, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements]" } }, "en-us": { "role": { "label": "Past service cost and losses (gains) arising from settlements, defined benefit plans", "negatedLabel": "Benefits for the period" } } }, "localname": "PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForPeriodDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r143" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Repayment of lease debt", "negatedTerseLabel": "Repayment of lease liabilities" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails", "http://www.inventivapharma.com/role/DisclosureDebtRepaymentsOfBorrowingsAndAccrualOfInterestsDetails", "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PercentageOfEntitysRevenue": { "auth_ref": [ "r253" ], "lang": { "en": { "role": { "documentation": "The percentage of the entity's revenue. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Percentage of entity's revenue", "terseLabel": "Contribution to Company's revenue (as a percent)" } } }, "localname": "PercentageOfEntitysRevenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption": { "auth_ref": [ "r82" ], "lang": { "en": { "role": { "documentation": "The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]" } }, "en-us": { "role": { "label": "Percentage of reasonably possible increase in actuarial assumption", "terseLabel": "Percentage of reasonably possible increase in actuarial assumption" } } }, "localname": "PercentageOfReasonablyPossibleIncreaseInActuarialAssumption", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "auth_ref": [ "r76", "r85" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForPeriodDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]" } }, "en-us": { "role": { "label": "Post-employment benefit expense, defined benefit plans", "negatedTotalLabel": "Total" } } }, "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForPeriodDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [ "r141" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "terseLabel": "Subscription of debt", "verboseLabel": "Loan obtained" } } }, "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNonDilutiveFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails", "http://www.inventivapharma.com/role/DisclosureDebtRepaymentsOfBorrowingsAndAccrualOfInterestsDetails", "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r140" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Capital increase, net of transaction costs", "verboseLabel": "Net proceeds from issuance of shares" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails", "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProductsAndServicesAxis": { "auth_ref": [ "r190", "r251" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Products and services [axis]" } } }, "localname": "ProductsAndServicesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ProductsAndServicesMember": { "auth_ref": [ "r190", "r251" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } }, "en-us": { "role": { "label": "Products and services [member]" } } }, "localname": "ProductsAndServicesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r5", "r41", "r145", "r162", "r164", "r167", "r246", "r248", "r258", "r269" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 }, "http://www.inventivapharma.com/role/StatementStatementsOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 }, "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Net loss for the period", "totalLabel": "Net loss for the period", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementStatementsOfComprehensiveIncomeLoss", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r48", "r109" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating profit (loss)" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r16", "r71" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property, plant and equipments", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentMember": { "auth_ref": [ "r72", "r115", "r193" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property, plant and equipment [member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "auth_ref": [ "r105", "r107", "r165" ], "lang": { "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Proportion of ownership interest in subsidiary", "terseLabel": "Percent of Ownership Interest" } } }, "localname": "ProportionOfOwnershipInterestInSubsidiary", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCreationOfInventivaUsSubsidiaryDetails", "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r184", "r185", "r186", "r198", "r227", "r259" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r184", "r185", "r186", "r198", "r227", "r259" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]" } } }, "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in property, plant and equipment [abstract]" } } }, "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RelatedPartiesMember": { "auth_ref": [ "r101" ], "lang": { "en": { "role": { "documentation": "This member stands for related parties. Related parties are persons or entities that are related to the entity that is preparing its financial statements (the reporting entity). (a) A person or a close member of that person\u2019s family is related to a reporting entity if that person: (i) has control or joint control over the reporting entity; (ii) has significant influence over the reporting entity; or (iii) is a member of the key management personnel of the reporting entity or of a parent of the reporting entity. (b) An entity is related to a reporting entity if any of the following conditions applies: (i) The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others). (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member). (iii) Both entities are joint ventures of the same third party. (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity. (v) The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity. (vi) The entity is controlled or jointly controlled by a person identified in (a). (vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity). (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity. [Refer: Joint ventures [member]; Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Related parties [member]" } } }, "localname": "RelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RepairsAndMaintenanceExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails": { "order": 9.0, "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses incurred for the day-to-day servicing of assets, which may include the cost of labour, consumables or small parts." } }, "en-us": { "role": { "label": "Repairs and maintenance expense", "negatedLabel": "Maintenance" } } }, "localname": "RepairsAndMaintenanceExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [ "r142" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Repayments of borrowings, classified as financing activities", "negatedLabel": "Repayment of debt", "negatedTerseLabel": "Repayment of bank borrowings" } } }, "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtRepaymentsOfBorrowingsAndAccrualOfInterestsDetails", "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RepaymentsOfCurrentBorrowings": { "auth_ref": [ "r144" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for repayments of current borrowings. [Refer: Current borrowings]" } }, "en-us": { "role": { "label": "Repayments of current borrowings", "terseLabel": "Repayments of borrowings" } } }, "localname": "RepaymentsOfCurrentBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r128" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "auth_ref": [ "r93" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Foreign currency translation reserve" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "auth_ref": [ "r10", "r93" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Currency translation adjustments" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "auth_ref": [ "r35" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } }, "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period", "terseLabel": "Net loss for the period" } } }, "localname": "RetainedEarningsProfitLossForReportingPeriod", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } }, "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period [member]", "terseLabel": "Net profit (loss)" } } }, "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r1", "r2", "r44", "r167", "r173", "r205", "r243", "r247", "r251", "r252", "r253" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "Revenue", "terseLabel": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueAndOperatingIncome": { "auth_ref": [ "r48" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Revenue and other operating income", "totalLabel": "Total revenues and other income" } } }, "localname": "RevenueAndOperatingIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromContractsWithCustomers": { "auth_ref": [ "r187", "r188" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "order": 1.0, "parentTag": "ifrs-full_Revenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } }, "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Sales" } } }, "localname": "RevenueFromContractsWithCustomers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReversalOfProvisionsForCostOfRestructuring": { "auth_ref": [ "r50" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of reversals of provisions for the cost of restructuring. [Refer: Restructuring provision]" } }, "en-us": { "role": { "label": "Reversal of provisions for cost of restructuring", "terseLabel": "Reversal of restructuring expenses" } } }, "localname": "ReversalOfProvisionsForCostOfRestructuring", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssetsMember": { "auth_ref": [ "r191" ], "lang": { "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Right of use" } } }, "localname": "RightofuseAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_SalesAndMarketingExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } }, "en-us": { "role": { "label": "Sales and marketing expense", "negatedLabel": "Marketing - Business development expenses" } } }, "localname": "SalesAndMarketingExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": { "auth_ref": [ "r223" ], "lang": { "en": { "role": { "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]" } }, "en-us": { "role": { "label": "Sensitivity analysis for types of market risk [text block]", "terseLabel": "Schedule of sensitivity analysis of the company's assets." } } }, "localname": "SensitivityAnalysisForEachTypeOfMarketRisk", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_ServicesReceivedRelatedPartyTransactions": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of services received in related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Services received, related party transactions", "terseLabel": "Consulting fees" } } }, "localname": "ServicesReceivedRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShareIssueRelatedCost": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } }, "en-us": { "role": { "label": "Share issue related cost", "negatedTerseLabel": "Transaction costs", "netLabel": "Offering expense" } } }, "localname": "ShareIssueRelatedCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremium": { "auth_ref": [ "r35" ], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium", "terseLabel": "Premiums related to share capital" } } }, "localname": "SharePremium", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Premiums related to share capital" } } }, "localname": "SharePremiumMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_SharebasedPaymentArrangementsMember": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } }, "en-us": { "role": { "label": "Sharebased compensation expense" } } }, "localname": "SharebasedPaymentArrangementsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationVestingOfBonusSharesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermBorrowingsMember": { "auth_ref": [ "r154", "r159" ], "lang": { "en": { "role": { "documentation": "This member stands for short-term borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Short-term debt" } } }, "localname": "ShorttermBorrowingsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "auth_ref": [ "r155" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "terseLabel": "Short-term deposits", "verboseLabel": "Other cash equivalents" } } }, "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "auth_ref": [ "r24" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Short-term deposits, not classified as cash equivalents", "terseLabel": "Short-term deposits" } } }, "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "auth_ref": [ "r106", "r108", "r178" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Subsidiaries [axis]" } } }, "localname": "SignificantInvestmentsInSubsidiariesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCreationOfInventivaUsSubsidiaryDetails", "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "StatementOfComprehensiveIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF FINANCIAL POSITION" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfIFRSCompliance": { "auth_ref": [ "r14" ], "lang": { "en": { "role": { "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs." } }, "en-us": { "role": { "label": "Statement of IFRS compliance [text block]", "terseLabel": "General principles and statement of compliance" } } }, "localname": "StatementOfIFRSCompliance", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfCompliance" ], "xbrltype": "textBlockItemType" }, "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense": { "auth_ref": [ "r57" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "order": 2.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]" } }, "en-us": { "role": { "label": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense", "verboseLabel": "Tax credits" } } }, "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxEffectOfForeignTaxRates": { "auth_ref": [ "r58" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "order": 5.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax effect of foreign tax rates", "terseLabel": "Tax rate differences" } } }, "localname": "TaxEffectOfForeignTaxRates", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "auth_ref": [ "r58" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "order": 1.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Tax expense (income) at applicable tax rate", "negatedLabel": "Tax benefit at theoretical rate" } } }, "localname": "TaxExpenseIncomeAtApplicableTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r184", "r185", "r186", "r198", "r227", "r259" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range [Member]", "terseLabel": "Maximum" } } }, "localname": "TopOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayables": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } }, "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Trade payables" } } }, "localname": "TradeAndOtherCurrentPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfTradePayablesBreakDownByPaymentDateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "auth_ref": [ "r32", "r36" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0 }, "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } }, "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } } }, "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade Receivables and Other Current Assets and Receivables" } } }, "localname": "TradeAndOtherCurrentReceivablesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TradeReceivablesMember": { "auth_ref": [ "r11", "r214", "r218", "r220" ], "lang": { "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Trade receivables" } } }, "localname": "TradeReceivablesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfRisksAxis": { "auth_ref": [ "r207", "r212", "r213", "r260", "r261", "r262", "r264" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of risks [axis]" } } }, "localname": "TypesOfRisksAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksMember": { "auth_ref": [ "r207", "r212", "r213", "r260", "r261", "r262", "r264" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } }, "en-us": { "role": { "label": "Risks [member]" } } }, "localname": "TypesOfRisksMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationVestingOfBonusSharesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "xbrltype": "stringItemType" }, "ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Underlying equity instrument and depositary receipts [axis]" } } }, "localname": "UnderlyingEquityInstrumentAndDepositaryReceiptsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UnderlyingEquityInstrumentMember": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "This member represents the standard value for the \u2018Underlying equity instrument and depositary receipts\u2019 axis if no other member is used." } }, "en-us": { "role": { "label": "Underlying equity instrument [member]" } } }, "localname": "UnderlyingEquityInstrumentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_UnusedProvisionReversedOtherProvisions": { "auth_ref": [ "r119" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]" } }, "en-us": { "role": { "label": "Unused provision reversed, other provisions", "negatedLabel": "Unused provision reversed, other provisions" } } }, "localname": "UnusedProvisionReversedOtherProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r121" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Useful life measured as period of time, intangible assets other than goodwill", "terseLabel": "Expected useful life of intangible assets" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "auth_ref": [ "r66" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Useful life measured as period of time, property, plant and equipment", "terseLabel": "Useful lives of property, plant and equipment" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WagesAndSalaries": { "auth_ref": [ "r87" ], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails": { "order": 4.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Wages and salaries", "negatedLabel": "Wages, salaries and similar costs" } } }, "localname": "WagesAndSalaries", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement", "terseLabel": "Subscription price" } } }, "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement", "terseLabel": "Exercise price (in euros)", "verboseLabel": "BSPCE exercise price ()" } } }, "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": { "auth_ref": [ "r201" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average fair value at measurement date, other equity instruments granted", "terseLabel": "Fair value per BSA at grant date ()", "verboseLabel": "Fair value per AGA at grant date ()" } } }, "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageSharePrice2019": { "auth_ref": [ "r197" ], "lang": { "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price", "verboseLabel": "Stock price at grant date (in euros)" } } }, "localname": "WeightedAverageSharePrice2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r112" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of outstanding shares used for computing basic loss per share" } } }, "localname": "WeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "sharesItemType" }, "iva_AccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Accounting Principles" } } }, "localname": "AccountingPrinciplesAbstract", "nsuri": "http://www.inventivapharma.com/20201231", "xbrltype": "stringItemType" }, "iva_AccruedExpensesRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued expenses recognized during the period.", "label": "Accrued Expenses Recognized", "terseLabel": "Accrued expenses recognized" } } }, "localname": "AccruedExpensesRecognized", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AccruedExpensesToBePaidToTaxAuthorities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses to be paid to the tax authorities.", "label": "Accrued Expenses To Be Paid to Tax Authorities", "terseLabel": "Accrued expenses to be paid to the tax authorities" } } }, "localname": "AccruedExpensesToBePaidToTaxAuthorities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_AccruedIncomeFromAbbottPayrollTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued income from Abbott.", "label": "Accrued Income From Abbott, Payroll Taxes", "terseLabel": "Accrued income from Abbott - payroll taxes" } } }, "localname": "AccruedIncomeFromAbbottPayrollTaxes", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_AccruedIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for accrued income.", "label": "Accrued income" } } }, "localname": "AccruedIncomeMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "iva_AccruedPayrollAndOtherEmployeeRelatedTaxes": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to accrued payroll and other employee related taxes.", "label": "Accrued Payroll And Other Employee Related Taxes" } } }, "localname": "AccruedPayrollAndOtherEmployeeRelatedTaxes", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iva_ActuarialAssumptionOfDiscountRatesAt0.10PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 0.10% used as actuarial assumptions", "label": "Discount rate at 0.10%" } } }, "localname": "ActuarialAssumptionOfDiscountRatesAt0.10PercentMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "iva_ActuarialAssumptionOfDiscountRatesAt0.35PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 0.35% used as actuarial assumptions", "label": "Discount rate at 0.35%" } } }, "localname": "ActuarialAssumptionOfDiscountRatesAt0.35PercentMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "iva_ActuarialAssumptionOfDiscountRatesAt0.45PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 0.45% used as actuarial assumptions.", "label": "Discount rate at 0.45%" } } }, "localname": "ActuarialAssumptionOfDiscountRatesAt0.45PercentMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "iva_ActuarialAssumptionOfDiscountRatesAt0.60PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 0.60% used as actuarial assumptions", "label": "Discount rate at 0.60%" } } }, "localname": "ActuarialAssumptionOfDiscountRatesAt0.60PercentMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "iva_ActuarialAssumptionOfDiscountRatesAt0.70PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 0.70% used as actuarial assumptions.", "label": "Discount rate at 0.70%" } } }, "localname": "ActuarialAssumptionOfDiscountRatesAt0.70PercentMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "iva_ActuarialAssumptionOfDiscountRatesAt0.75PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 0.75% used as actuarial assumptions.", "label": "Discount rate at 0.75%" } } }, "localname": "ActuarialAssumptionOfDiscountRatesAt0.75PercentMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "iva_ActuarialAssumptionOfDiscountRatesAt0.95PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 0.95% used as actuarial assumptions.", "label": "Discount rate at 0.95%" } } }, "localname": "ActuarialAssumptionOfDiscountRatesAt0.95PercentMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "iva_ActuarialAssumptionOfDiscountRatesAt1.00PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 1.00% used as actuarial assumptions.", "label": "Discount rate at 1.00%" } } }, "localname": "ActuarialAssumptionOfDiscountRatesAt1.00PercentMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "iva_ActuarialAssumptionOfDiscountRatesAt1.25PercentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 1.25% used as actuarial assumptions", "label": "Discount rate at 1.25%" } } }, "localname": "ActuarialAssumptionOfDiscountRatesAt1.25PercentMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "iva_ActuarialAssumptionOfRatesOfPayrollTaxes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The expected rate of payroll taxes used as a significant actuarial assumption to determine the present value of a defined benefit obligation.", "label": "Actuarial Assumption Of Rates Of Payroll Taxes", "terseLabel": "Payroll taxes" } } }, "localname": "ActuarialAssumptionOfRatesOfPayrollTaxes", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "xbrltype": "percentItemType" }, "iva_AdditionalProvisionsOtherLongTermProvisions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of additional other provisions made, classified as long-term.", "label": "Additional Provisions, Other Long-Term Provisions", "terseLabel": "Additions" } } }, "localname": "AdditionalProvisionsOtherLongTermProvisions", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AdditionalProvisionsOtherShortTermProvisions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of additional other provisions made, classified as short-term.", "label": "Additional Provisions, Other Short-Term Provisions", "terseLabel": "Additions" } } }, "localname": "AdditionalProvisionsOtherShortTermProvisions", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AdjustmentsForDepreciationAmortisationAndProvisions": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation, amortisation expense and provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Depreciation, Amortisation and Provisions", "terseLabel": "Depreciation, amortization and provisions" } } }, "localname": "AdjustmentsForDepreciationAmortisationAndProvisions", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "iva_AdjustmentsForSubscriptionsToShareWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for subscriptions to BSA share warrants.", "label": "Adjustments For Subscriptions to Share Warrants", "terseLabel": "Subscriptions to BSA share warrants" } } }, "localname": "AdjustmentsForSubscriptionsToShareWarrants", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "iva_AdjustmentsForTaxCredits": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for tax credit to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Tax Credits", "terseLabel": "Tax credits" } } }, "localname": "AdjustmentsForTaxCredits", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "iva_AdvancesToSuppliersNonCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for advances to suppliers, non-current.", "label": "Advances to suppliers - non-current" } } }, "localname": "AdvancesToSuppliersNonCurrentMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "iva_AgaBonusPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA Bonus plan", "label": "AGA Bonus Plans" } } }, "localname": "AgaBonusPlansMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "domainItemType" }, "iva_AgaBonusShareAwardPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA bonus share award plans.", "label": "AGA Bonus Share Award Plans Member" } } }, "localname": "AgaBonusShareAwardPlansMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "xbrltype": "domainItemType" }, "iva_AgreementWithGenowayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for agreement with Genoway.", "label": "Agreement with Genoway" } } }, "localname": "AgreementWithGenowayMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails" ], "xbrltype": "domainItemType" }, "iva_AgreementWithNovolyzeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for agreement with Novolyze.", "label": "Agreement with Novolyze" } } }, "localname": "AgreementWithNovolyzeMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails" ], "xbrltype": "domainItemType" }, "iva_AgreementWithSynthecobMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for agreement with Synthecob.", "label": "Agreement with Synthecob" } } }, "localname": "AgreementWithSynthecobMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails" ], "xbrltype": "domainItemType" }, "iva_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for American Depositary Shares, each representing one ordinary share.", "label": "American Depositary Shares, each representing one ordinary share" } } }, "localname": "AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "iva_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for American Depositary Shares.", "label": "American Depositary Shares" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "iva_AmountOfAdditionalClaim": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of additional claim.", "label": "Amount of additional claim", "terseLabel": "Amount of additional claim" } } }, "localname": "AmountOfAdditionalClaim", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfBankGuaranteeRelatedToPrincipal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of bank guarantee related to principal", "label": "Amount Of Bank Guarantee Related To Principal", "verboseLabel": "Amount of bank guarantee related to principal" } } }, "localname": "AmountOfBankGuaranteeRelatedToPrincipal", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfClaimPartiallyAcceptedByFrenchTaxAuthorities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of claim partially accepted by French tax authorities.", "label": "Amount Of Claim Partially Accepted By French Tax Authorities", "terseLabel": "Amount of claim partially accepted by French tax authorities" } } }, "localname": "AmountOfClaimPartiallyAcceptedByFrenchTaxAuthorities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfClaimRejectedByFrenchTaxAuthorities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Claim Rejected by French tax Authorities.", "label": "Amount of Claim Rejected by French tax Authorities", "terseLabel": "Amount of claim rejected by Authorities" } } }, "localname": "AmountOfClaimRejectedByFrenchTaxAuthorities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfCommitmentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of commitment received.", "label": "Amount of Commitment Received", "terseLabel": "Amount of commitment received" } } }, "localname": "AmountOfCommitmentReceived", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfFundRaised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of fund raised.", "label": "Amount of Fund Raised", "verboseLabel": "Amount of Fund Raised" } } }, "localname": "AmountOfFundRaised", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfImpactOnIncomeStatementForOtherProvisions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impact on Income Statement during the period for other provisions.", "label": "Amount Of Impact On Income Statement For Other Provisions", "terseLabel": "Impact on income (loss) statement" } } }, "localname": "AmountOfImpactOnIncomeStatementForOtherProvisions", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfIncreaseInMonthlyRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of increase in monthly rent.", "label": "Amount of Increase in Monthly Rent", "terseLabel": "Amount of increase in monthly rent" } } }, "localname": "AmountOfIncreaseInMonthlyRent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfOffsettingVatCreditReceivables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the settlement of duties in respective with VAT credit receivables.", "label": "Amount of Offsetting VAT Credit Receivables", "terseLabel": "Amount of offsetting against VAT credit receivables" } } }, "localname": "AmountOfOffsettingVatCreditReceivables", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfPurchasesInForeignCurrencyTranslatedToReportingCurrency": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amounts of purchases made in foreign currency, translated to the reporting currency.", "label": "Amount Of Purchases In Foreign Currency Translated To Reporting Currency", "terseLabel": "Foreign currency expense amount" } } }, "localname": "AmountOfPurchasesInForeignCurrencyTranslatedToReportingCurrency", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesForeignCurrencyTransactionsAndSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfReleaseOfTermAccountPledge": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of release of term account pledge.", "label": "Amount of Release of Term Account Pledge", "terseLabel": "Amount of Release of Term Account Pledge" } } }, "localname": "AmountOfReleaseOfTermAccountPledge", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfSubcontractingExpensesClaimedAbandoned": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of abandoned subcontracting expenses already claimed.", "label": "Amount of Subcontracting Expenses Claimed Abandoned", "terseLabel": "Amount of abandoned expenses claimed" } } }, "localname": "AmountOfSubcontractingExpensesClaimedAbandoned", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfSubcontractingProvisionReversed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of subcontracting expenses reversed.", "label": "Amount of Subcontracting Provision Reversed", "terseLabel": "Amount of expenses reversed" } } }, "localname": "AmountOfSubcontractingProvisionReversed", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfSubcontractingTaxCreditReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of subcontracting tax credit receivable.", "label": "Amount of Subcontracting Tax Credit Receivable", "terseLabel": "Amount of receivable" } } }, "localname": "AmountOfSubcontractingTaxCreditReceivable", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountOfSubcontractingTaxRebateGrantedByTaxAuthorities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of subcontracting tax rebate received from French tax authorities.", "label": "Amount of Subcontracting Tax Rebate Granted by Tax Authorities", "terseLabel": "Amount of expenses reversed" } } }, "localname": "AmountOfSubcontractingTaxRebateGrantedByTaxAuthorities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AmountPaidInCashForDuties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the net amount paid in cash to French tax authorities.", "label": "Amount Paid in Cash For Duties", "terseLabel": "Net amount paid by bank transfer" } } }, "localname": "AmountPaidInCashForDuties", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_AnnualIncreaseOfRentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of increase in annual rent.", "label": "Annual Increase of Rent, Percentage", "terseLabel": "Annual increase of rent in percentage" } } }, "localname": "AnnualIncreaseOfRentPercentage", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails" ], "xbrltype": "percentItemType" }, "iva_AtMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for at-the market offering (ATM).", "label": "ATM" } } }, "localname": "AtMarketOfferingMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "domainItemType" }, "iva_AverageLifeOtherEquityInstrumentsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The average life of other equity instruments granted.", "label": "Average Life, Other Equity Instruments Granted", "terseLabel": "Average life (years)" } } }, "localname": "AverageLifeOtherEquityInstrumentsGranted", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "xbrltype": "durationItemType" }, "iva_BenefitObligationPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of benefit obligation percentage.", "label": "Benefit Obligation Percentage" } } }, "localname": "BenefitObligationPercentage", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "percentItemType" }, "iva_BonusShareAwardPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for bonus share award plans.", "label": "Bonus share award plans" } } }, "localname": "BonusShareAwardPlansMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationVestingOfBonusSharesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "xbrltype": "domainItemType" }, "iva_BonusShareAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for bonus share awards.", "label": "AGA" } } }, "localname": "BonusShareAwardsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationVestingOfBonusSharesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_BorrowingsMaximumExtensionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period up to which the maturity term of the borrowings can be extended.", "label": "Borrowings, Maximum Extension Term", "terseLabel": "Extension of term of debt", "verboseLabel": "Extension of term of debt" } } }, "localname": "BorrowingsMaximumExtensionTerm", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNonDilutiveFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails" ], "xbrltype": "durationItemType" }, "iva_BorrowingsNumberOfLoansObtained": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of loans obtained by the company.", "label": "Borrowings, Number Of Loans Obtained", "terseLabel": "Number of loans obtained" } } }, "localname": "BorrowingsNumberOfLoansObtained", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails" ], "xbrltype": "integerItemType" }, "iva_Bsa2017PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2017 plan.", "label": "BSA - 2017 plan" } } }, "localname": "Bsa2017PlanMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_Bsa20181PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2018-1 plan.", "label": "BSA 2018-1" } } }, "localname": "Bsa20181PlanMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "domainItemType" }, "iva_Bsa2018PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2018 plan.", "label": "BSA - 2018 plan" } } }, "localname": "Bsa2018PlanMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_Bsa2019PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2019 plan.", "label": "BSA - 2019 plan" } } }, "localname": "Bsa2019PlanMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_BsaPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA plans.", "label": "BSA plans" } } }, "localname": "BsaPlansMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_BsaShareWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA share warrant.", "label": "BSA Share warrant [Member]" } } }, "localname": "BsaShareWarrantMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "xbrltype": "domainItemType" }, "iva_BsaShareWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA share warrants.", "label": "BSA share warrants" } } }, "localname": "BsaShareWarrantsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "xbrltype": "domainItemType" }, "iva_Bspce20131PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE 2013-1 plan.", "label": "BSPCE 2013-1" } } }, "localname": "Bspce20131PlanMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "xbrltype": "domainItemType" }, "iva_Bspce2013PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE - 2013 plan.", "label": "BSPCE - 2013 Plan [Member]" } } }, "localname": "Bspce2013PlanMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_Bspce2015PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE - 2015 plan.", "label": "BSPCE - 2015 Plan [Member]" } } }, "localname": "Bspce2015PlanMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_Bspce2021PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE 2021 plan.", "label": "BSPCE 2021" } } }, "localname": "Bspce2021PlanMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_BspceAndBsaShareWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE and BSA share warrants.", "label": "BSPCE and BSA share warrants" } } }, "localname": "BspceAndBsaShareWarrantsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "xbrltype": "domainItemType" }, "iva_BspcePlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE plans.", "label": "BSPCE plans" } } }, "localname": "BspcePlansMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_BspceShareWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE share warrants.", "label": "BSPCE Share Warrants [Member]" } } }, "localname": "BspceShareWarrantsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "xbrltype": "domainItemType" }, "iva_BvfPartnersL.p.NovoSNewEnterpriseAssociates17L.p.AndSofinnovaPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for BVF Partners L.P., Novo A/S, New Enterprise Associates 17, L.P. and Sofinnova Partners.", "label": "BVF Partners L.P., Novo A/S, New Enterprise Associates 17, L.P. and Sofinnova Partners" } } }, "localname": "BvfPartnersL.p.NovoSNewEnterpriseAssociates17L.p.AndSofinnovaPartnersMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails" ], "xbrltype": "domainItemType" }, "iva_CashUnderLiquidityAgreementCurrent": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "order": 2.0, "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash under liquidity agreement, classified as current.", "label": "Cash Under Liquidity Agreement, Current", "terseLabel": "Liquidity agreement - Cash account" } } }, "localname": "CashUnderLiquidityAgreementCurrent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "iva_ChangeInFairValueOfDerivatives": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of change in fair value of derivatives as of the reporting date recorded in other current liabilities.", "label": "Change In Fair Value Of Derivatives", "terseLabel": "Change in fair value of future currency contracts" } } }, "localname": "ChangeInFairValueOfDerivatives", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsRelatedToFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "iva_CirRelatingToSubcontractingOperations2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for cir relating to subcontracting operations 2017.", "label": "2017 CIR relating to subcontracting operations" } } }, "localname": "CirRelatingToSubcontractingOperations2017Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "domainItemType" }, "iva_ClaimIncludingSurchargeAndInterestRejectedByTaxAuthorities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of claim (including surcharge and interest) rejected by tax authorities.", "label": "Claim Including Surcharge And Interest Rejected By Tax Authorities", "terseLabel": "Claim for total amount" } } }, "localname": "ClaimIncludingSurchargeAndInterestRejectedByTaxAuthorities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails" ], "xbrltype": "monetaryItemType" }, "iva_ClassOfWarrantOrRightExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercised during the period.", "label": "Class Of Warrant Or Right, Exercised During Period", "terseLabel": "Number of warrants exercised" } } }, "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "sharesItemType" }, "iva_ClassOfWarrantOrRightGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights granted.", "label": "Class of Warrant or Right, Granted", "terseLabel": "Number of warrants granted" } } }, "localname": "ClassOfWarrantOrRightGranted", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "xbrltype": "sharesItemType" }, "iva_CollaborativeArrangementMilestonePaymentsReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the cumulative amount of research funding received in a collaborative arrangement.", "label": "Collaborative Arrangement, Milestone Payments Received", "terseLabel": "Milestone payments received" } } }, "localname": "CollaborativeArrangementMilestonePaymentsReceived", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "iva_CollaborativeArrangementMilestonePaymentsReceivedFollowingEnrollmentOfFirstPatient": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the milestone payments received following the enrollment of first patient in a collaborative arrangement.", "label": "Collaborative Arrangement, Milestone Payments Received Following The Enrollment Of First Patient", "terseLabel": "Milestone payments received following the enrollment of first patient" } } }, "localname": "CollaborativeArrangementMilestonePaymentsReceivedFollowingEnrollmentOfFirstPatient", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_CollaborativeArrangementReversalOfContractLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of reversal of contract liabilities recognized under IFRS 15.", "label": "Collaborative Arrangement, Reversal of Contract Liabilities", "terseLabel": "Reversal of contract liabilities" } } }, "localname": "CollaborativeArrangementReversalOfContractLiabilities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_CommitmentsAmountPayableForServicesReceivedUnderContract": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Commitment amount payable for services received under contract.", "label": "Commitments Amount Payable For Services Received Under Contract", "terseLabel": "Contract CRO with Spaulding" } } }, "localname": "CommitmentsAmountPayableForServicesReceivedUnderContract", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "iva_CommitmentsRelatedToFuturePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of commitments related to future payments.", "label": "Commitments Related to Future Payments" } } }, "localname": "CommitmentsRelatedToFuturePayments", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails" ], "xbrltype": "monetaryItemType" }, "iva_CompanyInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Company Information" } } }, "localname": "CompanyInformationAbstract", "nsuri": "http://www.inventivapharma.com/20201231", "xbrltype": "stringItemType" }, "iva_CompanyInformationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on company information.", "label": "Company Information [Text Block]", "terseLabel": "Company Information" } } }, "localname": "CompanyInformationTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformation" ], "xbrltype": "textBlockItemType" }, "iva_ConsolidationAdjustmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Consolidation Adjustments .", "label": "Consolidation Adjustments [Member]" } } }, "localname": "ConsolidationAdjustmentsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceConsolidatedFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "iva_ContractCmoWithFisherClinicalServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CMO with Fisher Clinical Services.", "label": "Contract CMO with Fisher Clinical Services [Member]" } } }, "localname": "ContractCmoWithFisherClinicalServicesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "domainItemType" }, "iva_ContractCroSignedWithDelpharmReimsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to contract CRO signed with Delpharm Reims.", "label": "Contract CRO signed with Delpharm Reims [Member]" } } }, "localname": "ContractCroSignedWithDelpharmReimsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "domainItemType" }, "iva_ContractCroSignedWithSyneosHealthClinicalResearchServicesLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to contract CRO signed with Syneos Health Clinical Research Services, LLC.", "label": "Contract CRO signed with Syneos Health Clinical Research Services, LLC [Member]" } } }, "localname": "ContractCroSignedWithSyneosHealthClinicalResearchServicesLlcMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "domainItemType" }, "iva_ContractCroSignedWithSynexusClinicalResearchGmbhMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to contract CRO signed with Synexus Clinical Research GmbH.", "label": "Contract CRO signed with Synexus Clinical Research GmbH" } } }, "localname": "ContractCroSignedWithSynexusClinicalResearchGmbhMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "domainItemType" }, "iva_ContractCroSignedWithUnitedBiosourceLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CRO signed with United BioSource LLC.", "label": "Contract CRO signed with United BioSource LLC [Member]" } } }, "localname": "ContractCroSignedWithUnitedBiosourceLlcMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "domainItemType" }, "iva_ContractCroWithResearchAssociatesGroupeB.vMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CRO with PRA.", "label": "Contract CRO with Research Associates Groupe B.V [Member]" } } }, "localname": "ContractCroWithResearchAssociatesGroupeB.vMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "domainItemType" }, "iva_ContractCroWithSpauldingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to contract CRO with Spaulding.", "label": "Contract CRO with Spaulding [Member]" } } }, "localname": "ContractCroWithSpauldingMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "domainItemType" }, "iva_ContractSignedWithCordenPharmaChenveSasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to contract signed with Corden Pharma Chenve SAS.", "label": "Contract signed with Corden Pharma Chenve SAS [Member]" } } }, "localname": "ContractSignedWithCordenPharmaChenveSasMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "domainItemType" }, "iva_CorrectiveClaimsFrenchResearchTaxCreditRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income recognized for corrective claims related to French Research Tax Credit (CIR).", "label": "Corrective Claims French Research Tax Credit, Revenue", "terseLabel": "Corrective claims - CIR" } } }, "localname": "CorrectiveClaimsFrenchResearchTaxCreditRevenue", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_CreditAgricoleBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Credit Agricole Bank.", "label": "Crdit Agricole bank" } } }, "localname": "CreditAgricoleBankMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "iva_CurrentTaxCreditReceivables": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "order": 1.0, "parentTag": "iva_OtherCurrentAssetsAndReceivables", "weight": 1.0 }, "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of current tax credit receivables", "label": "Current tax credit receivables", "terseLabel": "Tax receivables", "totalLabel": "Tax receivables" } } }, "localname": "CurrentTaxCreditReceivables", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "iva_CurrentTaxCreditResearch": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "order": 1.0, "parentTag": "iva_CurrentTaxCreditReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of tax credit research, classified as current.", "label": "Current Tax Credit Research", "terseLabel": "CIR" } } }, "localname": "CurrentTaxCreditResearch", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "iva_CurrentTaxCreditResearchCorrectiveClaims": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of tax credit research for corrective claims, classified as current.", "label": "Current Tax Credit Research, Corrective Claims", "terseLabel": "Corrective claims" } } }, "localname": "CurrentTaxCreditResearchCorrectiveClaims", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_CurrentTaxCreditResearchCurrentYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of tax credit research from current year, classified as current.", "label": "Current Tax Credit Research, Current Year", "terseLabel": "Receivable for current year" } } }, "localname": "CurrentTaxCreditResearchCurrentYear", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_CurrentTaxCreditResearchIncome": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "order": 3.0, "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of income from tax credit research.", "label": "Current Tax Credit Research Income", "terseLabel": "CIR" } } }, "localname": "CurrentTaxCreditResearchIncome", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "iva_CurrentTaxCreditResearchPriorPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of tax credit research from prior period, classified as current.", "label": "Current Tax Credit Research, Prior Period", "terseLabel": "Receivables from previous years not yet received" } } }, "localname": "CurrentTaxCreditResearchPriorPeriod", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_CurrentTaxCreditResearchPriorPeriodIncludingCorrectiveClaim": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of tax credit research from prior period including corrective claim, classified as current.", "label": "Current Tax Credit Research, Prior Period Including Corrective Claim", "terseLabel": "Receivables from previous years not yet received including corrective claim" } } }, "localname": "CurrentTaxCreditResearchPriorPeriodIncludingCorrectiveClaim", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_CurrentTradeReceivablesAveragePaymentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the average payment period for trade receivables.", "label": "Current Trade Receivables, Average Payment Period", "terseLabel": "Average payment period for trade receivables" } } }, "localname": "CurrentTradeReceivablesAveragePaymentPeriod", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "xbrltype": "durationItemType" }, "iva_CustomerAdvancesOrDepositsNoncurrent": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails": { "order": 5.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of customer advance or deposits non current.", "label": "Customer Advances or Deposits, Noncurrent", "terseLabel": "Advances to suppliers - non-current" } } }, "localname": "CustomerAdvancesOrDepositsNoncurrent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "iva_DavidNikodemMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for David Nikodem, a member of Sapidus Consulting Group LLC, a service provider to the Company.", "label": "David Nikodem" } } }, "localname": "DavidNikodemMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "xbrltype": "domainItemType" }, "iva_DecreaseThroughTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The decrease in equity resulting through transaction costs.", "label": "Decrease Through Transaction Costs", "negatedLabel": "Transaction costs" } } }, "localname": "DecreaseThroughTransactionCosts", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "iva_DecreasesInIntangibleAssetsOtherThanGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of decreases to intangible assets other than goodwill.", "label": "Decreases in intangible assets other than goodwill", "negatedLabel": "Decreases" } } }, "localname": "DecreasesInIntangibleAssetsOtherThanGoodwill", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "iva_DecreasesInPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of decreases in property, plant and equipment", "label": "Decreases in property, plant and equipment", "negatedLabel": "Decreases" } } }, "localname": "DecreasesInPropertyPlantAndEquipment", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "iva_DeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferencesUnrecognized": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "order": 6.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount due to unrecognized deferred tax assets related to tax losses and temporary differences for reconciliation between accounting profit and tax expense income.", "label": "Deferred Tax Assets Related To Tax Losses And Temporary Differences Unrecognized", "negatedLabel": "Non recognition of deferred tax assets related to tax losses and temporary differences" } } }, "localname": "DeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferencesUnrecognized", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "iva_DefinedBenefitPlanGainLossFromPlanCurtailmentsAndModifications": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForPeriodDetails": { "order": 3.0, "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized for plan curtailments and modifications related to defined benefit plan.", "label": "Defined Benefit Plan, Gain (Loss) From Plan Curtailments And Modifications", "terseLabel": "Plan curtailments and modifications" } } }, "localname": "DefinedBenefitPlanGainLossFromPlanCurtailmentsAndModifications", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForPeriodDetails" ], "xbrltype": "monetaryItemType" }, "iva_DepreciationAmortizationAndProvisions": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails": { "order": 1.0, "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to depreciation, amortization and provisions.", "label": "Depreciation, amortization and provisions", "negatedLabel": "Depreciation, amortization and provisions" } } }, "localname": "DepreciationAmortizationAndProvisions", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_DerivativeAssetForeignCurrencyForwardsCurrent": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "order": 4.0, "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the asset arising from a foreign currency forward contract classified as current.", "label": "Derivative Asset, Foreign Currency Forwards, Current", "terseLabel": "Foreign currency forwards" } } }, "localname": "DerivativeAssetForeignCurrencyForwardsCurrent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "iva_DescriptionOfAccountingPolicyForNonCurrentAssetsOtherThanPropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for non-current assets other than property, plant and equipment.", "label": "Description Of Accounting Policy For Non Current Assets Other Than Property, Plant And Equipment [Policy Text Block]", "terseLabel": "Other non-current assets" } } }, "localname": "DescriptionOfAccountingPolicyForNonCurrentAssetsOtherThanPropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "iva_DescriptionOfAccountingPolicyForOtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for other current assets.", "label": "Description Of Accounting Policy For Other Current Assets [Text Block]", "terseLabel": "Other current assets" } } }, "localname": "DescriptionOfAccountingPolicyForOtherCurrentAssetsTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "iva_DescriptionOfAccountingPolicyForOtherIncomePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for other income.", "label": "Description Of Accounting Policy For Other Income [Policy Text Block]", "terseLabel": "Other income" } } }, "localname": "DescriptionOfAccountingPolicyForOtherIncomePolicyTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "iva_DirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Directors.", "label": "Directors" } } }, "localname": "DirectorsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "xbrltype": "domainItemType" }, "iva_DisclosureOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeLossForRetirementBenefitObligationsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about actuarial gains (losses) recognized in comprehensive income (loss) for Retirement Benefit Obligations.", "label": "Disclosure Of Actuarial Gains And Losses Recognized In Comprehensive Income (Loss) For Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of actuarial gains and losses recognized in comprehensive income" } } }, "localname": "DisclosureOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeLossForRetirementBenefitObligationsExplanatory", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "xbrltype": "textBlockItemType" }, "iva_DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about assumptions used to measure Retirement Benefit Obligations.", "label": "Disclosure Of Assumptions Used To Measure Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of assumptions used to measure Retirement Benefit Obligations" } } }, "localname": "DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "xbrltype": "textBlockItemType" }, "iva_DisclosureOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of cash and cash equivalents.", "label": "Disclosure Of Cash And Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "iva_DisclosureOfChangesInBorrowingsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of changes in borrowings.", "label": "Disclosure Of Changes In Borrowings [Table Text Block]", "terseLabel": "Schedule of changes in borrowings" } } }, "localname": "DisclosureOfChangesInBorrowingsTableTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about change in the provision recorded in respect of defined benefit schemes.", "label": "Disclosure Of Changes In Provision Recorded In Respect Of Defined Benefit Schemes, Explanatory", "terseLabel": "Schedule of change in the provision recorded in respect of defined benefit schemes" } } }, "localname": "DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "xbrltype": "textBlockItemType" }, "iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about expense recognized in the statement of income (loss) for Retirement Benefit Obligations.", "label": "Disclosure Of Expenses Recognized In Statement Of Income (Loss) For Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of expense recognized in the statement of income (loss)" } } }, "localname": "DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "xbrltype": "textBlockItemType" }, "iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other non current assets.", "label": "Disclosure Of Other Noncurrent Assets [Table Text Block]", "terseLabel": "Schedule of other non current assets" } } }, "localname": "DisclosureOfOtherNoncurrentAssetsTableTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other operating income (expense).", "label": "Disclosure Of Other Operating Income Expense [Table Text Block]", "terseLabel": "Schedule of other operating income (expenses)" } } }, "localname": "DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesTables" ], "xbrltype": "textBlockItemType" }, "iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about provision recorded in respect of defined benefit schemes at the end of each reporting period.", "label": "Disclosure Of Provision Recorded In Respect Of Defined Benefit Schemes At End Of Each Reporting Period, Explanatory", "terseLabel": "Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period" } } }, "localname": "DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "xbrltype": "textBlockItemType" }, "iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for trade payables and other current liabilities.", "label": "Disclosure Of Trade Payables and Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of trade payables and other current liabilities" } } }, "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for trade payables and other current liabilities.", "label": "Disclosure Of Trade Payables and Other Current Liabilities [Text Block]", "terseLabel": "Trade Payables and Other Current Liabilities" } } }, "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "iva_DisclosureOfTradeReceivablesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of trade receivables.", "label": "Disclosure of Trade Receivables [Table Text Block]", "terseLabel": "Schedule of trade receivables" } } }, "localname": "DisclosureOfTradeReceivablesTableTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTables" ], "xbrltype": "textBlockItemType" }, "iva_Disposables": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails": { "order": 2.0, "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to disposables.", "label": "Disposables", "negatedLabel": "Disposables" } } }, "localname": "Disposables", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_DisputeUnresolvedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for scenario of the dispute remaining unresolved.", "label": "If dispute remains unresolved" } } }, "localname": "DisputeUnresolvedMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "domainItemType" }, "iva_EmployeeRelatedPayables": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to employee related payables.", "label": "Employee related payables", "verboseLabel": "Employee-related payables" } } }, "localname": "EmployeeRelatedPayables", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iva_EmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for employees.", "label": "Employees" } } }, "localname": "EmployeesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_EnergyAndLiquids": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails": { "order": 4.0, "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to energy and liquids.", "label": "Energy and liquids", "negatedLabel": "Energy and liquids" } } }, "localname": "EnergyAndLiquids", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_EquipmentAndToolingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for equipment and tooling.", "label": "Equipment and tooling" } } }, "localname": "EquipmentAndToolingMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "iva_ExpectedVolatility": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected volatility used to calculate fair value of warrants.", "label": "Expected volatility", "terseLabel": "Expected volatility" } } }, "localname": "ExpectedVolatility", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "xbrltype": "percentItemType" }, "iva_ExpectedVolatilityOtherEquityInstrumentsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The expected volatility of other equity instruments granted.", "label": "Expected Volatility, Other Equity Instruments Granted", "terseLabel": "Expected volatility" } } }, "localname": "ExpectedVolatilityOtherEquityInstrumentsGranted", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "xbrltype": "percentItemType" }, "iva_FairValueVariationGains": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gains recognized for variation in fair value.", "label": "Fair Value Variation Gains", "terseLabel": "Fair value variation gains / losses" } } }, "localname": "FairValueVariationGains", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_FairValueVariationLosses": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 4.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of losses recognized for variation in fair value.", "label": "Fair Value Variation Losses", "terseLabel": "Losses on change in fair value" } } }, "localname": "FairValueVariationLosses", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_Fees": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails": { "order": 5.0, "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to fees.", "label": "Fees", "negatedLabel": "Fees" } } }, "localname": "Fees", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_FinancialIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of financial income and expenses.", "label": "Financial Income and Expenses" } } }, "localname": "FinancialIncomeAndExpensesAbstract", "nsuri": "http://www.inventivapharma.com/20201231", "xbrltype": "stringItemType" }, "iva_FinancialIncomeAndExpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Financial Income And Expenses [Line Items]", "verboseLabel": "Financial income and expenses" } } }, "localname": "FinancialIncomeAndExpensesLineItems", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "stringItemType" }, "iva_FinancialIncomeAndExpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to disclosure of financial income and expenses.", "label": "Financial Income And Expenses [Table]" } } }, "localname": "FinancialIncomeAndExpensesTable", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "stringItemType" }, "iva_FinancialIncomeAndExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of financial income and expense.", "label": "Financial Income and Expenses [Table Text Block]", "terseLabel": "Schedule of financial income and expenses" } } }, "localname": "FinancialIncomeAndExpensesTableTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesTables" ], "xbrltype": "textBlockItemType" }, "iva_FinancialInstrumentsNumberOfContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of contracts entered under financial instruments.", "label": "Financial Instruments, Number of Contracts", "terseLabel": "Number of contracts under foreign currency forward" } } }, "localname": "FinancialInstrumentsNumberOfContracts", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "iva_FinancingFromSyndicateOfFrenchBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for financing from a syndicate of French banks.", "label": "Financing from a syndicate of French banks" } } }, "localname": "FinancingFromSyndicateOfFrenchBanksMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNonDilutiveFinancingDetails", "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails" ], "xbrltype": "domainItemType" }, "iva_FredericCrenAndPierreBroquaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Frederic Cren and Pierre Broqua.", "label": "Frederic Cren and Pierre Broqua" } } }, "localname": "FredericCrenAndPierreBroquaMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_FrenchResearchTaxCreditReceivableAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of French Research Tax Credit (CIR) receivable by the company.", "label": "French Research Tax Credit, Receivable Amount", "terseLabel": "French Research Tax Credit (CIR), amounts receivable" } } }, "localname": "FrenchResearchTaxCreditReceivableAmount", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_FrenchResearchTaxCreditReimbursementAmountDenied": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reimbursement under the French Research Tax Credit (CIR), denied by the French tax authority.", "label": "French Research Tax Credit, Reimbursement Amount Denied", "terseLabel": "Reimbursement denied by French tax authority" } } }, "localname": "FrenchResearchTaxCreditReimbursementAmountDenied", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_FrenchResearchTaxCreditWithheldPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of French Research Tax Credit (CIR), withheld during the period.", "label": "French Research Tax Credit Withheld, Percentage", "terseLabel": "Percentage of French Research Tax Credit (CIR) Withheld" } } }, "localname": "FrenchResearchTaxCreditWithheldPercentage", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "xbrltype": "percentItemType" }, "iva_FurnitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for furniture.", "label": "Furniture" } } }, "localname": "FurnitureMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "iva_GeneralFacilitiesMiscellaneousFixturesAndFittingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for general facilities, miscellaneous fixtures and fittings.", "label": "General facilities, miscellaneous fixtures and fittings" } } }, "localname": "GeneralFacilitiesMiscellaneousFixturesAndFittingsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "iva_GrossProceedsFromIssuingShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of gross proceeds from issuing shares.", "label": "Gross Proceeds From Issuing Shares", "terseLabel": "Gross proceeds from Initial Public Offering", "verboseLabel": "Gross proceeds from initial public offering" } } }, "localname": "GrossProceedsFromIssuingShares", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "iva_GuaranteeGivenToTaxAuthoritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for guarantee given to the tax authorities.", "label": "Guarantee given to the tax authorities" } } }, "localname": "GuaranteeGivenToTaxAuthoritiesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails" ], "xbrltype": "domainItemType" }, "iva_HoldingPeriodOfAwardsGrantedInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the holding period of awards granted in share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Holding Period Of Awards Granted In Share-Based Payment Arrangement", "terseLabel": "Holding period (year)" } } }, "localname": "HoldingPeriodOfAwardsGrantedInShareBasedPaymentArrangement", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "xbrltype": "durationItemType" }, "iva_IFRS16RestatementThreshold": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The threshold amount for restating leases under IFRS 16. Leases with underlying assets under such threshold amount are not restated as they are covered by the exemptions permitted under the standard.", "label": "I F R S 16 Restatement Threshold", "terseLabel": "Underlying assets of leases not restated" } } }, "localname": "IFRS16RestatementThreshold", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesLeasesContractsDetails" ], "xbrltype": "monetaryItemType" }, "iva_Ifrs16Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for IFRS 16.", "label": "IFRS 16" } } }, "localname": "Ifrs16Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesLeasesContractsDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsAdrMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Ifrs ADR Member\n.", "label": "ADS" } } }, "localname": "IfrsAdrMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsBalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "IFRS Balance Sheet Location [Axis]" } } }, "localname": "IfrsBalanceSheetLocationAxis", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "stringItemType" }, "iva_IfrsBalanceSheetLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "IFRS Balance Sheet Location [Domain]" } } }, "localname": "IfrsBalanceSheetLocationDomain", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for cash and cash equivalents.", "label": "Cash and cash equivalents" } } }, "localname": "IfrsCashAndCashEquivalentsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Ifrs Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of share per warrant", "verboseLabel": "Number of shares per BSA" } } }, "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "xbrltype": "sharesItemType" }, "iva_IfrsClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Outstanding", "terseLabel": "Number of share warrants outstanding" } } }, "localname": "IfrsClassOfWarrantOrRightOutstanding", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "sharesItemType" }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "xbrltype": "stringItemType" }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items" } } }, "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "iva_IfrsDirectorsAndOfficersLiabilityInsuranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Professional liability coverage for legal expenses and liability to shareholders, bondholders, creditors or others due to actions or omissions by a director or officer of a corporation or nonprofit organization.", "label": "Directors and Officers Liability Insurance" } } }, "localname": "IfrsDirectorsAndOfficersLiabilityInsuranceMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign currency forwards" } } }, "localname": "IfrsForeignExchangeForwardMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsRelatedToFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompletionOfFutureCurrencyContractDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUnwindingOfThreeForwardContractsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsGainLossOnTerminationOfLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "IFRS Gain (Loss) on Termination of Lease", "negatedLabel": "Early termination of lease contracts" } } }, "localname": "IfrsGainLossOnTerminationOfLease", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtRepaymentsOfBorrowingsAndAccrualOfInterestsDetails" ], "xbrltype": "monetaryItemType" }, "iva_IfrsGeneralAndAdministrativeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for general and administrative expense member.", "label": "General and administrative expenses" } } }, "localname": "IfrsGeneralAndAdministrativeExpenseMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsNumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of operating segments" } } }, "localname": "IfrsNumberOfOperatingSegments", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesSegmentInformationDetails" ], "xbrltype": "integerItemType" }, "iva_IfrsOtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities" } } }, "localname": "IfrsOtherCurrentLiabilitiesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsOtherOperatingIncome": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "order": 1.0, "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.", "label": "Ifrs Other Operating Income", "terseLabel": "Other" } } }, "localname": "IfrsOtherOperatingIncome", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "iva_IfrsResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development expense member.", "label": "Ifrs Research And Development Expense [Member]", "terseLabel": "Research and development expenses" } } }, "localname": "IfrsResearchAndDevelopmentExpenseMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsSaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "IFRS Sale of Stock [Axis]" } } }, "localname": "IfrsSaleOfStockAxis", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "stringItemType" }, "iva_IfrsSaleOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "IFRS Sale of Stock [Domain]" } } }, "localname": "IfrsSaleOfStockDomain", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsSalesAndMarketingExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for sales and marketing expense member.", "label": "Marketing - business development expenses" } } }, "localname": "IfrsSalesAndMarketingExpenseMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Ifrs Schedule of Components of Income Tax Expense Benefit [Table text block]", "terseLabel": "Schedule of income tax expense" } } }, "localname": "IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxTables" ], "xbrltype": "textBlockItemType" }, "iva_IfrsScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "IFRS Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "IfrsScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesTables" ], "xbrltype": "textBlockItemType" }, "iva_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "durationItemType" }, "iva_IfrsShareBasedPaymentArrangementTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Tranche one" } } }, "localname": "IfrsShareBasedPaymentArrangementTrancheOneMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsShareBasedPaymentArrangementTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Tranche three" } } }, "localname": "IfrsShareBasedPaymentArrangementTrancheThreeMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsShareBasedPaymentArrangementTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Tranche two" } } }, "localname": "IfrsShareBasedPaymentArrangementTrancheTwoMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "domainItemType" }, "iva_IfrsValueAddedTaxReceivableCurrent": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "order": 6.0, "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "IFRS Value Added Tax Receivable, Current", "terseLabel": "VAT receivables" } } }, "localname": "IfrsValueAddedTaxReceivableCurrent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "iva_IfrsVestingAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Ifrs Vesting [Axis]" } } }, "localname": "IfrsVestingAxis", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "stringItemType" }, "iva_IfrsVestingDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Ifrs Vesting [Domain]" } } }, "localname": "IfrsVestingDomain", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "domainItemType" }, "iva_ImpairmentOfTaxLossCarryBack": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment of tax loss carry back during the period.", "label": "Impairment Of Tax Loss Carry Back", "negatedLabel": "Impairment of tax loss carry back" } } }, "localname": "ImpairmentOfTaxLossCarryBack", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_IncreaseDecreaseInBorrowings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in borrowings.", "label": "Increase Decrease In Borrowings", "terseLabel": "Increase (Decrease) in borrowings" } } }, "localname": "IncreaseDecreaseInBorrowings", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "iva_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumptionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period.", "label": "Increase (Decrease) In Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption, Percent", "terseLabel": "Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption (as a percent)" } } }, "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumptionPercent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "xbrltype": "percentItemType" }, "iva_IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseDecreaseInDesignatedRiskComponent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in a financial instrument as a result of an increase (decrease) in a designated risk component that was reasonably possible at the end of the reporting period. Excludes defined benefit plan obligations.", "label": "Increase (Decrease) In Financial Instrument Due To Reasonably Possible Increase (Decrease) In Designated Risk Component", "terseLabel": "Impact of a 5% change in fair value" } } }, "localname": "IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseDecreaseInDesignatedRiskComponent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "monetaryItemType" }, "iva_IncreaseDecreaseInSharesThroughExerciseAndVestingOfEquityInstruments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in shares resulting from the exercise and vesting of equity instruments.", "label": "Increase (Decrease) In Shares Through Exercise And Vesting Of Equity Instruments", "terseLabel": "Exercise of BSAs/BSPCEs and vesting of AGAs (in shares)" } } }, "localname": "IncreaseDecreaseInSharesThroughExerciseAndVestingOfEquityInstruments", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "iva_IncreaseDecreaseInSharesThroughExerciseOfEquityInstruments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in shares resulting from the exercise of equity instruments.", "label": "Increase (Decrease) In Shares Through Exercise Of Equity Instruments", "terseLabel": "Exercise of BSAs/BSPCEs and AGAs (in shares)", "verboseLabel": "Number of new shares issued upon exercise of warrants" } } }, "localname": "IncreaseDecreaseInSharesThroughExerciseOfEquityInstruments", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "iva_IncreaseDecreaseThroughAppropriationOfShareIssuancePremium": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of a share issuance premium.", "label": "Increase (Decrease) Through Appropriation of Share Issuance Premium", "terseLabel": "Appropriation of the issue premium" } } }, "localname": "IncreaseDecreaseThroughAppropriationOfShareIssuancePremium", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "iva_IncreaseDecreaseThroughExerciseAndVestingOfEquityInstruments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise and vesting of equity instruments.", "label": "Increase (Decrease) Through Exercise And Vesting Of Equity Instruments", "terseLabel": "Exercise of BSAs/BSPCEs and vesting of AGAs" } } }, "localname": "IncreaseDecreaseThroughExerciseAndVestingOfEquityInstruments", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase decrease in reserves resulting from BSA share warrants subscription premium.", "label": "Increase (Decrease) Through Share Warrants Subscription Premium", "terseLabel": "BSA share warrants subscription premium" } } }, "localname": "IncreaseDecreaseThroughShareWarrantsSubscriptionPremium", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "iva_IncreaseInSharesThroughIssueOfOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The increase in shares resulting from the issuance of shares.", "label": "Increase In Shares Through Issue of Ordinary Shares", "terseLabel": "Issue of ordinary shares (in shares)", "verboseLabel": "Number of shares issued during the period" } } }, "localname": "IncreaseInSharesThroughIssueOfOrdinaryShares", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "iva_IncreasedIncurredStudiesFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increased incurred studies fee.", "label": "Increased Incurred Studies Fee", "terseLabel": "Increased incurred studies fee" } } }, "localname": "IncreasedIncurredStudiesFee", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_IncreasedTradePayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increased trade payables.", "label": "Increased Trade Payables", "terseLabel": "Increased trade payables" } } }, "localname": "IncreasedTradePayables", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_IncreasesInIntangibleAssetsOtherThanGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of increases to intangible assets other than goodwill.", "label": "Increases in intangible assets other than goodwill", "terseLabel": "Increases" } } }, "localname": "IncreasesInIntangibleAssetsOtherThanGoodwill", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "iva_IncreasesInPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of increases in property, plant and equipment", "label": "Increases in property, plant and equipment", "terseLabel": "Increases" } } }, "localname": "IncreasesInPropertyPlantAndEquipment", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "iva_IncreseInAmountPayableDueToExtendServicesRendered": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase in amount payable inrespect of clinical services received extended.", "label": "Increse In Amount Payable Due To Extend The Services Rendered", "terseLabel": "Increse in amount payable due to extend the services rendered" } } }, "localname": "IncreseInAmountPayableDueToExtendServicesRendered", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "xbrltype": "monetaryItemType" }, "iva_IndemnificationAmountReceivableUnderGuaranteeMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum indemnification under guarantee , classified as non-current receivable.", "label": "Indemnification Amount Receivable Under Guarantee, Maximum", "terseLabel": "Maximum indemnification amount", "verboseLabel": "Increase in prepaid expenses offset by Abbott Payment" } } }, "localname": "IndemnificationAmountReceivableUnderGuaranteeMaximum", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/StatementStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "iva_IndemnificationAmountReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of indemnification received under guarantee.", "label": "Indemnification Amount Received", "terseLabel": "Indemnification amount received" } } }, "localname": "IndemnificationAmountReceived", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_InitialPublicOfferingCostsAndFollowOnOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of Initial Public Offering (IPO) costs and follow-on offering costs.", "label": "Initial Public Offering Costs And Follow On Offering Costs", "negatedLabel": "IPO costs and follow-on offering" } } }, "localname": "InitialPublicOfferingCostsAndFollowOnOfferingCosts", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_InitialPublicOfferingInsuranceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of pension cost related to IPO.", "label": "Initial Public Offering Insurance Costs" } } }, "localname": "InitialPublicOfferingInsuranceCosts", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_InitialPublicOfferingTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of transaction cost related to IPO.", "label": "Initial Public Offering Transaction Costs" } } }, "localname": "InitialPublicOfferingTransactionCosts", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_InsuranceContractCoveragePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of insurance contract.", "label": "Insurance Contract, Coverage Period", "terseLabel": "Contracts coverage period" } } }, "localname": "InsuranceContractCoveragePeriod", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "durationItemType" }, "iva_InsuranceCoveragePremium": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of premium of insurance coverage obtained.", "label": "Insurance Coverage Premium", "terseLabel": "Insurance amount" } } }, "localname": "InsuranceCoveragePremium", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "iva_InventivaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva Inc, U.S. affiliate.", "label": "Inventiva Inc." } } }, "localname": "InventivaIncMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCreationOfInventivaUsSubsidiaryDetails", "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "iva_InventivaS.aMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva S.A, U.S. affiliate.", "label": "Inventiva S.A" } } }, "localname": "InventivaS.aMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "domainItemType" }, "iva_InventiveS.aMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Inventive S.A\n .", "label": "Inventive S.A [Member]" } } }, "localname": "InventiveS.aMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceConsolidatedFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "iva_InventiveincMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Inventive Inc", "label": "Inventive Inc [Member]" } } }, "localname": "InventiveincMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureGeneralPrinciplesAndStatementOfComplianceConsolidatedFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "iva_InvestmentThresholdMinimumMaturityTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold minimum maturity term of the investments, considered for determination of discount rate for actuarial assumptions used to determine the present value of a defined benefit obligation.", "label": "Investment, Threshold Minimum Maturity Term", "terseLabel": "Threshold minimum maturity term for Eurozone AA rated corporate bonds" } } }, "localname": "InvestmentThresholdMinimumMaturityTerm", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "xbrltype": "durationItemType" }, "iva_IslsConsultingAndDavidNikademMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for ISLS Consulting and David nikadem member.", "label": "ISLS Consulting and David Nikadem" } } }, "localname": "IslsConsultingAndDavidNikademMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_IslsConsultingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for ISLS Consulting, a company owned by Jean Louis Junien, a director of the Company", "label": "ISLS Consulting" } } }, "localname": "IslsConsultingMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_IssuePremiumPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The issue premium price per share.", "label": "Issue Premium Per Share", "terseLabel": "Issue premium per share" } } }, "localname": "IssuePremiumPerShare", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails" ], "xbrltype": "perShareItemType" }, "iva_ItSystems": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails": { "order": 6.0, "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to it systems.", "label": "IT Systems", "negatedLabel": "IT Systems" } } }, "localname": "ItSystems", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_JeremyGoldbergMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Jeremy Goldberg.", "label": "Jeremy Goldberg" } } }, "localname": "JeremyGoldbergMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_JpgHealthcareLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for JPG Healthcare LLC.", "label": "JPG Healthcare LLC" } } }, "localname": "JpgHealthcareLlcMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_KarenAachFormerAdministratorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Karen Aach (former administrator).", "label": "Karen Aach (former administrator)" } } }, "localname": "KarenAachFormerAdministratorMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_LibraryOfCompoundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for library of compounds.", "label": "Library of compounds" } } }, "localname": "LibraryOfCompoundsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "iva_LiquidityAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of days used to determine liquidity agreement term in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Liquidity Agreement Term" } } }, "localname": "LiquidityAgreementTerm", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityLiquidityAgreementDetails" ], "xbrltype": "durationItemType" }, "iva_LongTermDepositAccountsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for long term deposit accounts.", "label": "Long-term deposit accounts" } } }, "localname": "LongTermDepositAccountsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "iva_LongTermSecurityDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term securiy deposits.", "label": "Long-term security deposits" } } }, "localname": "LongTermSecurityDepositsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "iva_MaximumAggregateSalesProceedsFromIssuanceOfShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the maximum aggregate sales proceeds under issuance of shares.", "label": "Maximum Aggregate Sales Proceeds From Issuance Of Shares", "terseLabel": "Maximum aggregate sales proceeds" } } }, "localname": "MaximumAggregateSalesProceedsFromIssuanceOfShares", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "xbrltype": "monetaryItemType" }, "iva_MaximumPotentialAmountOfSaleOfOrdinaryShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the maximum potential amount of sale of ordinary shares.", "label": "Maximum Potential Amount Of Sale Of Ordinary Shares", "terseLabel": "Maximum potential amount of sale of ordinary shares" } } }, "localname": "MaximumPotentialAmountOfSaleOfOrdinaryShares", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "iva_MaximumSubcontractingExpensesToBeClaimed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum subcontracting expenses to be claimed.", "label": "Maximum Subcontracting Expenses to be Claimed", "terseLabel": "Maximum expenses to be claimed" } } }, "localname": "MaximumSubcontractingExpensesToBeClaimed", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_MaximumTaxAdjustmentRisk": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to maximum tax adjustment risk.", "label": "Maximum tax adjustment risk", "terseLabel": "Maximum tax adjustment risk" } } }, "localname": "MaximumTaxAdjustmentRisk", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_MinimumAmountPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount payable inrespect of clinical services received.", "label": "Minimum Amount Payable" } } }, "localname": "MinimumAmountPayable", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "xbrltype": "monetaryItemType" }, "iva_NetExpenseOnChangeInFairValueInFinancialIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net expense on change in fair value in financial income.", "label": "Net Expense On Change In Fair Value In Financial Income", "terseLabel": "Net expense on change in fair value in financial income" } } }, "localname": "NetExpenseOnChangeInFairValueInFinancialIncome", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "iva_NewBonusShareAwardPlan20171Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2017-1).", "label": "AGA 2017-1" } } }, "localname": "NewBonusShareAwardPlan20171Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_NewBonusShareAwardPlan2017PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans, AGA 2017 Plan.", "label": "AGA 2017" } } }, "localname": "NewBonusShareAwardPlan2017PlanMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "xbrltype": "domainItemType" }, "iva_NewBonusShareAwardPlan20181Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2018-1).", "label": "AGA 2018-1" } } }, "localname": "NewBonusShareAwardPlan20181Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_NewBonusShareAwardPlan20182Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2018-2).", "label": "AGA 2018-2" } } }, "localname": "NewBonusShareAwardPlan20182Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_NewBonusShareAwardPlan20183Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2018-3).", "label": "AGA 2018-3" } } }, "localname": "NewBonusShareAwardPlan20183Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_NewBonusShareAwardPlan2018PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans, AGA 2018 Plan.", "label": "AGA 2018" } } }, "localname": "NewBonusShareAwardPlan2018PlanMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "xbrltype": "domainItemType" }, "iva_NewBonusShareAwardPlan20191Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2019-1).", "label": "AGA 2019-1" } } }, "localname": "NewBonusShareAwardPlan20191Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationVestingOfBonusSharesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "domainItemType" }, "iva_NewBonusShareAwardPlan20192Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2019-2).", "label": "AGA 2019-2" } } }, "localname": "NewBonusShareAwardPlan20192Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationBonusShareAwardPlansagaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_NewBonusShareAwardPlan2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans, AGA 2019 Plan.", "label": "AGA 2019 plans" } } }, "localname": "NewBonusShareAwardPlan2019Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "xbrltype": "domainItemType" }, "iva_NewBonusShareAwardPlanAga20211Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021-1)", "label": "AGA 2021-1" } } }, "localname": "NewBonusShareAwardPlanAga20211Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_NewBonusShareAwardPlanAga2021BisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021-bis).", "label": "AGA 2021-bis" } } }, "localname": "NewBonusShareAwardPlanAga2021BisMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_NewBonusShareAwardPlanAga2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021)", "label": "AGA 2021" } } }, "localname": "NewBonusShareAwardPlanAga2021Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_NewBsa20211ShareWarrantPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for new BSA 2021-1 share warrant plan.", "label": "BSA - Plan 2021-1" } } }, "localname": "NewBsa20211ShareWarrantPlanMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_NewBsa2021ShareWarrantPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for new BSA 2021 share warrant plan.", "label": "BSA 2021" } } }, "localname": "NewBsa2021ShareWarrantPlanMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "domainItemType" }, "iva_NewEnterpriseAssociatesNeaBvfPartnersL.p.SofinnovaPartnersAndNovoHoldingsSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for New Enterprise Associates (NEA), as well as BVF Partners L.P., Sofinnova Partners and Novo Holdings A/S.", "label": "New Enterprise Associates (NEA), as well as BVF Partners L.P., Sofinnova Partners and Novo Holdings A/S" } } }, "localname": "NewEnterpriseAssociatesNeaBvfPartnersL.p.SofinnovaPartnersAndNovoHoldingsSMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "domainItemType" }, "iva_NewShareWarrantPlansBsa2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for new share warrant plans (\"BSA 2018\").", "label": "BSA 2018" } } }, "localname": "NewShareWarrantPlansBsa2018Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "domainItemType" }, "iva_NewShareWarrantPlansBsa2019BisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 bis).", "label": "BSA 2019 bis" } } }, "localname": "NewShareWarrantPlansBsa2019BisMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_NewShareWarrantPlansBsa2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for new share warrant plans (\"BSA 2019\").", "label": "BSA 2019" } } }, "localname": "NewShareWarrantPlansBsa2019Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "domainItemType" }, "iva_NewShareWarrantPlansBsa2019TerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 ter).", "label": "BSA 2019 ter" } } }, "localname": "NewShareWarrantPlansBsa2019TerMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNewShareWarrantPlansbsaDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "domainItemType" }, "iva_NonCurrentAdvancesToSuppliers": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount represents the non current advances of suppliers.", "label": "Non Current Advances To Suppliers", "terseLabel": "Advance to suppliers, Non current" } } }, "localname": "NonCurrentAdvancesToSuppliers", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "monetaryItemType" }, "iva_NonCurrentLongTermDepositsFromCustomers": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails": { "order": 3.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents information about non current long term deposits from customers.", "label": "Non Current Long Term Deposits From Customers", "terseLabel": "Longterm deposit accounts" } } }, "localname": "NonCurrentLongTermDepositsFromCustomers", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "iva_NonCurrentSecurityDeposits": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The non-current amount of security deposits.", "label": "Non-current Security Deposits", "terseLabel": "Security deposits" } } }, "localname": "NonCurrentSecurityDeposits", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "iva_NonTransferableDiscountOtherEquityInstrumentsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The non-transferrable discount of other equity instruments granted.", "label": "Non-transferable Discount, Other Equity Instruments Granted", "terseLabel": "Non-transferable discount" } } }, "localname": "NonTransferableDiscountOtherEquityInstrumentsGranted", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "xbrltype": "percentItemType" }, "iva_NotionalAmountOfForwardContractsCompleted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The notional amount of forward contracts completed during the period.", "label": "Notional Amount of Forward Contracts Completed", "terseLabel": "Amount of future currency contracts completed" } } }, "localname": "NotionalAmountOfForwardContractsCompleted", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompletionOfFutureCurrencyContractDetails" ], "xbrltype": "monetaryItemType" }, "iva_NumberOfAtmEmissions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of ATM emissions.", "label": "Number Of ATM Emissions", "terseLabel": "Number of ATM emissions" } } }, "localname": "NumberOfAtmEmissions", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "integerItemType" }, "iva_NumberOfCapitalIncreases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of capital increases completed by the company.", "label": "Number Of Capital Increases", "terseLabel": "Number of capital increases" } } }, "localname": "NumberOfCapitalIncreases", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "integerItemType" }, "iva_NumberOfCorporateOfficersWhoCancelledTheirShareWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of corporate officers who cancelled their share warrants under the share-based payment arrangement.", "label": "Number Of Corporate Officers Who Cancelled Their Share Warrants", "terseLabel": "Number of corporate officers who cancelled their share warrants" } } }, "localname": "NumberOfCorporateOfficersWhoCancelledTheirShareWarrants", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "integerItemType" }, "iva_NumberOfDerivativeContractsCompleted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of derivative contracts completed during the period.", "label": "Number Of Derivative Contracts Completed", "terseLabel": "Number of future currency contracts completed" } } }, "localname": "NumberOfDerivativeContractsCompleted", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsRelatedToFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCompletionOfFutureCurrencyContractDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails" ], "xbrltype": "integerItemType" }, "iva_NumberOfExecutiveDirectorsUnderDirectorsAndOfficersLiabilityInsuranceCoverage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of executive directors of the Company under \"Directors and Officers Liability Insurance\".", "label": "Number of Executive Directors under Directors and Officers Liability Insurance Coverage", "terseLabel": "Number of executive directors under directors' and officers' liability insurance" } } }, "localname": "NumberOfExecutiveDirectorsUnderDirectorsAndOfficersLiabilityInsuranceCoverage", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "integerItemType" }, "iva_NumberOfExistingShareholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of existing shareholders of the company.", "label": "Number Of Existing Shareholders", "terseLabel": "Number of existing shareholders" } } }, "localname": "NumberOfExistingShareholders", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "integerItemType" }, "iva_NumberOfForwardContractsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of foreign forward contracts expired.", "label": "Number of Forward Contracts Expired", "terseLabel": "Number of contracts expired" } } }, "localname": "NumberOfForwardContractsExpired", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUnwindingOfThreeForwardContractsDetails" ], "xbrltype": "integerItemType" }, "iva_NumberOfInsuranceContractsNewlyEnteredToCoverRisksRelatedToOfferingAndToProtectEconomicDamage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of insurance contracts newly entered.", "label": "Number of Insurance Contracts Newly Entered to Cover Risks Related to Offering and to Protect Economic Damage", "terseLabel": "Number of new insurances entered" } } }, "localname": "NumberOfInsuranceContractsNewlyEnteredToCoverRisksRelatedToOfferingAndToProtectEconomicDamage", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "integerItemType" }, "iva_NumberOfLoansObtainedGuaranteedByFrenchState": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of loans obtained which are guaranteed by the french state.", "label": "Number Of Loans Obtained Guaranteed By The French State", "terseLabel": "Number of loans obtained guaranteed by the french state" } } }, "localname": "NumberOfLoansObtainedGuaranteedByFrenchState", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationNonDilutiveFinancingDetails" ], "xbrltype": "integerItemType" }, "iva_NumberOfNewSharesIssuedUponVestingOfAwardsInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new shares issued upon vesting of awards under share-based payment arrangement", "label": "Number Of New Shares Issued Upon Vesting Of Awards In Share-based Payment Arrangement", "terseLabel": "Number of new shares issued upon vesting" } } }, "localname": "NumberOfNewSharesIssuedUponVestingOfAwardsInShareBasedPaymentArrangement", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "sharesItemType" }, "iva_NumberOfOtherEquityInstrumentsForfeitedAsPartOfRedundancyInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement, as part of the redundancy plan.", "label": "Number Of Other Equity Instruments, Forfeited As Part Of Redundancy, In Share-based Payment Arrangement", "terseLabel": "Number of awards forfeited as part of the redundancy plan" } } }, "localname": "NumberOfOtherEquityInstrumentsForfeitedAsPartOfRedundancyInShareBasedPaymentArrangement", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "sharesItemType" }, "iva_NumberOfOtherEquityInstrumentsForfeitedDueToEmployeeSRefusalInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement, due to refusal by an employee.", "label": "Number Of Other Equity Instruments, Forfeited Due To Employee's Refusal, In Share-based Payment Arrangement", "terseLabel": "Number of awards forfeited refused by an employee" } } }, "localname": "NumberOfOtherEquityInstrumentsForfeitedDueToEmployeeSRefusalInShareBasedPaymentArrangement", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "sharesItemType" }, "iva_NumberOfOtherEquityInstrumentsForfeitedDueToVoluntaryDeparturesInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement, as a result of voluntary departures.", "label": "Number Of Other Equity Instruments, Forfeited Due To Voluntary Departures, In Share-based Payment Arrangement", "terseLabel": "Number of awards forfeited as a result of voluntary departures" } } }, "localname": "NumberOfOtherEquityInstrumentsForfeitedDueToVoluntaryDeparturesInShareBasedPaymentArrangement", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "sharesItemType" }, "iva_NumberOfPledgesOverCash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of pledges that the company has pledged over cash.", "label": "Number Of Pledges Over Cash", "terseLabel": "Number of pledges over cash" } } }, "localname": "NumberOfPledgesOverCash", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "integerItemType" }, "iva_NumberOfPotentialNewSharesFromShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of total potential new shares from the share-based payment arrangement.", "label": "Number Of Potential New Shares From Share-based Payment Arrangement", "terseLabel": "Number of total potential new shares" } } }, "localname": "NumberOfPotentialNewSharesFromShareBasedPaymentArrangement", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareMovementsInNumberOfSharesIssuableUponExerciseDetails" ], "xbrltype": "sharesItemType" }, "iva_NumberOfSharesPerOtherEquityInstrumentGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares that each equity instruments other than share options granted in a share-based payment arrangement, entitles the holder.", "label": "Number Of Shares Per Other Equity Instrument Granted", "terseLabel": "Number of shares per AGA" } } }, "localname": "NumberOfSharesPerOtherEquityInstrumentGranted", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "xbrltype": "sharesItemType" }, "iva_NumberOfShortTermDeposits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of short-term deposits of the company.", "label": "Number Of Short-Term Deposits", "terseLabel": "Number of short-term deposits" } } }, "localname": "NumberOfShortTermDeposits", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationReinvestmentOfShortTermUsdDepositsDetails" ], "xbrltype": "integerItemType" }, "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to amount of all operating expenses.", "label": "Operating Expense Excluding Other Operating Income Expense", "negatedTotalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenseExcludingOtherOperatingIncomeExpense", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_OtherAccruedTaxesAndEmployeeRelatedExpenses": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of accrued taxes and employee related expenses.", "label": "Other Accrued taxes And Employee Related Expenses", "terseLabel": "Other accrued taxes and employeerelated expenses" } } }, "localname": "OtherAccruedTaxesAndEmployeeRelatedExpenses", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iva_OtherCurrentAssetsAndReceivables": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other current assets and receivables as of balance sheet date.", "label": "Other Current Assets And Receivables", "totalLabel": "Other current assets and receivables" } } }, "localname": "OtherCurrentAssetsAndReceivables", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "iva_OtherCurrentAssetsAndReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other current assets and receivables.", "label": "Other Current Assets and Receivables" } } }, "localname": "OtherCurrentAssetsAndReceivablesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "iva_OtherCurrentTaxReceivables": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "order": 2.0, "parentTag": "iva_CurrentTaxCreditReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of other tax receivables, classified as current.", "label": "Other Current Tax Receivables", "terseLabel": "Other" } } }, "localname": "OtherCurrentTaxReceivables", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "iva_OtherIncomeFromOrdinaryActivities": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of other income from ordinary activities.", "label": "Other income from ordinary activities", "terseLabel": "Other income", "totalLabel": "Total other income" } } }, "localname": "OtherIncomeFromOrdinaryActivities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "iva_OtherLongTermProvisionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Long term provisions" } } }, "localname": "OtherLongTermProvisionsAbstract", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "stringItemType" }, "iva_OtherMiscellaneousPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for other miscellaneous payables.", "label": "Other miscellaneous payables" } } }, "localname": "OtherMiscellaneousPayablesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "iva_OtherNonCurrentAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Other Non Current Assets [Line Items]" } } }, "localname": "OtherNonCurrentAssetsLineItems", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "stringItemType" }, "iva_OtherNonCurrentAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to other non-current assets.", "label": "Other Non Current Assets [Table]" } } }, "localname": "OtherNonCurrentAssetsTable", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "stringItemType" }, "iva_OtherOperatingExpenses": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails": { "order": 7.0, "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other operating expenses.", "label": "Other operating expenses", "negatedLabel": "Other" } } }, "localname": "OtherOperatingExpenses", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_OtherOperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Other Operating Income (expenses)" } } }, "localname": "OtherOperatingIncomeExpenseAbstract", "nsuri": "http://www.inventivapharma.com/20201231", "xbrltype": "stringItemType" }, "iva_OtherOperatingIncomeExpenseFromNonOrdinaryActivities": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss": { "order": 5.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of operating income (expense) from non-ordinary activities that the entity does not separately disclose in the same statement or note.", "label": "Other operating income (expense) from non-ordinary activities", "terseLabel": "Other operating income (expenses)", "totalLabel": "Other operating income (expenses)" } } }, "localname": "OtherOperatingIncomeExpenseFromNonOrdinaryActivities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails", "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "monetaryItemType" }, "iva_OtherOperatingIncomeExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Other Operating Income (Expense) [Line Items]" } } }, "localname": "OtherOperatingIncomeExpenseLineItems", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "iva_OtherOperatingIncomeExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to other operating income (expense).", "label": "Other Operating Income (Expense) [Table]" } } }, "localname": "OtherOperatingIncomeExpenseTable", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "iva_OtherOperatingIncomeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other operating income (expenses).", "label": "Other Operating Income (Expenses)" } } }, "localname": "OtherOperatingIncomeExpensesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "iva_OtherReceivablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for other receivables.", "label": "Other receivables" } } }, "localname": "OtherReceivablesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "iva_OtherShortTermProvisionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Short term provisions" } } }, "localname": "OtherShortTermProvisionsAbstract", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "stringItemType" }, "iva_OutstandingCommitments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of outstanding commitment.", "label": "Outstanding Commitments", "terseLabel": "Outstanding Commitments" } } }, "localname": "OutstandingCommitments", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "iva_Patents": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails": { "order": 8.0, "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to patents.", "label": "Patents", "negatedLabel": "Patents" } } }, "localname": "Patents", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_PayablesForPayrollTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable by the company for payroll taxes including penalties and late payment interest.", "label": "Payables For Payroll Taxes", "terseLabel": "Payroll taxes payable", "verboseLabel": "Accrued expense" } } }, "localname": "PayablesForPayrollTaxes", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_PayablesForPayrollTaxesMaximumIndemnificationAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum indemnification amount available to the company for payroll taxes payable.", "label": "Payables For Payroll Taxes, Maximum Indemnification Amount", "terseLabel": "Maximum indemnification amount (the \"Abbott Guarantee\")" } } }, "localname": "PayablesForPayrollTaxesMaximumIndemnificationAmount", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_PaymentsReceivedFromResearchTaxCredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount received from Research Tax Credit (CIR).", "label": "Payments Received From Research Tax Credit", "terseLabel": "Amount of entire CIR received" } } }, "localname": "PaymentsReceivedFromResearchTaxCredit", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationPaymentsReceivedFromResearchTaxCreditDetails" ], "xbrltype": "monetaryItemType" }, "iva_PaymentsReceivedFromResearchTaxCreditRelatingToSubcontractingExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount received from Research Tax Credit (CIR) relating to subcontracting expenses.", "label": "Payments Received From Research Tax Credit Relating To Subcontracting Expenses", "terseLabel": "Amount of additional reimbursements of CIR" } } }, "localname": "PaymentsReceivedFromResearchTaxCreditRelatingToSubcontractingExpenses", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationPaymentsReceivedFromResearchTaxCreditDetails" ], "xbrltype": "monetaryItemType" }, "iva_PayrollTaxes": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails": { "order": 2.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A class of employee benefits expense that represents payroll taxes.", "label": "Payroll taxes", "negatedLabel": "Payroll taxes" } } }, "localname": "PayrollTaxes", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "monetaryItemType" }, "iva_PercentageOfDilutionSubjectToRegulatoryLimitForAggregateSalesProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of dilution subject to regulatory limit for aggregate sales proceeds under issuance of shares.", "label": "Percentage Of Dilution Subject To Regulatory Limit For Aggregate Sales Proceeds", "terseLabel": "Percentage of dilution subject to regulatory limit" } } }, "localname": "PercentageOfDilutionSubjectToRegulatoryLimitForAggregateSalesProceeds", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "xbrltype": "percentItemType" }, "iva_PercentageOfFrenchResearchTaxCreditCirReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of French Research Tax Credit (CIR), received during the period.", "label": "Percentage of French Research Tax Credit (CIR) received", "terseLabel": "Percentage of French Research Tax Credit (CIR) received" } } }, "localname": "PercentageOfFrenchResearchTaxCreditCirReceived", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "percentItemType" }, "iva_PercentageOfReasonablyPossibleIncreaseDecreaseInRiskAssumption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The reasonably possible percentage of the increase (decrease) in the designated risk component used to determine the value of the financial instrument. Excludes defined benefit plan obligations.", "label": "Percentage Of Reasonably Possible Increase (Decrease) In Risk Assumption", "terseLabel": "Percentage of reasonably possible increase (decrease) in risk assumption" } } }, "localname": "PercentageOfReasonablyPossibleIncreaseDecreaseInRiskAssumption", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "percentItemType" }, "iva_PeriodForTaxCreditRecoverable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the period for tax credit recoverable if not used by the Company to pay income tax.", "label": "Period For Tax Credit Recoverable", "terseLabel": "Period for tax credit recoverable if not used by the Company to pay income tax" } } }, "localname": "PeriodForTaxCreditRecoverable", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "durationItemType" }, "iva_PermanentDifferencesForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "order": 3.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount due to permanent differences for reconciliation between accounting profit and tax expense income.", "label": "Permanent Differences for Reconciliation Between Accounting Profit and Tax Expense Income", "terseLabel": "Permanent differences" } } }, "localname": "PermanentDifferencesForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "xbrltype": "monetaryItemType" }, "iva_PersonnelCostsAndHeadcount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Personnel costs and headcount", "label": "Personnel costs and headcount", "terseLabel": "Schedule of Personnel costs and headcount" } } }, "localname": "PersonnelCostsAndHeadcount", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesTables" ], "xbrltype": "textBlockItemType" }, "iva_PledgeAsPercentageOfSumNotCoveredByIndemnityPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the pledge as percentage of sum not covered by the indemnity.", "label": "Pledge As Percentage Of Sum Not Covered By The Indemnity, Percent", "terseLabel": "Amount of pledge as a percentage of sum not covered by the indemnity to be received" } } }, "localname": "PledgeAsPercentageOfSumNotCoveredByIndemnityPercent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "percentItemType" }, "iva_PledgeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to pledge.", "label": "Pledge [Axis]" } } }, "localname": "PledgeAxis", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "stringItemType" }, "iva_PledgeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to pledge.", "label": "Pledge [Domain]" } } }, "localname": "PledgeDomain", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "domainItemType" }, "iva_PledgeOverCashOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for pledge over cash, one.", "label": "Pledge over cash, one" } } }, "localname": "PledgeOverCashOneMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "domainItemType" }, "iva_PledgeOverCashTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for pledge over cash, two.", "label": "Pledge over cash, two" } } }, "localname": "PledgeOverCashTwoMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "domainItemType" }, "iva_PremisesAndFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for premises and facilities.", "label": "Premises and facilities" } } }, "localname": "PremisesAndFacilitiesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails" ], "xbrltype": "domainItemType" }, "iva_PrepaymentsOfInsuranceCostsDeferredCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prepayment of insurance costs deferred as on carrying date, classified as current.", "label": "Prepayments of Insurance Costs, Deferred, Current", "terseLabel": "Deferral of insurance costs" } } }, "localname": "PrepaymentsOfInsuranceCostsDeferredCurrent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_ProceedsFromDisposalsOfFixedAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Proceeds from disposals of fixed assets.", "label": "Proceeds From Disposals of Fixed Assets", "terseLabel": "Proceeds - Disposals of fixed assets" } } }, "localname": "ProceedsFromDisposalsOfFixedAssets", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_ProceedsFromFrenchResearchTaxCredit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from French Research Tax Credit (CIR).", "label": "Proceeds From French Research Tax Credit", "terseLabel": "French Research Tax Credit (CIR), payments received" } } }, "localname": "ProceedsFromFrenchResearchTaxCredit", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_ProceedsFromIssueOfEquityNetOfTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of proceeds from issuance of equity net of transaction costs.", "label": "Proceeds from Issue of Equity Net of Transaction Costs", "terseLabel": "Capital increase in cash" } } }, "localname": "ProceedsFromIssueOfEquityNetOfTransactionCosts", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the disposal of property, plant and equipment and intangible assets, classified as investing activities.", "label": "Proceeds From Sales Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "terseLabel": "Disposals of property, plant and equipment and intangible assets" } } }, "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "iva_ProceedsFromSubscriptionOfNewLeases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from subscription of new leases", "label": "Proceeds from subscription of new leases", "terseLabel": "Subscription new leases" } } }, "localname": "ProceedsFromSubscriptionOfNewLeases", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtRepaymentsOfBorrowingsAndAccrualOfInterestsDetails" ], "xbrltype": "monetaryItemType" }, "iva_ProvisionForCirRelatedToTaxAuditForYears2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Provision For French Research Tax Credit Related To Tax Audit For Years 2017", "label": "ProvisionForCirRelatedToTaxAuditForYears2017" } } }, "localname": "ProvisionForCirRelatedToTaxAuditForYears2017Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "xbrltype": "domainItemType" }, "iva_ProvisionForFrenchResearchTaxCredit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of provision for French Research Tax Credit (CIR).", "label": "Provision For French Research Tax Credit", "negatedLabel": "CIR provision", "terseLabel": "CIR provision" } } }, "localname": "ProvisionForFrenchResearchTaxCredit", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_ProvisionForFrenchResearchTaxCreditContestedByTaxAuthorities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of provision for French Research Tax Credit (CIR) contested by tax authorities.", "label": "Provision For French Research Tax Credit Contested by Tax Authorities", "terseLabel": "Initial provision" } } }, "localname": "ProvisionForFrenchResearchTaxCreditContestedByTaxAuthorities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYears2013To2015Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Provision For French Research Tax Credit Related To Tax Audit For Years 2013 to 2015.", "label": "Provision for CIR related to tax audit for years 2013 to 2015" } } }, "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYears2013To2015Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "xbrltype": "domainItemType" }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded20132014And2015Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for provision for French Research Tax Credit (CIR) related to tax audit for the years ended December 31, 2013, 2014 and 2015.", "label": "CIR 2013-2015" } } }, "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded20132014And2015Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2013To2015And2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2013 to 2015 and 2017.", "label": "Provision for CIR risk related to tax audit for the years ended December 31, 2013 to December 31, 2015 and December 31, 2017" } } }, "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2013To2015And2017Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2017", "label": "CIR 2017" } } }, "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2017Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "domainItemType" }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2017To2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information provision for french research tax credit related to tax audit for years ended 2017 to 2019.", "label": "Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2017 To 2019 [Member]" } } }, "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2017To2019Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2018And2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2018 and 2019.", "label": "Provision for CIR risk related to tax audit for the year ended December 31, 2018 and 2019" } } }, "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2018And2019Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationResearchTaxCreditDetails" ], "xbrltype": "domainItemType" }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2018.", "label": "Provision for CIR risk related to tax audit for the year ended December 31, 2018" } } }, "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2018Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationResearchTaxCreditDetails" ], "xbrltype": "domainItemType" }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2019.", "label": "Provision for CIR risk related to tax audit for the year ended December 31, 2019" } } }, "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2019Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "xbrltype": "domainItemType" }, "iva_ProvisionForResearchTaxCredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of provision for Research tax credit.", "label": "Provision For Research Tax Credit", "terseLabel": "Provision for research tax credit" } } }, "localname": "ProvisionForResearchTaxCredit", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_ProvisionForRetirementBenefitObligations": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails": { "order": 3.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of provision for retirement obligations during the period.", "label": "Provision For Retirement Benefit Obligations", "negatedLabel": "Provisions for retirement benefit obligations" } } }, "localname": "ProvisionForRetirementBenefitObligations", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesPersonnelCostsAndHeadcountDetails" ], "xbrltype": "monetaryItemType" }, "iva_ProvisionForRiskOnPayrollTaxes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of provision for payroll taxes.", "label": "Provision For Risk On Payroll Taxes", "terseLabel": "Provision for risk on payroll taxes" } } }, "localname": "ProvisionForRiskOnPayrollTaxes", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_ProvisionForTaxAdjustmentRiskInRespectOfPayrollTaxesForYearsEnded20162017And2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for provision for tax adjustment risk in respect of payroll taxes with regard to the years ended December 31, 2016, 2017 and 2018.", "label": "Provision for tax adjustment risk in respect of payroll taxes for the years ended December 31, 2016, 2017 and 2018" } } }, "localname": "ProvisionForTaxAdjustmentRiskInRespectOfPayrollTaxesForYearsEnded20162017And2018Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "domainItemType" }, "iva_ProvisionForTaxAuditForYearsEnded20132014And2015Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for provision related to tax audit for the fiscal years 2016, 2017 and 2018.", "label": "Provision related to tax audit for the years ended 2013, 2014 and 2015" } } }, "localname": "ProvisionForTaxAuditForYearsEnded20132014And2015Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "domainItemType" }, "iva_ProvisionForTaxAuditForYearsEnded20162017And2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for provision for French Research Tax Credit Related to Tax Audit for Years Ended 2016 to 2018.", "label": "Provision for tax audit for the years ended December 31, 2016 - 2018" } } }, "localname": "ProvisionForTaxAuditForYearsEnded20162017And2018Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "domainItemType" }, "iva_ProvisionForTaxAuditForYearsEnded2016And2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Provision For Tax Audit For Years Ended 2016 and 2017.", "label": "Provision for tax audit for the years ended December 31, 2016 and December 31, 2017" } } }, "localname": "ProvisionForTaxAuditForYearsEnded2016And2017Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "iva_PublicOfferingOfSecuritiesInsuranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Public Offering of Securities Insurance.", "label": "Public Offering of Securities Insurance" } } }, "localname": "PublicOfferingOfSecuritiesInsuranceMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase Of Property Plant And Equipment And Intangile Assets Classified As Investing Activities", "label": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "negatedLabel": "Purchases of property, plant and equipment and intangible assets" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "iva_PurchasesInForeignCurrencyAsPercentageOfOperatingExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage amount of operating expenses that were paid in a currency other than the reporting currency.", "label": "Purchases In Foreign Currency As A Percentage Of Operating Expenses", "terseLabel": "Foreign currency expenses as a percentage of operating expenses" } } }, "localname": "PurchasesInForeignCurrencyAsPercentageOfOperatingExpenses", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesForeignCurrencyTransactionsAndSegmentInformationDetails" ], "xbrltype": "percentItemType" }, "iva_ReceiptOfMilestonePaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to receipt of milestone payment.", "label": "Receipt Of Milestone Payments [Member]", "terseLabel": "Receipt Of milestone payments" } } }, "localname": "ReceiptOfMilestonePaymentsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "xbrltype": "domainItemType" }, "iva_ReclassificationOfAccumulatedDeficitRetainedEarningsToPremiumToShareCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reclassification of (Accumulated Deficit) Retained Earnings to Premium to Share Capital", "label": "Reclassification of (Accumulated Deficit) Retained Earnings to Premium to Share Capital", "terseLabel": "Reclassification of debit retained earnings to premium related to share capital" } } }, "localname": "ReclassificationOfAccumulatedDeficitRetainedEarningsToPremiumToShareCapital", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "iva_ReinvestmentOfShortTermDeposits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term deposits reinvested during the period.", "label": "Reinvestment Of Short-Term Deposits", "terseLabel": "Reinvestment of short-term USD deposits" } } }, "localname": "ReinvestmentOfShortTermDeposits", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationReinvestmentOfShortTermUsdDepositsDetails" ], "xbrltype": "monetaryItemType" }, "iva_RentalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of assets given under rent.", "label": "Rental Period", "terseLabel": "Rental period" } } }, "localname": "RentalPeriod", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails" ], "xbrltype": "durationItemType" }, "iva_ResearchAndDevelopmentCollaborationWithBoehringerIngelheimMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development collaboration with Boehringer Ingelheim.", "label": "BI" } } }, "localname": "ResearchAndDevelopmentCollaborationWithBoehringerIngelheimMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "iva_ResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Research and Development, Marketing - Business Development and General and Administrative Expenses" } } }, "localname": "ResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesAbstract", "nsuri": "http://www.inventivapharma.com/20201231", "xbrltype": "stringItemType" }, "iva_ResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research and development, marketing - business development and general and administrative expenses.", "label": "Research And Development Marketing - Business Development And General And Administrative Expenses [Text Block]", "terseLabel": "Research and Development, Marketing - Business Development and General and Administrative Expenses" } } }, "localname": "ResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpenses" ], "xbrltype": "textBlockItemType" }, "iva_ResearchAndDevelopmentMarketingTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of Research and Development, Marketing.", "label": "Research and Development, Marketing [Table Text Block]", "terseLabel": "Schedule of Research and Development, Marketing" } } }, "localname": "ResearchAndDevelopmentMarketingTableTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesTables" ], "xbrltype": "textBlockItemType" }, "iva_ResearchCollaborationWithAbbvieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for research collaboration with AbbVie.", "label": "AbbVie" } } }, "localname": "ResearchCollaborationWithAbbvieMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "xbrltype": "domainItemType" }, "iva_ResearchEquipmentAndServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for research equipment and services.", "label": "Research equipment and services" } } }, "localname": "ResearchEquipmentAndServicesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsCommitmentsReceivedDetails" ], "xbrltype": "domainItemType" }, "iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "A component of equity representing retained earnings excluding profit (loss) for the reporting period, and treasury shares", "label": "Retained earnings excluding profit (loss) for the reporting period and treasury shares", "terseLabel": "Reserves" } } }, "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member represent a component of equity consisting of retained earnings excluding the current reporting period, and treasury shares.", "label": "Retained earnings excluding profit (loss) from current reporting period and treasury shares [Member]", "terseLabel": "Other reserves" } } }, "localname": "RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "iva_RevenueAndOperatingIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Revenue And Operating Income [Abstract]", "terseLabel": "Revenues and other income" } } }, "localname": "RevenueAndOperatingIncomeAbstract", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/StatementStatementsOfIncomeLoss" ], "xbrltype": "stringItemType" }, "iva_RevenueAndOtherIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Revenues and Other Income" } } }, "localname": "RevenueAndOtherIncomeAbstract", "nsuri": "http://www.inventivapharma.com/20201231", "xbrltype": "stringItemType" }, "iva_RevenueAndOtherIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue and other income.", "label": "Revenue and Other Income [Table Text Block]", "terseLabel": "Schedule of revenue and other income" } } }, "localname": "RevenueAndOtherIncomeTableTextBlock", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeTables" ], "xbrltype": "textBlockItemType" }, "iva_RevenueFromResearchPartnershipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for revenue from research partnerships.", "label": "Revenue From Research Partnerships [Member]" } } }, "localname": "RevenueFromResearchPartnershipsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "iva_ReversalOfImpairmentOnCarryBackReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reversal of impairment of tax loss carry back receivable during the period.", "label": "Reversal Of Impairment On Carry Back Receivable", "terseLabel": "Reversal of impairment on the carry back receivable" } } }, "localname": "ReversalOfImpairmentOnCarryBackReceivable", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_RiskFreeInterestRateOtherEquityInstrumentsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate of other equity instruments granted.", "label": "Risk-Free Interest Rate, Other Equity Instruments Granted", "terseLabel": "Risk-free rate" } } }, "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "xbrltype": "percentItemType" }, "iva_ScheduleOfInventoryDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Schedule of Inventory Disclosure [Line Items]" } } }, "localname": "ScheduleOfInventoryDisclosureLineItems", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesDetails" ], "xbrltype": "stringItemType" }, "iva_ScheduleOfInventoryDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to inventories.", "label": "Schedule of Inventory Disclosure [Table]" } } }, "localname": "ScheduleOfInventoryDisclosureTable", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesDetails" ], "xbrltype": "stringItemType" }, "iva_ServiceAgreementForClinicalServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to service agreement for clinical services.", "label": "Service Agreement For Clinical Services[ Member]" } } }, "localname": "ServiceAgreementForClinicalServicesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "xbrltype": "domainItemType" }, "iva_ServiceAgreementWithEchosensMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Service agreement with Echosens.", "label": "Service agreement with Echosens [Member]" } } }, "localname": "ServiceAgreementWithEchosensMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "domainItemType" }, "iva_ServiceProvidersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to service providers.", "label": "Service Providers" } } }, "localname": "ServiceProvidersMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsPlansDetails" ], "xbrltype": "domainItemType" }, "iva_ShareWarrantPlansBsa2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Share Warrant Plans Bsa 2017.", "label": "Share Warrant Plans Bsa 2017", "terseLabel": "BSA - 2017" } } }, "localname": "ShareWarrantPlansBsa2017Member", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "domainItemType" }, "iva_SharesIssuedPricePerShare1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share price of equity shares issued.", "label": "Shares Issued Price Per Share 1", "terseLabel": "Price per share", "verboseLabel": "Funds raised, price per share" } } }, "localname": "SharesIssuedPricePerShare1", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreaseOf147MillionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationUsd1077MillionInitialPublicOfferingDetails" ], "xbrltype": "perShareItemType" }, "iva_ShortTermDepositAccountsCurrent": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "order": 5.0, "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short term deposits accounts, classified as current.", "label": "Short-Term Deposit Accounts, Current", "terseLabel": "Short-term deposit accounts" } } }, "localname": "ShortTermDepositAccountsCurrent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "iva_ShortTermDepositAccountsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for short-term deposit accounts.", "label": "Short-term deposit accounts" } } }, "localname": "ShortTermDepositAccountsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "domainItemType" }, "iva_SocieteGeneraleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Societe Generale.", "label": "Socit Gnrale" } } }, "localname": "SocieteGeneraleMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/DisclosureDebtDebtAndBorrowingsDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "iva_StatementOfComplianceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "General principles and statement of compliance" } } }, "localname": "StatementOfComplianceAbstract", "nsuri": "http://www.inventivapharma.com/20201231", "xbrltype": "stringItemType" }, "iva_StockPriceReferenceOtherEquityInstrumentsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The stock price reference of other equity instruments granted.", "label": "Stock Price Reference, Other Equity Instruments Granted", "terseLabel": "Stock price reference" } } }, "localname": "StockPriceReferenceOtherEquityInstrumentsGranted", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBonusShareAwardPlansDetails" ], "xbrltype": "perShareItemType" }, "iva_Studies": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails": { "order": 10.0, "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to studies.", "label": "Studies", "negatedLabel": "Studies" } } }, "localname": "Studies", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_SubscriptionOfBankBorrowings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Subscription of bank borrowings.", "label": "Subscription Of Bank Borrowings", "terseLabel": "Subscription of bank borrowings" } } }, "localname": "SubscriptionOfBankBorrowings", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDebtRepaymentsOfBorrowingsAndAccrualOfInterestsDetails" ], "xbrltype": "monetaryItemType" }, "iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription premium price per share of other equity instruments granted in share-based payment arrangement.", "label": "Subscription Premium Price Per Share Of Other Equity Instruments Granted", "terseLabel": "Subscription premium price per share ()" } } }, "localname": "SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "xbrltype": "perShareItemType" }, "iva_SubsidiesIncome": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "order": 2.0, "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of income from subsidies.", "label": "Subsidies income", "terseLabel": "Subsidies" } } }, "localname": "SubsidiesIncome", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "iva_SupportCosts": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails": { "order": 11.0, "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to support costs.", "label": "Support costs", "negatedLabel": "Support costs (including taxes)" } } }, "localname": "SupportCosts", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_TaxAuditForPayrollTaxesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for tax audit for payroll taxes.", "label": "Tax audit for payroll taxes" } } }, "localname": "TaxAuditForPayrollTaxesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "xbrltype": "domainItemType" }, "iva_TaxAuditProposedTaxAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of proposed tax adjustment (including penalties and late payment interest) received from French tax authorities.", "label": "Tax Audit, Proposed Tax Adjustment", "terseLabel": "Proposed tax adjustment", "verboseLabel": "Proposed payroll tax adjustment" } } }, "localname": "TaxAuditProposedTaxAdjustment", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_TaxCreditReceivedPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of amount received for tax credit.", "label": "Tax Credit Received, Percent", "terseLabel": "Percentage of amount received for tax credit" } } }, "localname": "TaxCreditReceivedPercent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "iva_TaxCreditsReceivableResearchCreditsFromCurrentTaxYearCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of research tax credit receivables attributable to the current tax year, classified as current.", "label": "Tax Credits Receivable, Research Credits from Current Tax Year, Current", "terseLabel": "Research tax credits receivable from current tax year" } } }, "localname": "TaxCreditsReceivableResearchCreditsFromCurrentTaxYearCurrent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_TaxCreditsReceivableResearchCreditsFromPriorTaxYearsCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of research tax credit receivables attributable to prior tax years, classified as current.", "label": "Tax Credits Receivable, Research Credits from Prior Tax Years, Current", "verboseLabel": "Corrective claims for additional reimbursements of CIR, prior years" } } }, "localname": "TaxCreditsReceivableResearchCreditsFromPriorTaxYearsCurrent", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_TaxDeductionAmountForAdditionalClaim": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of tax deduction amount for additional claim", "label": "Tax Deduction Amount for Additional Claim", "terseLabel": "Tax deduction amount for Additional claim" } } }, "localname": "TaxDeductionAmountForAdditionalClaim", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "xbrltype": "monetaryItemType" }, "iva_TaxDisputeesWithFrenchTaxAuthoritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for tax disputes with French tax authorities.", "label": "Tax Disputees With French Tax Authorities" } } }, "localname": "TaxDisputeesWithFrenchTaxAuthoritiesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "domainItemType" }, "iva_TaxEffectOfTaxCredits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to tax effect of tax credits.", "label": "Tax effect of tax credits", "verboseLabel": "Amount received for tax credit" } } }, "localname": "TaxEffectOfTaxCredits", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "iva_TaxNoticeOfRecoverySuspensionGuarantee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of guarantee required for the suspension of notice of recovery issued by tax authorities.", "label": "Tax Notice Of Recovery Suspension Guarantee", "terseLabel": "Guarantee as condition to suspend AMR" } } }, "localname": "TaxNoticeOfRecoverySuspensionGuarantee", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_TermDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for term deposits.", "label": "Term deposits [Member]", "terseLabel": "Term deposits" } } }, "localname": "TermDepositsMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "iva_TermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of contract\tTerm of Contract\tTerm of Contract\t\t\t\tYes\tdurationItemType\tduration\t\tfalse\ttrue\tThe total period of contract for services received.", "label": "Term of Contract", "terseLabel": "Term of contract" } } }, "localname": "TermOfContract", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "durationItemType" }, "iva_TotalPaymentOfDutiesToFrenchTaxAuthorities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the total amount paid to French tax authorities.", "label": "Total Payment of Duties to French Tax Authorities", "terseLabel": "Total amount paid to French tax authorities" } } }, "localname": "TotalPaymentOfDutiesToFrenchTaxAuthorities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_TradePayableAndOtherCurrentLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Line Items]" } } }, "localname": "TradePayableAndOtherCurrentLiabilitiesLineItems", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfTradePayablesBreakDownByPaymentDateDetails" ], "xbrltype": "stringItemType" }, "iva_TradePayableAndOtherCurrentLiabilitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Table]" } } }, "localname": "TradePayableAndOtherCurrentLiabilitiesTable", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesSummaryOfTradePayablesBreakDownByPaymentDateDetails" ], "xbrltype": "stringItemType" }, "iva_TradePayablesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of trade payables and other current liabilities.", "label": "Trade Payables And Other Current Liabilities.", "totalLabel": "Trade payables and other current liabilities" } } }, "localname": "TradePayablesAndOtherCurrentLiabilities", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iva_TradePayablesAndOtherCurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payables and Other Current Liabilities" } } }, "localname": "TradePayablesAndOtherCurrentLiabilitiesAbstract", "nsuri": "http://www.inventivapharma.com/20201231", "xbrltype": "stringItemType" }, "iva_TradePayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for trade payables.", "label": "Trade payables" } } }, "localname": "TradePayablesMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Trade Receivables and Other Current Assets and Receivables [Line Items]" } } }, "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "xbrltype": "stringItemType" }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to trade receivables and other current assets and receivables.", "label": "Trade Receivables and Other Current Assets and Receivables [Table]" } } }, "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "xbrltype": "stringItemType" }, "iva_TresoPlusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Treso plus.", "label": "Treso plus [Member]", "terseLabel": "Treso plus" } } }, "localname": "TresoPlusMember", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "iva_UnusedProvisionReclassifiedOtherLongTermProvisions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount reclassified for unused other provisions, classified as long-term.", "label": "Unused Provision Reclassified Other Long Term Provisions", "negatedLabel": "Reclassified" } } }, "localname": "UnusedProvisionReclassifiedOtherLongTermProvisions", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_UnusedProvisionReclassifiedOtherProvisions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount reclassified for unused other provisions.", "label": "Unused Provision Reclassified, Other Provisions", "negatedLabel": "Unused provision reclassified, other povisions" } } }, "localname": "UnusedProvisionReclassifiedOtherProvisions", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_UnusedProvisionReversedOtherShortTermProvisions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount reversed for unused other provisions, classified as short-term.", "label": "Unused Provision Reversed, Other Short-Term Provisions", "negatedLabel": "Reversals" } } }, "localname": "UnusedProvisionReversedOtherShortTermProvisions", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "iva_WaiverClaim": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Waiver of CIR 2017 claim.", "label": "Waiver Claim" } } }, "localname": "WaiverClaim", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeExpensesDetails" ], "xbrltype": "monetaryItemType" }, "iva_WarrantsAverageLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average life used to calculate fair value of warrants.", "label": "Warrants, Average Life", "terseLabel": "Average life (years)" } } }, "localname": "WarrantsAverageLife", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "xbrltype": "durationItemType" }, "iva_WarrantsFairValueAtGrantDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fair value at grant date per warrant.", "label": "Warrants, Fair Value at Grant Date", "terseLabel": "Fair value at grant date ()" } } }, "localname": "WarrantsFairValueAtGrantDate", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "xbrltype": "perShareItemType" }, "iva_WarrantsRiskFreeInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk free interest rate used to calculate fair value of warrants.", "label": "Warrants, Risk Free Interest Rate", "terseLabel": "Risk-free rate" } } }, "localname": "WarrantsRiskFreeInterestRate", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "xbrltype": "percentItemType" }, "iva_WarrantsSubscriptionPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The subscription price per warrant.", "label": "Warrants, Subscription Price", "terseLabel": "Subscription price ()" } } }, "localname": "WarrantsSubscriptionPrice", "nsuri": "http://www.inventivapharma.com/20201231", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "xbrltype": "perShareItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "xbrltype": "stringItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 13 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24" }, "r1": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24" }, "r100": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2021-03-24" }, "r101": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard", "URIDate": "2021-03-24" }, "r102": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "21", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_c&doctype=Standard", "URIDate": "2021-03-24" }, "r103": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2021-03-24" }, "r104": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2021-03-24" }, "r105": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r106": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2021-03-24" }, "r107": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r108": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24" }, "r109": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24" }, "r110": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r111": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard", "URIDate": "2021-03-24" }, "r112": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2021-03-24" }, "r113": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2021-03-24" }, "r114": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r115": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24" }, "r116": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r117": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Paragraph": "84", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84_a&doctype=Standard", "URIDate": "2021-03-24" }, "r118": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Paragraph": "84", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84_b&doctype=Standard", "URIDate": "2021-03-24" }, "r119": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Paragraph": "84", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84_d&doctype=Standard", "URIDate": "2021-03-24" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard", "URIDate": "2021-03-24" }, "r120": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Paragraph": "84", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84&doctype=Standard", "URIDate": "2021-03-24" }, "r121": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2021-03-24" }, "r122": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2021-03-24" }, "r123": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r124": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2021-03-24" }, "r125": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2021-03-24" }, "r126": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard", "URIDate": "2021-03-24" }, "r127": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "119", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2021-03-24" }, "r128": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r129": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2021-03-24" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard", "URIDate": "2021-03-24" }, "r130": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "32A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2021-03-24" }, "r131": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_76&doctype=Standard", "URIDate": "2021-03-24" }, "r132": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2021-03-24" }, "r133": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2021-03-24" }, "r134": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard", "URIDate": "2021-03-24" }, "r135": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2021-03-24" }, "r136": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r137": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "14", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2021-03-24" }, "r138": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "14", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_14&doctype=Standard", "URIDate": "2021-03-24" }, "r139": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16&doctype=Standard", "URIDate": "2021-03-24" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_16&doctype=Standard", "URIDate": "2021-03-24" }, "r140": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r141": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2021-03-24" }, "r142": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2021-03-24" }, "r143": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r144": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r145": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r146": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2021-03-24" }, "r147": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2021-03-24" }, "r148": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r149": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "21", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard", "URIDate": "2021-03-24" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r150": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r151": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r152": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r153": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r154": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2021-03-24" }, "r155": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r156": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "46", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_46&doctype=Standard", "URIDate": "2021-03-24" }, "r157": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24" }, "r158": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2021-03-24" }, "r159": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI", "URIDate": "2021-03-24" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2021-03-24" }, "r160": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "8", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r161": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r162": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24" }, "r163": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r164": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r165": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "19B", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2021-03-24" }, "r166": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "2", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_2_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r167": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r168": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r169": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r17": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2021-03-24" }, "r170": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r171": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r172": { "Clause": "ix", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r173": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r174": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r175": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r176": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r177": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r178": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r179": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Section": "Nature of the risks associated with an entity's interests in consolidated structured entities", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS12_g14-17_TI", "URIDate": "2021-03-24" }, "r18": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2021-03-24" }, "r180": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24" }, "r181": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24" }, "r182": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24" }, "r183": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard", "URIDate": "2021-03-24" }, "r184": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r185": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r186": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24" }, "r187": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "113", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2021-03-24" }, "r188": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "114", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard", "URIDate": "2021-03-24" }, "r189": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r19": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24" }, "r190": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r191": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r192": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24" }, "r193": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r194": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard", "URIDate": "2021-03-24" }, "r195": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard", "URIDate": "2021-03-24" }, "r196": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2021-03-24" }, "r197": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2021-03-24" }, "r198": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2021-03-24" }, "r199": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r2": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard", "URIDate": "2021-03-24" }, "r20": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "k", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2021-03-24" }, "r200": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r201": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24" }, "r202": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "51", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2021-03-24" }, "r203": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "IG23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_IG23&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r204": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r205": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r206": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "14", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_14_a&doctype=Standard", "URIDate": "2021-03-24" }, "r207": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "21C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2021-03-24" }, "r208": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r209": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "24C", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_24C_b_vi&doctype=Standard", "URIDate": "2021-03-24" }, "r21": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "l", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2021-03-24" }, "r210": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r211": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r212": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r213": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r214": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r215": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2021-03-24" }, "r216": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2021-03-24" }, "r217": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2021-03-24" }, "r218": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r219": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2021-03-24" }, "r22": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "n", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2021-03-24" }, "r220": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2021-03-24" }, "r221": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "36", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_36&doctype=Standard", "URIDate": "2021-03-24" }, "r222": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "39", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2021-03-24" }, "r223": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "40", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2021-03-24" }, "r224": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2021-03-24" }, "r225": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2021-03-24" }, "r226": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_6&doctype=Standard", "URIDate": "2021-03-24" }, "r227": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r228": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2021-03-24" }, "r229": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2021-03-24" }, "r23": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "o", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2021-03-24" }, "r230": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2021-03-24" }, "r231": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8&doctype=Standard", "URIDate": "2021-03-24" }, "r232": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r233": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r234": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r235": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r236": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r237": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r238": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B52", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r239": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG20D", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r24": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24" }, "r240": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r241": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Defined terms", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2021-03-24" }, "r242": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Scope", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2021-03-24" }, "r243": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2021-03-24" }, "r244": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2021-03-24" }, "r245": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2021-03-24" }, "r246": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24" }, "r247": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2021-03-24" }, "r248": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r249": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24" }, "r25": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "56", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_56&doctype=Standard", "URIDate": "2021-03-24" }, "r250": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2021-03-24" }, "r251": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r252": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2021-03-24" }, "r253": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r254": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "9", "Paragraph": "6.6.4", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_6.6.4&doctype=Standard", "URIDate": "2021-03-24" }, "r255": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "9", "Paragraph": "7.2.34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2021-03-24" }, "r256": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard", "URIDate": "2021-03-24" }, "r257": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2021-03-24" }, "r258": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2021-03-24" }, "r259": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard", "URIDate": "2021-03-24" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2021-03-24" }, "r260": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "124", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_124&doctype=Standard", "URIDate": "2021-03-24" }, "r261": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "125", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_125&doctype=Standard", "URIDate": "2021-03-24" }, "r262": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24" }, "r263": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r264": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2021-03-24" }, "r265": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2021-03-24" }, "r266": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "C32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2021-03-24" }, "r267": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "9", "Paragraph": "7.2.42", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2021-03-24" }, "r268": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_b&doctype=Standard", "URIDate": "2021-03-24" }, "r269": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2021-03-24" }, "r27": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard", "URIDate": "2021-03-24" }, "r270": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "4", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&doctype=Standard&book=b&dita_xref=IFRS04_g36-39M_TI", "URIDate": "2021-03-24" }, "r271": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r272": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r273": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r274": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "8", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r275": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG28", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r276": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r277": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_b&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r278": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r279": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r28": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r280": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r281": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r282": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r283": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r284": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r285": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r286": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r287": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r288": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r289": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r29": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "68", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_68&doctype=Standard", "URIDate": "2021-03-24" }, "r3": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard", "URIDate": "2021-03-24" }, "r30": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard", "URIDate": "2021-03-24" }, "r31": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r32": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "70", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_70&doctype=Standard", "URIDate": "2021-03-24" }, "r33": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24" }, "r34": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2021-03-24" }, "r35": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24" }, "r36": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard", "URIDate": "2021-03-24" }, "r37": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r38": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r39": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24" }, "r4": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2021-03-24" }, "r40": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r41": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24" }, "r42": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2021-03-24" }, "r43": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2021-03-24" }, "r44": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2021-03-24" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2021-03-24" }, "r46": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2021-03-24" }, "r47": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2021-03-24" }, "r48": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24" }, "r49": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2021-03-24" }, "r5": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2021-03-24" }, "r50": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_98_b&doctype=Standard", "URIDate": "2021-03-24" }, "r51": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard", "URIDate": "2021-03-24" }, "r52": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r53": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard", "URIDate": "2021-03-24" }, "r54": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2021-03-24" }, "r55": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r56": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2021-03-24" }, "r57": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80_e&doctype=Standard", "URIDate": "2021-03-24" }, "r58": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2021-03-24" }, "r59": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r6": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r60": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2021-03-24" }, "r61": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2021-03-24" }, "r62": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_a&doctype=Standard", "URIDate": "2021-03-24" }, "r63": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2021-03-24" }, "r64": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2021-03-24" }, "r65": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "37", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard", "URIDate": "2021-03-24" }, "r66": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2021-03-24" }, "r67": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2021-03-24" }, "r68": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2021-03-24" }, "r69": { "Clause": "ix", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_ix&doctype=Standard", "URIDate": "2021-03-24" }, "r7": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r70": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r71": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2021-03-24" }, "r72": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard", "URIDate": "2021-03-24" }, "r73": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2021-03-24" }, "r74": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2021-03-24" }, "r75": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2021-03-24" }, "r76": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "135", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2021-03-24" }, "r77": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "140", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2021-03-24" }, "r78": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "141", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2021-03-24" }, "r79": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "141", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_141&doctype=Standard", "URIDate": "2021-03-24" }, "r8": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24" }, "r80": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "142", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_142&doctype=Standard", "URIDate": "2021-03-24" }, "r81": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "144", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_144&doctype=Standard", "URIDate": "2021-03-24" }, "r82": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "145", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_145_a&doctype=Standard", "URIDate": "2021-03-24" }, "r83": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "145", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_145&doctype=Standard", "URIDate": "2021-03-24" }, "r84": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2021-03-24" }, "r85": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "5", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_5&doctype=Standard", "URIDate": "2021-03-24" }, "r86": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "57", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_57_a&doctype=Standard", "URIDate": "2021-03-24" }, "r87": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "9", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_9&doctype=Standard", "URIDate": "2021-03-24" }, "r88": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Section": "Scope", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2021-03-24" }, "r89": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2021-03-24" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24" }, "r90": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2021-03-24" }, "r91": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI", "URIDate": "2021-03-24" }, "r92": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2021-03-24" }, "r93": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2021-03-24" }, "r94": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2021-03-24" }, "r95": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r96": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24" }, "r97": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r98": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r99": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard", "URIDate": "2021-03-24" } }, "version": "2.1" }